MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O

(MSG O
O O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O

aniracetam O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 O
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
O O
, O
is O
ineffective O
on O
the O

GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

ethanol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Changes O
of O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
: O
naloxone O
reversal.AIM O
: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP O
response I
element I
binding I
protein I
(CREB) O
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
and O
its O
withdrawal O
. O
METHODS O
: O
Ethanol O
was O
given O
in O
drinking O
water O
at O
the O
concentration O
of O
6 O
% O
(v/v) O
, O
for O
one O
month O
. O

Changes O
in O
the O
levels O
of O
CREB O
and O
phospho-CREB O
(p-CREB) O
protein O
in O
the O

9-hydroxyrisperidone O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
ABCB1 O
polymorphisms O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety.Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
, O
mainly O
by O
the O
cytochrome O
P450 O
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O

9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein O
(P-gp) O
, O
a O
transport O
protein O
involved O

Tomudex O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin O
E-cdk2 O
activation O
. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) O
expression O
and O
the O
increase O
in O
cyclin O
E O
and O
cdk2 O
kinase O
activities O
. O
Activation O
of O
cyclin O
E O
and O
cdk2 O
kinases O
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O

of O
DNA O
synthesis O
. O
The O
changes O
in O

9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 O
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O

[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-( O

hydr O
oxymethyl)-3-(1-adamantyl)-hexahydrocannabinol B
] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O

L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O

enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
o O
enalkiren B
, O
a O
novel O
, O
dipeptide O
reni I
n O
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
including O
rheumatoid O
arthritis O
. O
Auranofin O
, O
an O
Au(I) O
compound O
, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug O
. O
However O
, O
the O
mechanism O
as O
to O
how O
auranofin O
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified O
. O
Our O
results O
demonstrated O
that O
auranofin O
suppressed O
TLR4-mediated O
activation O
of O
transcription O
factors O
, O
NF-kappaB O
and O
IRF3 O
, O
and O
expression O
of O
COX-2 O
, O
a O

pro-inflammatory O
enzyme O
. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O

MG132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O

and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O

Tomudex O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
inhibition O
of O
DNA O
synthesis O
, O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin O
E-cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O

. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O

Sar O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AngII O
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
Sar(1),Gln(2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O

range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

TZD O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD O
inhibition O
of O
aromatase O
plays O
a O
role O
in O
their O
effects O
on O
bone O
metabolism O
. O
Mouse O
osteoblasts O
were O
cultured O
with O
and O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone O
, O
pioglitazone O

or O
rosiglitazone O
. O
Cell O
growth O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
activity O
, O
and O

SB216763 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O

ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O

memantine O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
theoretically O
confer O
disease-modifying O
activity O
in O
AD O
by O
inhibiting O
the O
"weak" O
NMDA O
receptor-dependent O
excitotoxicity O
that O
has O
been O
hypothesized O
to O
play O
a O
role O
in O
the O
progressive O
neuronal O
loss O
that O
underlies O
the O
evolving O
dementia O
. O
Moreover O
, O
recent O
in O
vitro O
studies O
suggest O
that O
memantine O
abrogates O
beta-amyloid O
(Abeta) O
toxicity O
and O
possibly O
inhibits O
Abeta O
production O
. O
Considerable O
attention O
has O
focused O
on O
the O
investigation O
of O
theories O
to O
explain O
the O
better O
tolerability O

of O
memantine O
over O
other O
NMDA O
receptor O
antagonists O
, O
particularly O
those O
that O
act O
by O
a O
similar O
channel O
blocking O
mechanism O

vitamin O
E O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax O
/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O

cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O

t-butyl O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
O O
. O
Felodipine O
and O

p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O

PhIP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O

a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O

clomipramine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
antagonist O
tropisetron O
did O
not O
affect O
it O
. O
The O
5-HT(2B/2C)-receptor O
antagonist O
SB O
206553 O
facilitated O
hyperglycemia O
induced O
by O
clomipramine O
, O
although O
the O
5-HT(2A)-receptor O
antagonist O
ketanserin O
was O
without O
effect O
. O
Clomipramine-induced O
hyperglycemia O
was O
reduced O
by O
prior O
adrenalectomy O
. O
These O
results O
suggest O
that O
clomipramine O
induces O
hyperglycemia O
in O
mice O
by O

blocking O
the O
5-HT(2B O
) O
and/or O
5-HT(2C) O
receptors O
, O
which O
results O
in O
facilitation O
of O
adrenaline O
release O
. O

meloxicam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ng/mL; O
meloxicam O
steady O
state O
: O
1850.12+/-829.93 O
ng/mL) O
than O
after O
a O
single O
dose O
(P O
< O
.001) O
. O
CONCLUSION O
: O
These O
data O
show O
that O
meloxicam O
inhibits O
TXB2 O
generation O
at O
clinically O
relevant O
doses O
, O
although O
less O
potently O
than O
diclofenac O
. O
Thus O
our O
data O
suggest O
that O
the O
COX-2 O
preference O
of O
meloxicam O
observed O
in O
vitro O
may O
not O
result O
in O
clinical O
advantages O
when O
the O
higher O
dose O
of O
15 O

mg O
is O
needed O
. O
Because O
of O
the O
increase O
in O
EC50 O
at O
steady O
state O
, O
COX-1 O
is O
relatively O
spared O
when O
the O
lower O
dose O
of O
7.5 O
mg O

sodium O
nitroprusside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
o O
sodium B
nitroprusside O
on O
HIF- O
1 O
activation O
is O
not O
dependent O
on O
nitric B
oxide-soluble O
guanylyl O
cyclase O
pathway.Adaptation O
to O
hypoxia O
and O
maintenance O
of O
O(2) O
homeostasis O
involve O
a O
wide O
range O
of O
responses O
that O
occur O
at O
different O
organizational O
levels O
in O
the O
body O
. O
One O
of O
the O
most O
important O

Anastrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O

Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O
mimics O
the O
substrate O
, O
is O
converted O
by O
the O
enzyme O
to O
a O
reactive O
intermediate O
, O
and O
results O
in O
inactivation O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors O
) O
can O
be O
derived O
to O
be O
about O
13 O
nM O

, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O

bromfenac O
sodium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
o O
cyclooxygenase B
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac O
tromethamine O
and O
bromfenac O
sodiu O
m.OBJECTIVE O
: O
To O
compare O
the O
cyclooxygenase O
(COX) O
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
ketorolac O
tromethamine O
(ketorolac) O
and O
bromfenac O
sodium O

(bromfenac) O
. O
METHODS O
: O
Cyclooxygenase O
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O

Thr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
production O
. O
In O
several O
other O
cell O
lineages O
, O
insulin O
is O
able O
to O
stimulate O
p21-activated O
protein O
kinase O
1 O
(Pak1) O
. O
Here O
we O
determined O
the O
role O
of O
Pak1 O
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr O
423 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak O
inhibitor O

2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
(IPA3) O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O

4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ESI O
complex O
forms O
during O
inactivation) O
. O
On O
the O
basis O
of O
k(inact)/K(i) O
values O
, O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
is O
almost O
two O
orders O
of O
magnitude O
more O
potent O
than O
benzoylacrylate O
, O
a O
chemically O
analogous O
olefinic O
inactivator O
that O
lacks O

the O
peptide O
moiety O
. O
Stereochemical O
studies O
established O
that O
PAM O
inactivation O
by O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic O
acid O
is O
stereospecific O
with O
respect O
to O
the O
moiety O
at O
the O
P(2) O
position O
, O
which O
is O
consistent O
with O
previous O
results O
with O
substrates O
and O
reversible O
inhibitors O
. O
In O
contrast O
, O
2 O
, O
4-dioxo-5-acetamido-6-phenylhexanoic O
acid O
, O
which O
is O
a O
competitive O
inhibitor O
with O
respect O
to O
ascorbate O
, O
exhibits O

GS-6-DHSG O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
GS-6-DHSG) O
in O
RAW O
264.7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O

glutathione-S-transferase O
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O
6-DHSG O
and O
other O
α,β-unsaturated O
carbonyl O
compounds O
. O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
O O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O

inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O

N-(thiophen-2-yl) O
benzamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
and O
synthesis O
o O
N-(thiophen-2-yl) B
benzamide O
derivatives O
as O
BRAF O
(V600 O
E) O
inhibitors.The O
V600E O
BRAF O
kinase O
mutation O
, O
which O
activates O
the O
downstream O
MAPK O
signaling O
pathway O
, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas O
. O
In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
O O

TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
p O
rotein B

anthracycline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O
5-fluorouracil) O
chemotherapy O
. O
These O
results O
showed O
that O
WNT6 O
and O
Cav1 O
are O
upregulated O
by O
chemotherapeutics O
and O
enhance O
the O
resistance O
of O
GC O
cells O
to O
anthracycline O
drugs O
. O
Understanding O
the O
molecular O
mechanisms O
driving O
WNT6/Cav1-induced O

drug O
resistance O
will O
provide O
benefits O
in O
developing O
new O
therapies O
for O
GC O
. O

rilmenidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Species-specific O
pharmacological O
properties O
of O
human O
alpha(2A)-adrenoceptors.On O
the O
basis O
of O
data O
obtained O
in O
rabbits O
, O
the O
imidazoline O
receptor O
ligand O
rilmenidine O
has O
been O
suggested O
to O
decrease O
blood O
pressure O
in O
humans O
by O
activating O
central O
alpha(2A)-adrenoceptors O
. O
A O
prerequisite O
for O
this O
hypothesis O
was O
the O
unproved O
assumption O
that O
rabbit O
and O
human O
alpha(2A)-adrenoceptors O
are O
equally O
activated O
by O
rilmenidine O
. O
Because O

alpha(2A)-adrenoceptors O
in O
the O
brain O
and O

HCO3 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) O
benzoic O
acid O
, O
which O
inhibits O
the O
cystic O
fibrosis O
transmembrane O
conductor O
regulator O
(CFTR) O
, O
dose O
dependently O
inhibited O
S3226-induced O
DBS O
. O
In O
conclusion O
, O
only O
specific O
apical O
NHE3 O
inhibition O
increased O
DBS O
, O
whereas O
prostaglandin O
synthesis O
, O
Na+-HCO3- O
cotransporter O
activation O
, O
or O
intracellular O
HCO3- O

formation O
by O
carbonic O
anhydrase O
was O
not O
involved O
. O
Because O
NHE3 O
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion O
channel O
inhibitor O
and O
because O
reciprocal O
CFTR O
regulation O
has O
been O
previously O
shown O
between O
NHE3 O
and O
apical O
membrane O
anion O
transporters O
, O
we O
speculate O
that O
NHE3 O
inhibition O
increased O
DBS O

glycine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
GDC O
, O
EC O
2.1.1.10) O
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O

(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O

4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
(BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O

[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O

4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O

[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
5-Lipoxygenase O
inhibitors O
: O
a O
review O
of O
recent O
patents O
(2010 O
- O
2012).Introduction O
: O
5-Lipoxygenase O
(5-LO) O
is O
a O
crucial O
enzyme O
of O
the O
arachidonic O
acid O
(AA) O
cascade O
and O
catalyzes O
the O
formation O
of O
bioactive O
leukotrienes O
(LTs) O
with O
the O
help O
of O
FLAP O
, O
the O
5-LO-activating O
protein O
. O
LTs O
are O
inflammatory O
mediators O
playing O
a O
pathophysiological O
role O
in O
different O
diseases O
like O

asthma O
, O
allergic O
rhinitis O
as O
well O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B O
-dependent O
transcription O
from O
the O
Ig O
kappa O
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

diphenylhydantoin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
established O
sodium O
channel O
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O
this O
study O
, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
diphenylhydantoin O
and O
examined O
their O
ability O
to O
inhibit O
human O
Na(V)1.5 O
sodium O
channels O
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells O
. O
Phenyl O
ring O
substitutions O
were O
examined O

including O
para-methyl O
, O
para-fluoro O
, O
para-chloro O
, O
ortho-chloro O
and O
meta-chloro O
. O
We O
have O
found O
that O
phenyl O
ring O
substitutio O
ns O
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O
with O

gemcitabine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK O
expression O
and O
gemcitabine O
sensitivity O
, O
whereas O
expression O
of O
TS O
, O
DHFR O
, O
and O
GARFT O
was O
predictive O
of O
pemetrexed O
chemosensitivity O
. O
These O
data O
demonstrated O
that O
1) O
gemcitabine O
and O
pemetrexed O
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt O
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O
gene O
expression O
profile O
of O
critical O

genes O
may O
predict O
for O
drug O
chemosensitivity; O
and O
3) O
pemetrexed O
enhances O
dCK O
and O
hENT1 O
expression O
, O
thus O
suggesting O
the O
role O
of O
gene-expression O
modulation O

epinephrine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
used O
. O
The O
[3H]DHA O
binding O
was O
to O
a O
single O
receptor O
population O
with O
a O
dissociation O
constant O
of O
0.42 O
nM O
, O
as O
would O
be O
expected O
for O
wild-type O
beta2AR O
. O
Agonist O
competition O
assays O
with O
[3H]DHA O
showed O
the O
following O
rank O
order O
of O
potency O
: O
isoproterenol O
epinephrine> O
norepinephrine O
, O
consistent O
with O
beta2AR O
interaction O
. O
Isoproterenol-stimulated O
cyclic O
AMP O
levels O
were O
5-fold O
higher O
in O

infected O
cells O
compared O
to O
controls O
(314 O
+/- O
43 O
vs O
. O
63.4 O
+/- O
9.6 O
nmol/dish; O
n O
= O
3) O
. O
Receptor O
trafficking O
demonstrated O
surface O
expression O
of O
beta2AR O
with O
vehicle O
treatment O
and O
internalization O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O

(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O
Moreover O
, O
histological O
examination O
, O
including O
hematoxylin-eosin O
(H&E) O
staining O
, O
masson O
trichrome O
(Masson) O
staining O
, O
and O
periodic O
Schiff-methenamine O
(PASM) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O

mitiglinide O
acts O
as O
NOT O
for O
what O
entity O
? O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O

(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2 O
/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

metformin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
C O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2 O
, O
while O
no O
alteration O
of O
pro-apoptotic O
Bax O
was O
observed O
. O
Compound O
C O
diminished O
AMPK O
phosphorylation O
and O
enzymatic O
activity O
, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl O
CoA O
carboxylase O
. O
AMPK O
activators O
metformin O
and O
AICAR O
partly O
prevented O
the O
cell O
cycle O
block O
, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C O
. O

The O
small O
interfering O
RNA O
(siRNA) O
targeting O
of O
human O
AMPK O
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest O
, O
but O
failed O
to O
induce O
oxidative O
stress O

U0126 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O

on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
O O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O

Sulindac O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic O
GMP-dependent O
protein O
kinase O
(PKG); O
(b) O
activate O
c-jun O
NH2-terminal O
kinase O
(JNK O
); O
(c) O
inhibit O

extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin O
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1 O
) O
, O
tumor O

necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O

'sparing O
effect' O
and O
should O

ethanol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
drinking O
water O
decreased O
the O
level O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(-75 O
%) O
at O
the O
time O
of O
exposure O
to O
ethanol O
. O
The O
decrement O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
remained O
at O
24 O
h O
(-35 O
%) O
and O
72 O
h O
(-28 O
%) O
of O
ethanol O
withdrawal O
, O
which O
recovered O
toward O
control O
level O
after O
7 O
d O
of O
ethanol O
withdrawal O
. O
However O
, O
chronic O
ethanol O
, O
as O
well O
as O
ethanol O
withdrawal O
failed O
to O
produce O
any O
significant O
alteration O
in O
the O
level O
of O

CREB O
protein O
in O
the O
nucleus O
accumbens O
. O

ciprofloxacin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O

. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O

tinzaparin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
tinzaparin O
to O
14-18 O
monomers O
reduced O
inhibition O
slightly O
, O
while O
the O
pentasaccharide O
fondaparinux O
was O
without O
effects O
. O
To O
confirm O
molecular O
recognition O
of O
tinzaparin O
by O
VLA-4 O
, O
a O
surface O
acoustic O
wave-biosensor O
was O
applied O
. O
A O
VLA-4 O
containing O
membrane O
preparation O
of O
MV3 O
cells O
was O
immobilised O
at O
the O
sensors O
to O
allow O
for O
detection O
of O
kinetic O
binding O
constants O
of O
tinzaparin O
compared O
to O
VCAM-1 O
. O
Tinzaparin O
binds O

to O
VLA-4 O
with O
affinity O
in O
the O
low O
micromolar O
range O
(4.61 O
x O
10(-6) O
M) O
, O
which O
clearly O
indicates O
specific O
molecular O
recognition O
. O
Furthermore O
, O
tinzaparin O
displays O
a O
nearly O

clopidogrel O
acts O
as O
NOT O
for O
what O
entity O
? O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
O O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O

stably O
expressed O
in O
CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O

acetaldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
O O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O

Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O

PLP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
its O
cofactor O
, O
pyridoxal O
phosphate O
(PLP) O
. O
This O
conclusion O
is O
based O
on O
the O
following O
observations O
. O
Firstly O
, O
the O
V(max) O
of O
GAD O
was O
increased O
when O
ApoCaM O
was O
present O
whereas O
the O
affinity O
for O
the O
substrate O
, O
glutamate O
, O
was O
not O
affected O
. O
Secondly O
, O
the O
affinity O
of O
GAD O
for O
PLP O
was O
increased O
in O
the O
presence O
of O
ApoCaM O
. O
Thirdly O
, O
results O
from O
calmodulin-agarose O
affinity O
column O
chromatography O
studies O
indicated O
a O
direct O
interaction O

or O
binding O
between O
ApoCaM O
and O
GAD O
. O
Fourthly O
, O
ApoCaM O
was O
found O
to O
be O
copurified O
with O
GAD65/GAD67 O
by O
anti-GAD65/67 O
immunoaffinity O
column O

Oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
O O
, O
hedgehog O
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O

oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O

sulindac O
sulfide O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O
also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O

The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O

cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
in O
hibits O
the O
transcrip O
tion O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
NOT O
for O
what O
entity O
? O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O

, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O

[3H]-prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O

1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O

SFO O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O

in O
plaque O
. O

4-methoxy-2-naphthylamide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O

L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
O O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O

Tamoxifen O
acts O
as O
NOT O
for O
what O
entity O
? O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER O
-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER-positive O
cancers O
. O
Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O

refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O

Pyrrolidine O
dithiocarbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O

proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGF O
R/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O

Flavonoids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
O O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O

quercetin O
derivatives O
(1 O
-6) O
af O
fected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O

troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O

HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF O
/ME O
K/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O

WIN O
55,212 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 O
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O

[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabino O
l] O
, O
and O
AM4054 O

[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O

5-(dipentylamino)-5-oxo-pentanoic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK O
) O
antagonists O
. O
The O
most O
potent O
compound O
, O

D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O

alcohol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
view O
that O
condensation O
products O
of O
dopamine O
and O
alcohol-derived O
aldehyde O
(tetrahydroisoquinolines) O
play O
a O
role O
remains O
controversial O
. O
There O
is O
, O
however O
, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol O
on O
the O
binding O
properties O
of O
opioid O
receptors O
, O
as O
well O
as O
modulation O
of O
opioid O
peptide O
synthesis O
and O
secretion O
(e.g O
. O
a O
suggested O
increase O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O

to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O
morphine O
have O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoi O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716 O
A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O

Nle O
acts O
as O
PART-OF O
for O
what O
entity O
? O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
Nle(4) O
, O
D-Phe(7)]α-melanocyte-stimulating O
hormone O

(NDP-α-MSH O
) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O

Swertiamarin O
acts O
as O
NOT O
for O
what O
entity O
? O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4 O
; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O

significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O

amrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE O
4 O
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O

much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

Ziprasidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
PET O
study O
of O
dopamine O
D2 O
and O
serotonin O
5-HT2 O
receptor O
occupancy O
in O
patients O
with O
schizophrenia O
treated O
with O
therapeutic O
doses O
of O
ziprasidone.OBJECTIVE O
: O
Ziprasidone O
is O
an O
atypical O
antipsychotic O
drug O
that O
shows O
a O
higher O
affinity O
for O
serotonin O
5-HT(2) O
receptors O
compared O
with O
dopamine O
D(2) O
receptors O
in O
vitro O
. O
The O
affinity O
of O
ziprasidone O
for O
these O
receptors O

in O
vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study O
. O
METHOD O
: O
The O
authors O
conducted O
a O

TCDD O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR O
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD O
) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O

Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O

phosphatidylinositol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
O O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O

are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O
kinase O
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

mimosine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
o O
MCP-1 O
and O
MIP-2 O
transcription O
and O
translation O
by O
mimosin O
e O
in O
muscle O
tissue O
infected O
with O
the O
parasite O
Trichinella O
spiralis.Mimosine O
is O
a O
non-toxic O
plant O
aminoacid O
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase O
. O
In O
this O
study O
we O
infected O
mice O
with O
T O
. O

mannose O
6-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
mannose O
6-phosphate)/IGF2R O
( O
insulin-like O
growth O
factor O
II O
receptor O
) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O

invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O

. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O

PGs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic O
anhydrase O
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
PGs) O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA O
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O

edrophonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O

=tacrine>pyridostigmine=edrophonium O
=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

cAMP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs/cAMP O
signalling O
pathway O
. O

'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c O
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O
with O
sitagliptin O
O O
. O
These O
findings O
suggest O
that O
add-on O
therapy O

sitagliptin O
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O
patient's O
demographic O
profile O
. O
Stratified O
analysis O
based O
on O
the O
insulin O
regimen O

reboxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
the O
sustained O
elevation O
of O
extracellular O
NE O
levels O
observed O
in O
these O
mice O
. O
A O
pronounced O
NET O
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting O
ADs O
such O
as O
reboxetine O
O O
, O
desipramine O
, O
and O
imipramine O
. O
Citalopram O
, O
which O
is O
devoid O
of O
affinity O
for O
the O
NET O
, O
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O

mice O
. O
In O
the O
FST O
, O
reboxetine O
, O
desipramine O
, O
imipramine O
, O
and O
citalopram O
administered O
acutely O
did O
not O
reduce O

Cholesterol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
cholesterol O
synthesis O
. O
Although O
there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
O O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O

pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
is O
injected O
to O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investi O

gated O
O O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O

5-(dipentylamino)-5-oxo-pentanoic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O

D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O

imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR O
-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O

leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O

streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-co O
ntroll B
ed O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O

diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
in O
the O
nucleus O
accumbens O
. O
However O
, O
when O
naloxone O
was O
administered O
concurrently O
with O
ethanol O
treatment O
, O
it O
antagonized O
the O
down-regulation O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(142 O
%) O
of O
rats O
exposed O
to O
ethanol O
. O
CONCLUSION O
: O
A O
long-term O
intake O
of O
ethanol O
solution O
down-regulates O
the O
phosphorylation O
of O
CREB O
in O
the O
nucleus O
accumbens O
, O
and O
those O
changes O
can O
be O
reversed O
by O
naloxone O
, O
which O
may O
be O
one O
kind O
of O

the O
molecular O
mechanisms O
associated O
with O
ethanol O
dependence O
. O

GW572016 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
HRG O
, O
an O
ErbB3 O
ligand O
. O
GW572016 O
, O
a O
reversible O
small O
molecule O
inhibitor O
of O
EGFR O
and O
ErbB2 O
tyrosine O
kinases O
, O
inhibits O
baseline O
p95ErbB2 O
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts O
. O
Inhibition O
of O
p95ErbB2 O
, O
p185ErbB2 O
, O
and O
EGFR O
phosphorylation O
by O

GW572016 O
resulted O
in O
the O
inhibition O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
O O
, O
and O
cyclin O
D O
steady-state O
protein O
levels O
. O
Increased O
phosphorylation O
of O
p95ErbB2 O
and O
AKT O
in O
response O
to O
HRG O
was O
abrogated O
to O
varying O
degrees O
by O
GW572016 O
. O
In O
contrast O
, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 O
phosphorylation O
or O
the O

benzofuran O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
o O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolas O
e.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) I
hydrolase I
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O

known O
pro-inflammatory O

Gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O

(PPRE O
)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib(a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O

, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O
role O
of O
galectin-3 O
and O
platelet O
collagen O
receptors O
in O
platelet-induced O
COX-2 O
overexpression O
. O
Inhibitors O

IPA3 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr423 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak O
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
(IPA3 O
) O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O

cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O
were O
reduced O
in O
male O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O

CdCl2 O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro-apoptotic O

protein O
Bax O
. O

HSYA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O

phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

TDI O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
HDC O
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O
chain O
reaction O
(RT-PCR) O
. O
RESULTS O
: O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O

allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O
rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O

lovastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lymphocyte O
function-associated O
antigen O
(LFA-1) O
belongs O
to O
the O
family O
of O
beta2-integrins O
and O
plays O
an O
important O
role O
in O
T-cell O
activation O
and O
leukocyte O
migration O
to O
sites O
of O
inflammation O
. O
We O
report O
here O
that O
lovastatin O
, O
a O
drug O
clinically O
used O
for O
lowering O
cholesterol O
levels O
, O
inhibits O
the O
interaction O
of O
human O
LFA-1 O
with O
its O
counter-receptor O
intercellular O
adhesion O
molecule-1 O
O O
. O
Using O
nuclear O
magnetic O
resonance O
spectroscopy O

X O
-ray O
crystallography O
we O
show O
that O
the O
inhibitor O
binds O
to O
a O
highly O
conserved O
domain O
of O
the O
LFA-1 O
alpha-chain O
called O
the O
I-domain O
. O
The O
first O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
thymidine O
metabolism O
enzyme O
may O
be O
a O
crucial O
factor O
that O
affects O
the O
antitumor O
activity O
of O
TAS-102 O
. O
In O
the O
present O
study O
, O
we O
measured O
the O
enzyme O
activity O
of O
thymidine O
kinase O
(TK) O
, O
thymidine O
phosphorylase O
(TP) O
and O
thymidilate O
synthase O
(TS) O
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102 O
O O
. O
Antitumor O
activity O
of O
TAS-102 O
appears O
to O
be O
associated O
with O
TK O
, O
tumor O

and O
TS O
. O
However O
, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK O
and O
TP O

aniline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O

and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O

(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O

guaiacol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Both O
expression O
systems O
yielded O
proteins O
that O
bound O
heme O
tightly O
. O
The O
isolated O
YLR205c O
protein O
underwent O
reduction O
in O
the O
presence O
of O
either O
NADPH-cytochrome O
P450 O
reductase O
or O
NADH-putidaredoxin-putidaredoxin O
reductase O
but O
did O
not O
exhibit O
heme O
oxygenase O
activity O
. O
The O
protein O
exhibited O
modest O
H(2)O(2)-dependent O
peroxidase O
activities O
with O
guaiacol O
O O
, O
potassium O
iodide O
, O

2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic O
acid O
(ABTS) O
. O
Thus O
, O
YLR205c O
codes O
for O
a O
hemoprotein O
of O
unknown O
physiological O
function O
that O
exhibits O
peroxidase O
activity O
. O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O

PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
O O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
enhance O
our O
understanding O
of O
NMDA O
receptor O
activation O
and O
facilitate O
the O
development O
of O
novel O
therapeutics O
. O
Here O
, O
we O
investigated O
the O
structural O
determinants O
for O
(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone O
(CIQ) O
, O
a O
GluN2C/2D-selective O
positive O
allosteric O
modulator O
. O
We O
show O
that O

CIQ O
does O
not O
bind O
to O
the O
amino-terminal O
domain O
of O
the O
NMDA O
receptor O
and O
does O
not O
share O
structural O
determinants O
with O
modulators O
acting O
at O
the O
agonist-binding O
domain O
dimer O
interface O
or O
ion O
channel O
pore O
. O
Rather O
, O
we O
identified O
critical O
determinants O
of O
CIQ O
modulation O
in O
the O
region O
near O
the O
first O
transmembrane O
helix O
of O
GluN2D O
, O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
regions O
and O
the O
structural O
characteristics O
of O
the O
resulting O
DNA O
associations O
in O
vivo O
remain O
poorly O
understood O
. O
We O
analysed O
the O
role O
of O
the O
MBD O
in O
MeCP2-chromatin O
associations O
in O
vivo O
using O
an O
MeCP2 O
mutant O
Rett O
syndrome O
mouse O
model O
Mecp2(tm)(1)(.)(1)(Jae)) O
in O
which O
exon O
3 O
deletion O
results O
in O
an O
N O
-terminal O
truncation O
of O
the O
protein O
, O
including O
most O
of O
the O
MBD O
. O
Our O
results O
show O
that O
in O
mutant O
mice O
, O
the O
truncated O
form O
of O
MeCP2 O

(ΔMeCP2) O
is O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
liver O
, O
albeit O
at O

diacylglycerol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
O O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O

activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O

prostaglandin O
E2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NADPH O
Oxidase O
NOX5-S O
and O
Nuclear O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 O
(COX-2)-derived O
prostaglandin O
E2 O

(PGE2) O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 O
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
three O
subunits O
and O
their O
redundancy O
and O
specificity O
is O
essential O
for O
understanding O
the O
ubiquitous O
FGF O
signaling O
system O
in O
health O
and O
disease O
. O
Previously O
, O
we O
reported O
that O
a O
primary O
heparin O
or O
heparan O
sulfate O
binding O
site O
resides O
in O
a O
distinct O
sequence O
in O
immunoglobulin O
(Ig)-like O
module O
II O
of O
the O
three O
modules O
of O
FGFR O
O O
. O
Here O
we O
report O
that O
in O
the O
absence O
of O
flanking O
sequences O
, O
isolated O
Ig O
module O
II O
of O
FGFR1 O
supports O
the O
binding O

FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
in O
respective O
order O
of O
affinity O
. O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha O
1B-adrenoceptors O
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O

to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O

17-phenyl-trinor-PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O

sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
O O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca O
2+ O
channels O
is O
pos O
sibly O
mediated O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4 O
. O
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase O
1A1) O
, O
47% O
(CYP3A4) O
, O
to O
240% O
(CYP2C9) O
of O
primary O
human O
hepatocytes O
. O
The O
CYP3A4 O
activity O
could O
be O
induced O
2-fold O
by O

rifampicin O
O O
, O
whereas O
CYP2C9 O
activity O
remained O
equally O
high O
. O
The O
HepaRG-AMC-BAL O
secreted O
bile O
acids O
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile O
salts O
. O
Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O

Curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
s O
ignif I
icant B
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expressio O
4/NF-κB O

signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O

Thr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK O
at O
Thr O
172 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O

. O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O

xanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
xanthine O
derivatives O
on O
dipeptidyl O
peptidase O
4.A O
series O
of O
xanthine O
derivatives O
in O
which O
a O
methylene O
was O
inserted O
at O
position O
8 O
of O
xanthine O
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl O
peptidase O
4 O
(DPP-4 O
) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series O
, O
the O
compounds O
with O

4-methyl-quinazoline-2-yl-methyl O
group O
at O
N-1 O
position O
and O
2-aminoethylaminomethyl O
group O
gave O
better O
activities O
. O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O

hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholest O
atic O
(EEC) O
rats O
O O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
report O
unexpected O
rearrangements O
to O
the O
insulin/IGF-1 O
pathway O
, O
whereby O
the O
insulin-like O
receptor O
DAF-2 O
and O
3-phosphoinositide-dependent O
protein O
kinase O
PDK-1 O
oppose O
AKT-1 O
to O
promote O
DNA O
damage-induced O
apoptosis O
. O
While O
DNA O
damage O
does O
not O
affect O
phosphorylation O
at O
the O
PDK-1 O
site O
Thr350/Thr308 O
of O
AKT-1 O
, O
it O
increased O
phosphorylation O
at O
Ser517/Ser O
473 O
. O
Although O
ablation O
of O

daf-2 O
or O
pdk-1 O
completely O
suppressed O
akt-1-dependent O
apoptosis O
, O
the O
transcriptional O
activation O
of O
CEP-1 O
was O
unaffected O
, O
suggesting O
that O
daf-2 O
and O
pdk-1 O
act O
independently O
or O
downstream O
of O
cep-1 O
and O
akt-1 O
. O
Ablation O
of O
the O
akt-1 O
paralog O
akt-2 O

phenol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O

metalloenzyme O
carbonic O
anhydrase O
(CA O
O O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp O
) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O

hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
B O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL O
) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O

(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O

phenolic O
acids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
o O
mammalian B
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acid O
s.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O

glucose-6-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reduced O
in O
G6pc2 O
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O
Glucose-6-phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium O
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O
mice O
. O
These O
data O
suggest O
that O
G6pc2 O
represents O
a O
novel O
, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose-6-phosphate O
O O
, O
thereby O
reducing O
glycolytic O
flux O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O

fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O

acetaldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
O O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O

Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O

prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
Transport-P O
. O
Polymerase O
chain O
reactions O
and O
DNA O
sequencing O
of O
the O
products O
demonstrated O
that O
only O
the O
alpha(1B) O
sub-type O
of O
adrenoceptors O
is O
present O
in O
GnRH O
cells O
. O
3 O
. O
In O
COS O
cells O
transfected O
with O
alpha(1b) O
adrenoceptor O
cDNA O
and O
in O
DDT(1) O
MF-2 O
cells O
which O
express O
native O
alpha(1B) O
adrenoceptors O
, O
[(3)H]-prazosin O
was O
displaced O
by O
unlabelled O

prazosin O
in O
a O
normal O
equilibrium O
process O
, O
with O
no O
prazosin O
paradox O
in O
concentrations O
up O
to O
10(-6) O
M O
. O
In O
DDT(1) O
MF-2 O
cells O
, O
[(3)H]-prazosin O
was O
displaced O
likewise O
by O
a O
series O
of O
alpha(1) O
adrenergic O
agonists O
, O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
in O
duced O
by O
indomethac O
in O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
stud O
e O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O

and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O

2,6-dimethyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl O
- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O

, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O

some O
role O
in O
CP O
55,940 O
binding O
but O

6-DHSG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(LPS)-stimulated O
RAW O
264.7 O
cells O
. O
The O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
(GS-6-DHSG) O
in O
RAW O
264.7 O
cells O
, O
via O

a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase O
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O
6-DHSG O
and O

mitiglinide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O

K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

thiourea O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resultin O
thiourea O
compounds O
with O
the O
lipoprotei O
n O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O

1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 O
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O

PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
multitasking O
signal O
transduction O
inhibitors.An O
article O
presented O
in O
this O
issue O
of O
Molecular O
Pharmacology O
(p O
. O
1527) O
provides O
an O
intriguing O
example O
of O
how O
tyrosine O
kinase O
inhibitors O
can O
be O
put O
to O
many O
uses O
. O
In O
this O
article O
, O
the O
action O
of O
dasatinib O
(BMS-354825) O
is O
contrasted O
with O
that O
of O
imatinib O
, O
a O
kinase O
inhibitor O
th O
at I
is I
c O
urrently O
being O
used O
to O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders O
. O
Both O
pharmacologic O
inhibitors O
target O

several O
tyrosine O
kinases O
, O
including O
Bcr-Abl O
and O
the O
platelet-derived O
growth O
factor O
receptor O
(PDGFR) O
. O
Up O
to O
this O
point O
, O
the O

iloprost O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O

: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
. O

TAK-441 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibito O
TAK-441 O
for O
the O
inhibition O
of O
Gli O
1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O

mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
(TAK-441) O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O

inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O

DBDCT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
O O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O

Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O

astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol O
-preferring O
(P) O
rats O

(125)I-azidoglibenclamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2 O
SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
O O
, O
implying O

the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O

DBDCT O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O
increased O
TUNEL O
positive O

staining O
. O
In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT O
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O
mitochondria-mediated O
pathway O
. O

calcium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
C O
. O
elegans O
by O
showing O
that O
genetic O
programs O
actively O
promote O
longevity O
at O
cold O
temperatures O
. O
We O
find O
that O
TRPA-1 O
, O
a O
cold-sensitive O
TRP O
channel O
, O
detects O
temperature O
drop O
in O
the O
environment O
to O
extend O
lifespan O
. O
This O
effect O
requires O
cold-induced O
, O
TRPA-1-mediated O
calcium O
influx O
and O
a O
calcium-sensitive O
PKC O
that O
signals O
to O
the O
transcription O
factor O
DAF-16/FOXO O
. O
Human O
TRPA1 O
can O
functionally O
substitute O
for O
worm O
TRPA-1 O
in O
promoting O
longevity O
. O
Our O
results O
reveal O
a O
previously O
unrecognized O

function O
for O
TRP O
channels O
, O
link O
calcium O
signaling O
to O
longevity O
, O
and O
, O
importantly O
, O
demonstrate O
that O
genetic O
programs O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O

(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O

N-hydroxy-4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O

immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O

(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fiseti O
n O
treat O
ment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O

MXF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O

due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O

acyl-CoAs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
. O
Kinetic O
constants O
of O
the O
mutant O
CrAT O
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O
(Gly553) O
to O
methionine O
in O
carnitine O
octanoyltransferase O
(COT) O
decreased O
activity O
toward O
its O
natural O
substrates O
, O
medium- O
and O
long-chain O
acyl-CoAs O
O O
, O
and O
increased O
activity O
toward O

acyl-CoAs O
. O
Another O
CrAT O
mutant O
, O
M564A O
, O
was O
prepared O
and O
tested O
in O
the O
same O
way O
, O
with O
similar O
results O
. O
We O
conclude O
that O
Met564 O
blocks O
the O
entry O
of O
medium- O
and O
long-chain O

cirazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human O
subtype-I1 O
imidazol(in)e O
receptor O
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O

minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O

a O
promising O
anti-tumor O
agent O
. O

Orlistat O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
the O
gastrointestinal O
tract O
to O
decrease O
systemic O
absorption O
of O
dietary O
fat O
. O
In O
several O
trials O
lasting O
up O
to O
2 O
years O
, O
orlistat O
was O
more O
effective O
than O
diet O
alone O
for O
weight O
reduction O
and O
maintenance O
of O
lost O
weight O
. O
Orlistat O
treatment O
also O
results O
in O
modest O
improvements O
in O
total O
cholesterol O
, O
low-density O
lipoprotein O
O O
, O
blood O
pressure O
, O
and O
fasting O
glucose O
and O
insulin O
concentrations O
. O
The O
major O
adverse O
effects O
are O
gastrointestinal O
, O
usually O
occur O
early O
in O
therapy O
, O
and O

to O
decrease O
with O
continued O
treatment O
. O
Because O
orlistat O
may O
decrease O
the O
absorption O
of O

acetylcarnitine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Redesign O
of O
carnitine O
acetyltransferase O
specificity O
by O
protein O
engineering.In O
eukaryotes O
, O
L-carnitine O
is O
involved O
in O
energy O
metabolism O
by O
facilitating O
beta-oxidation O
of O
fatty O
acids O
. O
Carnitine O
acetyltransferases O
CrAT) O
catalyze O
the O
reversible O
conversion O
of O
acetyl-CoA O
and O
carnitine O
to O
acetylcarnitine O
and O
free O
CoA O
. O
To O
redesign O
the O
specificity O
of O
rat O
CrAT O
toward O
its O
substrates O
, O
we O

mutated O
Met564 O
. O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O
the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O
IRS O
serine O
phosphorylation O
. O
Studies O
with O
genetically O
modified O
mice O
reveal O
that O
these O
kinases O
integrate O
signals O
from O
metabolic O
and O

inflammatory O
stresses O
in O
adipose O
tissue O
, O
liver O
, O
and O
hy O
poth B
alamus B
leading O
to O
peripheral O
and O
central O
insulin O
resistance O
. O
Moreover O
, O
IKKbeta/NF-kappaB O
and O
JNK1 O
pathways O
in O
myeloid O
cells O
represent O

BPs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O

expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O

doxycycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
adenoviral O
vector O
(AdVEGF) O
in O
the O
brain O
. O
Mice O
were O
treated O
with O
doxycycline O
or O
minocycline O
, O
respectively O
, O
at O
1 O
, O
5 O
, O
10 O
, O
30 O
, O
50 O
, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week O
. O
Our O
results O
have O
shown O
that O
MMP-9 O
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O

Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O

acetyl-CoA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reversible O
conversion O
of O
acetyl-CoA O
and O
carnitine O
to O
acetylcarnitine O
and O
free O
CoA O
. O
To O
redesign O
the O
specificity O
of O
rat O
CrAT O
toward O
its O
substrates O
, O
we O
mutated O
Met564 O
. O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT O
, O
and O
lower O
activity O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
O O

Kinetic O
con O
stants B
of O
the O
mutant O
CrAT O
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O

etomidate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
o O
alpha B
2B-adrenoceptors O
mediates O
the O
cardiovascular O
effects O
of O
etomidat O
e.BACKGROUND O
: O
The O
intravenous O
anesthetic O
etomidate O
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor O
agonists O
of O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
O O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O

in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O

wortmannin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O

Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O

some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O

was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

Sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
(Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE O
(PDE6) O
, O
which O
produces O
visual O
changes O
through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O
well O
documented O
in O
the O
majority O
of O
men O
with O
ED O

irrespective O
of O
aetiology O
. O
The O
aetiology O
of O
ED O
, O
also O
, O
does O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK O

)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

linuron O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
ReProTect O
, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed O
. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM O
, O
if O
needed O
. O
A O
few O
compounds O
, O
17alpha-methyltestosterone O
(17alpha-MT) O
, O
vinclozolin O
and O
linuron O
, O
were O
studied O
using O
a O
real O
world O
scenario O
, O
i.e. O
, O
assuming O
that O
their O
interaction O
with O
the O
AR O
was O
not O
known O
: O
A O
prescreening O
for O
agonism O
and O
true O
, O
competitive O
antagonism O
was O

used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action O
, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O
the O
final O

N-(thiophen-2-yl) O
benzamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
and O
synthesis O
o O
N-(thiophen-2-yl) B
benzamide O
derivatives O
as O
BRA O
F(V600E) O
inhibitors.The O
V600E O
BRAF O
kinase O
mutation O
, O
which O
activates O
the O
downstream O
MAPK O
signaling O
pathway O
, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas O
. O
In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O

aspirin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
radiolabeled O
3H O
or O
14C O
aspirin O
, O
the O
only O
approach O
used O
to O
date O
for O
the O
detection O
of O
proteins O
acetylated O
by O
aspirin O
. O
In O
a O
recent O
study O
using O
protein-specific O
anti-acetyl O
lysine O
antibodies O
and O
immunological O
methods O
, O
we O
demonstrated O
the O
ability O
of O
aspirin O
to O
acetylate O
the O
tumor O
suppressor O
protein O
p53 O
O O
. O
In O
this O
review O
, O
we O
present O
current O
research O
from O
the O
literature O
on O
the O
aspirin-induced O
acetylation O
of O
proteins O
. O
We O
also O
describe O
an O
immunological O
approach O
to O
detecting O

proteins O
in O
aspirin-treated O
cells O
, O
and O
demonstrate O
that O
multiple O
proteins O
are O

corticosteroid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin O
releasing O
hormone O
(CRH O
) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O

during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O

SNP O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
HIF-1-mediated O
transcriptional O
responses O
to O
hypoxia O
. O
We O
demonstrate O
that O
among O
the O
three O
nitrates O
, O
only O
SNP O
inhibits O
HIF-1 O
activation O
in O
response O
to O
hypoxia O
. O
In O
contrast O
, O
NTG O
or O
ISDN O
does O
not O
affect O
HIF-1 O
activity O
. O
SNP O
inhibits O
the O
accumulation O
of O
HIF-1alpha O
, O
the O
regulatory O
subunit O
of O
HIF-1 O
, O
and O
the O
transcriptional O
activation O
of O
HIF-1alpha O
via O
a O
mechanism O
that O
is O
not O
dependent O
on O
either O
NO O

or O
soluble O
guanylate O
cyclase O
. O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O

Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O

Ketorolac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1 O
hour O
before O
LPS O
. O
MAIN O
OUTCOME O
MEASURES O
: O
PGE(2) O
production O
in O
vitro O
, O
measured O
by O
enzyme O
immunoassay; O
fluorescein O
isothiocyanate O
(FITC)-dextran O
leakage O
into O
the O
anterior O
chamber O
, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) O
levels O
in O
vivo O
, O
measured O
by O
ELISA O
immunoassay O
. O
RESULTS O
: O
Ketorolac O
was O
six O
times O
more O
active O
against O

COX-1 O
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 O
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac O
was O
approximately O
32 O
times O
more O
active O
against O
COX-2 O
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 O
(IC(50) O
= O
0.210 O
microM) O
. O
In O
the O
animal O
model O
, O
both O
drugs O

Orlistat O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
for O
severe O
gas O
trointe O
stinal O
discomfort O
and O
the O
modest O
degree O
of O
weight O
loss O
may O
limit O
the O
agent's O
clinical O
utility O
. O
Its O
long-term O
safety O
and O
effectiveness O
for O
weight O
maintenance O
, O
cost-effectiveness O
of O
treatment O
, O
and O
overall O
reduction O
in O
obesity-related O
morbidity O
and O
mortality O
remain O
to O
be O
determine O
e O
inhibitor O
for O
the O
management O
of O
obesity.Orlistat O
, O
a O
weight-loss O
agent O
with O
a O
novel O
mechanism O
of O
action O
, O
recently O
was O
approved O
by O
the O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
obesity O
. O
It O

inhibits O
gastric O
and O
pancreatic O
lipases O
in O
the O
lumen O
of O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
O O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
seems O
reasonable O
to O
continue O
insulin O
glargine O
if O
required O
to O
achieve O
excellent O
glycaemic O
control O
. O
A O
head-to-head O
comparison O
between O
insulin O
detemir O
and O
NPH O
insulin O
in O
women O
with O
type O
1 O
diabetes O
showed O
that O
while O
foetal O
outcomes O
did O
not O
differ O
, O
fasting O
plasma O
glucose O
improved O
with O
insulin O
detemir O
without O
an O
increased O
incidence O
of O
hypoglycaemia O
. O
The O
greater O
evidence O
base O
supports O
the O
use O
of O
insulin O
detemir O
as O
the O
first O
line O
long-acting O
analogue O
in O
pregnancy O
but O
the O

lack O
of O
definitive O
foetal O
benefits O
means O
that O
there O
is O
no O
strong O

acarbose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
utility O
o O
acarbose B
, O
an O
alpha-glucosidas B
e O
inhibitor O
in O
cardiometabolic O
disorders.Diabetes O
is O
associated O
with O
an O
increase O
risk O
for O
cardiovascular O
disease O
(CVD) O
. O
Recently O
, O
macrovascular O
complications O
of O
diabetes O
have O
been O
shown O
to O
start O
before O
the O
development O
of O
diabetes O
. O
Indeed O
, O
several O
clinical O
studies O
have O
confirmed O
the O
increased O

sulindac O
sulfide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
strongly O
induces O
phosphorylation O
of O
ERK1/2 O
and O
Bad O
in O
HT29 O
colon O
cancer O
cells O
. O
EGF-stimulated O
phosphorylation O
of O
ERK O
and O
Bad O
is O
blocked O
by O
pretreatment O
with O
U0126 O
, O
a O
selective O
MAP O
kinase O
kinase O
(MKK)1/2 O
inhibitor O
. O
Similarly O
, O
pretreatment O
with O
sulindac O
sulfide O
blocks O
the O
ability O
of O
EGF O
to O
induce O
ERK1/2 O
and O
Bad O
phosphorylation O
, O
but O

also O
down-regulates O
total O
Bad O
but O
not O
ERK1/2 O
protein O
levels O
. O
The O
ability O
of O
sulindac O
to O
block O
ERK1/2 O
signaling O
by O
the O
EGF O
receptor O
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA O
) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O

type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O

calcium O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
tetra-aspartate O
motif O
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium O
(KD O
~1.6 O
mM) O
, O
which O
stimulates O
autoactivation O
. O
Unexpectedly O
, O
calcium O
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations O
. O
Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G O
and O
K23_I24insIDK O
was O
not O
stimulated O
by O
calcium O
O O
. O
Finally O
, O
the O
activation O
peptide O
mutants O
exhibited O
reduced O
secretion O
from O
transfected O
cells O
, O
and O
secreted O

levels O
were O
inversely O
proportional O
with O
autoactivation O
rates O
. O
We O
conclude O
that O
D19A O
, O
D22G O
, O
K23R O
and O
K23_I24insIDK O
form O
a O
mechanistically O
distinct O
subset O
of O
hereditary O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O

permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

quercetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O

. O
All O
mammalia O
n O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O

moxidectin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O

GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O

AMP O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto O
-phosphodiesterase O
O O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O

uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O

compound O
C O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O

by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O

U50,488H O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
down-regulation O
of O
the O
hkor O
. O
Coexpression O
of O
GRK2 O
or O
GRK2 O
and O
arrestin-2 O
permitted O
etorphine O
to O
induce O
down-regulation O
of O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I O
or O
rab7 O
N125I O
blunted O
U50,488H O
-induced O
down-regulation O
. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O

[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
(proteasome O
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin-treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O

IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O

acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O

2'CMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O

inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O

aconitine O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
exposure O
of O
highly O
toxi O
aconitine O
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome O
P450 O
3 O
A O
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O
liquid O
chromatography-tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone.Aconitum O
species O
are O
widely O
used O
to O
treat O
rheumatism O
, O
cardiovascular O
diseases O
, O
and O
tumors O
in O
China O
and O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinase O
s O
VEGF B
R/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O

monoamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O

noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O

β-Lapachone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model O
β-Lapachone O
(β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone O
oxidoreductase-1 I

(NQO1) O
. O
NQO1 O
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O

ZD1839 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine O
kinase O
inhibito O
ZD1839 O
("Iressa") O
inhibits O
HER O
2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O

U50,488H O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
. O
Coexpression O
of O
GRK2 O
or O
GRK2 O
and O
arrestin-2 O
permitted O
etorphine O
to O
induce O
down-regulation O
of O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I O
or O
rab7-N125I O
blunted O
U50,488H O
-induced O
down-regulation O
. O
Pretreatment O
with O

lysosomal O
enzyme O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
(proteasome O
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O

cAMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
779 O
amino O
acids O
, O
including O
a O
putative O
cGMP O
binding O
sequence O
in O
the O
amino-terminal O
portion O
of O
the O
molecule O
and O
a O
catalytic O
domain O
that O
is O
16-47% O
identical O
in O
amino O
acid O
sequence O
to O
those O
of O
other O
PDE O
families O
. O
Recombinant O
PDE10A O
transfected O
and O
expressed O
in O
COS-7 O
cells O
hydrolyzed O
cAMP O
and O
cGMP O
with O
Km O
values O
of O
0.26 O
and O
7.2 O
microM O
, O
respectively O
, O
and O
Vmax O
with O
cGMP O
was O
almost O
twice O
that O
with O
cAMP O
. O
Of O
the O

PDE O
inhibitors O
tested O
, O
dipyridamole O
was O
most O
effective O
, O
with O
IC50 O
values O
of O
1.2 O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
o O
arylhydroxylamine B
carcinogens O
by O
human O
NADH B
cytochrome O
b5 O
reductas O
e O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O

mesalamine O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
colorectal O
sensitivity O
and O
pain O
were O
assessed O
by O
measuring O
the O
abdominal O
withdrawal O
response O
and O
spinal O
c-Fos O
expression O
. O
In O
healthy O
rats O
, O
ATB-429 O
dose O
dependently O
(25 O
, O
50 O
, O
or O
100 O
mg/kg) O
attenuated O
CRD-induced O
hypersensitivity O
and O
significantly O
inhibited O
CRD-induced O
overexpression O
of O
spinal O
c-FOS O
mRNA O
, O
whereas O
mesalamine O
had O
no O
effect O
. O
ATB-429-induced O
antinociception O
was O
reversed O
by O
glibenclamide O
, O
a O

ATP-sensitive O
K(+) O
(K(ATP)) O
channel O
inhibitor O
. O
The O
antinociceptive O
effect O
of O
ATB-429 O
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O

fumarate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Fumarate O
reductase O
is O
essential O
for O
Helicobacter O
pylori O
colonization O
of O
the O
mouse O
stomach O
Fumarate O
reductase O
(FRD) O
is O
the O
key O
enzyme O
in O
fumarate O
respiration O
induced O
by O
anaerobic O
growth O
of O
bacteria O
. O
In O
Helicobacter O
pylori O
, O
this O
enzyme O
appears O
to O
be O
constitutively O
expressed O
under O
microaerobic O
conditions O
and O
is O
not O
essential O
for O
its O
survival O
in O
vitro O
. O
In O
this O
study O
, O
the O
role O
of O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O

β-catenin O
O O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O

retinoblastoma O
protein O
(pRb O
) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
O O

and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O

β-Lap O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model.β-Lapachone O
β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone O
oxidoreductase-1 I
( O

NQO1 O
) O
. O
NQO1 O
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O

troglitazone O
acts O
as O
NOT O
for O
what O
entity O
? O
among O
those O
tested O
. O
In O
activated O
microglia O
, O
15d-PGJ2 O
suppressed O
iNOS O
promoter O
activity O
, O
iNOS O
mRNA O
, O
and O
protein O
levels O
. O
The O
action O
of O
15d-PGJ2 O
does O
not O
appear O
to O
involve O
its O
nuclear O
receptor O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma) O
because O
troglitazone O
, O
a O
specific O
ligand O
of O
PPARgamma O
, O
was O
unable O
to O
inhibit O
iNOS O
induction O
, O
and O
neither O
troglitazone O
nor O
15d-PGJ2 O
could O
stimulate O
the O
activity O

of O
a O
PPAR-dependent O
promoter O
in O
the O
absence O
of O
cotransfected O
PPARgamma O
. O
15d-PGJ2 O
did O
not O
block O
nuclear O
translocation O
or O
DNA-binding O
activity O
of O
the O
transcription O
factor O
NFkappaB O
, O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
often O
accompanied O
by O
high O
TS O
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O

hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 O
expression O
, O
may O
be O
resistant O
to O
TAS-102 O
. O

Dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-ind O
uced B
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reactio O
t O
and O
ERK O
and O
JNK O
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines.Our O
previous O
study O
has O
revealed O
that O
dioscin O
, O
a O
compound O
with O

anti-inflammatory O
, O
lipid-lowering O
, O
anticancer O
and O
hepatoprotective O
effects O
, O
may O
induce O
autophagy O
in O
hepatoma O
cells O
. O
Autophagy O
is O
a O
lysosomal O
degradation O
pathway O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys O
59-Asp71) O

, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O

Rg1 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O

down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O

carbacyclin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O

inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
. O
An O

DMBT O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O

DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5 O
) O
. O
We O
found O
that O
reduction O
of O
the O

carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O

glutamine O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
rat O
kynurenine O
aminotransferase/glutamine O
transaminase O
K O
mRNAs.Kynurenic O
acid O
(KA) O
is O
an O
endogenous O
glutamate O
receptor O
antagonist O
at O
the O
level O
of O
the O
different O
ionotropic O
glutamate O
receptors O
. O
One O
of O
the O
enzymes O
responsible O
for O
the O
production O
of O
KA O
, O
kynurenine O
aminotransferase O
I O
KATI) B
, O
also O
catalyses O
the O
reversible O
transamina O
tion O
of O
glutamine O
to O

oxoglutaramic O
acid O
(GTK O
, O
EC O
2.6.1.15) O
. O
The O
enzyme O
exists O
in O
a O
cytosolic O
and O
in O
a O
mitochondrial O
form O
because O
of O
the O
presence O
of O
two O
different O
KATI O
mRNAs O
coding O
for O
a O
protein O
respectively O
with O
and O
without O
leader O
sequence O

auranofin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
. O
Our O
results O
first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin O
exerts O
anti-rheumatic O
activity O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
O O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O

to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) I
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O
channel O
was O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
O O

c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O
biology O
, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib O

sulindac O
sulfone O
acts O
as O
NOT O
for O
what O
entity O
? O
that O
COX-1 O
and O
COX-2 O
inhibitors O
could O
inhibit O
the O
in O
vitro O
growth O
of O
human O
lung O
cancer O
cell O
lines O
. O
In O
this O
report O
, O
we O
evaluated O
the O
growth-inhibitory O
effects O
of O
sulindac O
sulfide O
, O
a O
COX-1 O
and O
COX-2 O
inhibitor; O
exisulind O
sulindac O
sulfone) O
, O
a O
novel O
proapoptotic O
agent O
that O
does O
not O
inhibit O
COX O
enzymes; O
and O
nordihydroguaiaretic O
acid O
(NDGA) O
, O
a O

lipoxygenase O
inhibitor O
on O
human O
lung O
cancer O
cell O
lines O
. O
We O
compared O
these O
effects O
with O
those O
of O
13-cis-retinoic O
acid O
, O
a O
chemoprevention O
agent O
, O
and O
with O
the O
cytotoxic O
chemotherapeutic O
agents O
paclitaxel O
and O

etomidate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- O
and O
alpha2C-receptors O

than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O

compound O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O

phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O

OMT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O

ischemia O
. O

p-chloro O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
O O
, O
oxidized O
and O

exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O

MPTP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O

increase O
in O
Bax O
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved-caspase-3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O

amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O

dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O

non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O

AMPA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
rings O
, O
which O
have O
previously O
been O
incorporated O
as O
5-substituents O
in O
AMPA O
analogues O
, O
as O
exemplified O
by O
1 O
were O
also O
synthesized O
. O
Compounds O
4b-h O
were O
either O
inactive O
(4e,f) O
or O
weaker O
than O
4a O
as O
affinity O
ligands O
for O
GluR1-4 O
and O
GluR5 O
with O
relative O
potencies O
comparable O
with O
those O
of O
the O
corresponding O
AMPA O
analogues O
as O
AMPA O
receptor O
agonists O
. O
Compounds O
4a-h O
may O
be O
useful O
tools O
for O
the O
progressing O
pharmacophore O
mapping O
of O
the O

GluR5 O
agonist O
binding O
site O
. O

CsA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
anti-IL-2 O
R O
monoclonal O
antibodies O
(moAbs) O
, O
anti-Tac O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 O
R O
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O

(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O

phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O

N-propargyl-1R(+)-aminoindan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O

is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O

m-CPBG O
acts O
as O
AGONIST O
for O
what O
entity O
? O
selective O
5-HT3 O
receptor O
agonist O
, O
induced O
a O
significant O
increase O
in O
blood O
glucose O
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O
fed O
states O
. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia O
. O
The O
hyperglycemic O
effect O
of O
m-CPBG O
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron O
, O
a O
specific O
5-HT3 O
receptor O
antagonist O
, O
indicating O
that O
the O
effects O
here O
obtained O
with O
m-CPBG O
were O
a O
result O
of O
its O
interaction O
with O

5-HT3 O
receptors O
. O
Third O
ventricle O
injections O
of O
ondansetron O
alone O
were O
not O
able O
to O
modify O
blood O
glucose O
in O
non-stressed O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O

, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A O
; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O

oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O

isoproterenol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
and O
butoxamine O
inhibited O
isoproterenol-mediated O
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O
61 O
and O
9268 O
+/- O
512 O
nM O
, O
respectively) O
. O
Together O
, O
this O
pharmacological O
profile O
of O
subtype-selective O
betaAR O
antagonists O
indicates O
that O
in O
this O
model O
, O
beta1AR O
activation O
is O
responsible O
for O
the O
enhanced O
hippocampal O
CA3 O
network O
activity O
initiated O
by O
isoproterenol O
O O

STX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
In O
the O
blood O
was O
analyzed O
the O
genotoxic O
and O
hematological O
parameters O
. O
The O
hepatosomatic O
index O
and O
the O
relative O
condition O
factor O
did O
not O
show O
a O
significant O
difference O
between O
the O
exposed O
and O
control O
groups O
. O
The O
values O
of O
mean O
corpuscular O
hemoglobin O
concentration O
and O
mean O
corpuscular O
hemoglobin O
increased O
in O
the O
STX O
group O
. O
The O
hepatic O
tissue O
from O
both O
groups O
exhibited O
a O
typical O
pattern O
that O
have O
been O
already O
described O
for O
most O
teleost O
fish O
. O
The O
results O
suggested O
the O
generation O
of O
reactive O
oxygen O
species O
, O
with O
increased O
activity O
of O
GPx O
and O

BLT-4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
BLT-4) O
, O
blocked O
ABCA1 O

-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O

15d-PGJ2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
absence O
of O
cotransfected O
PPARgamma O
. O
15d-PGJ2 O
did O
not O
block O
nuclear O
translocation O
or O
DNA-binding O
activity O
of O
the O
transcription O
factor O
NFkappaB O
, O
but O
it O
did O
inhibit O
the O
activity O
of O
an O
NFkappaB O
reporter O
construct O
, O
suggesting O
that O
the O
mechanism O
of O
suppression O
of O
microglial O
iNOS O
by O
15d-PGJ2 O
may O
involve O
interference O
with O
NFkappaB O
transcriptional O
activity O
in O
the O
nucleus O
. O
Thus O
, O
our O
data O
suggest O
the O
existence O
of O
a O
novel O
pathway O
mediated O
by O

cyclopentenone O
prostaglandins O
, O
which O
may O
represent O
part O
of O
a O
feedback O
mechanism O
leading O
to O
the O
cessation O
of O
inflammatory O

aminoglycoside O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 O
activity O
induced O
by O
gentamicin O
C.Megalin O
, O
a O
family O
of O
endocytic O
receptors O
related O
to O
the O
low-density O
lipoprotein O
(LDL) O
receptor O
, O
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside O
accumulation O
. O
We O
previously O
reported O
that O
aminoglycoside O
antibiotics O
reduce O
SGLT1 O
-dependent O
glucose O
transport O
in O
pi O
g O
prox I
imal O
tubular O
epithelial O

LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity O
. O
In O
this O
study O
, O
using O
a O
model O
of O
gentamicin O
C O
(GMC)-induced O
reduction O
in O
SGLT1 O
activity O
, O
we O
examined O
whether O
ligands O
for O
megalin O

gefitinib O
acts O
as O
NOT O
for O
what O
entity O
? O
gefitinib O
and O
erlotinib O
. O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding O
affinity O
. O
The O

T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O

Ser40 O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
a O
half-time O
of O
about O
20 O
s O
for O
the O
kinetic O
transient O
. O
Secondly O
, O
nonhyperbolic O
saturation O
behaviour O
was O
found O
for O
H4biopterin O
with O
a O
pronounced O
negative O
cooperativity O
(0.39 O
< O
h O
< O
0.58; O
[S]0.5 O
= O
24 O
+/- O
4 O
microM) O
. O
On O
phosphorylation O
of O
Ser40 O
by O
protein O
kinase O
A O
O O
, O
the O
affinity O
for O
H4biopterin O
increased O
([S]0.5 O
= O
11 O
+/- O
2 O
microM) O
and O
the O

cooperativity O
was O
amplified O
(h O
= O
0.27 O
+/- O
0.03) O
. O
The O
dimeric O
C-terminal O
deletion O
mutant O
(Delta473-528) O
of O
hTH1 O
also O
showed O
negative O
cooperativity O
of O
H4biopterin O

meclofenamate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 O
channel O
openers O
. O
Extracellular O
application O
of O
meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 O

K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O
activated O
KCNQ2/Q3 O
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV O
, O
respectively) O
and O
by O

olanzapine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM O
. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O

that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
production O
were O
analysed O
by O
flow O
cytometry O
and O
ELISA O
, O
respectively O
. O
Airway O
hyperreactivity O
was O
sustainably O
reduced O
only O
when O
PGE2 O
administration O
was O
restricted O
to O
the O
initial O
5 O
days O
of O
exposure O
to O
HDM O
. O
Lung O
inflammation O
, O
IL-4 O
production O
, O
and O
airway O
mast O
cell O
activity O
were O
also O
prevented O
under O
this O
early O
short-term O
treatment O
with O
PGE2 O
O O
. O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O

osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
that O
the O
thymidine O
metabolism O
enzyme O
may O
be O
a O
crucial O
factor O
that O
affects O
the O
antitumor O
activity O
of O
TAS-102 O
. O
In O
the O
present O
study O
, O
we O
measured O
the O
enzyme O
activity O
of O
thymidine O
kinase O
(TK) O
, O
thymidine O
phosphorylase O
(TP) O
and O
thymidilate O
synthase O
(TS) O
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102 O
O O
. O
Antitumor O
activity O
of O
TAS-102 O
appears O
to O
be O
associated O
with O
TK O

tumor O
growth O
and O
TS O
. O
However O
, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK O
and O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Parkinson's O
disease.Parkinson's O
disease O
(PD) O
is O
the O
second O
most O
common O
neurodegenerative O
disorder O
, O
affecting O
1% O
to O
2% O
of O
people O
older O
than O
60 O
years O
. O
Treatment O
of O
PD O
consists O
of O
symptomatic O
therapies O
while O
neuroprotective O
strategies O
have O
remained O
elusive O
. O
Rasagiline O
is O
a O
novel O
, O
potent O
, O
and O
irreversible O
monoamine O
oxidase O
type O
B O
(MAO-B) O
inhibitor O
which O
has O
been O
approved O
for O
treatment O
of O
PD O
. O
Rasagiline O
inhibits O
MAO-B O

more O
potently O
than O
selegiline O
and O
has O
the O
advantage O
of O
once-daily O
dosing O
. O
In O
several O
large O
, O
randomized O
, O
placebo-controlled O
trials O
, O
rasagiline O
has O
demonstrated O
efficacy O

KB-R7943 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O

YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor O
Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin I
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O

0.1 O

(+/-)-Modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O

dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT O
) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JH O
W O
00 O
7 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine O
rhodopsin O
O O
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O

with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halot O
hane-labeled O
rhod O
opsin B
revealed O

epinastine O
acts O
as O
AGONIST-INHIBITOR O
for O
what O
entity O
? O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1 O
5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O

epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O

Fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O

a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O

pThr O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr O
-Pro O
moieties O
in O
signaling O
proteins O
from O

cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Micha O
el I
ad O
ducts O
at O

CCl4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O

suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O

etorphine O
acts O
as O
NOT O
for O
what O
entity O
? O
the O
human O
kappa-opioid O
receptor O
(hkor) O
stably O
expressed O
in O
Chinese O
hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H O
treatment O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
mechanisms O
underlying O
this O
process O
. O
U50 O
, O
488H O
caused O
a O
significant O
down-regulation O
of O
the O
hkor O
, O
although O
etorphine O
did O
not O
. O
Neither O
U50,488H O
nor O
etorphine O
caused O
down-regulation O
of O
the O
rat O
kappa-opioid O
receptor O
. O
Thus O
, O
similar O
to O
internalization O
, O
there O
are O
agonist O

and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid O
receptors O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
arrestin-2(319-418) O
or O
dynamin O
I-K44A O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O

amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O

Vinblastine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mechanisms O
. O
In O
conclusion O
, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
rol O
e O
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine O
in O
melanoma O
treatmen O
A) O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms.Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site O
, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O

available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Histamine O
and O
asthma O
: O
an O
appraisal O
based O
on O
specific O
H1-receptor O
antagonism O
H1-receptor O
antagonists O
have O
been O
utilized O
, O
following O
their O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O

Reboxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
stress O
disorder O
(PTSD) O
in O
the O
general O
population O
. O
Alterations O
in O
norepinephrine O
and O
serotonin O
systems O
have O
been O
proposed O
as O
mechanisms O
involved O
in O
the O
pathophysiology O
of O
the O
condition O
, O
with O
treatment O
directed O
at O
these O
neurotransmitter O
systems O
. O
Reboxetine O
, O
a O
selective O
norepinephrine O
reuptake O
inhibitor O
, O
exhibits O
high O
affinity O
and O
selectivity O
for O
the O
human O
norepinephrine O
transporter O
O O
. O
Inasmuch O
as O
PTSD O
may O
be O
associated O
with O
dysregulation O

noradrenergic O
activity O
, O
the O
present O
double-blind O
randomized O
clinical O
trial O
intended O
to O
evaluate O
reboxetine's O
efficacy O
in O
the O
management O
of O
MVA-rel O
ated O
PTSD O
and O
to O
compare O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
change O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
O O
, O
glutamate O
synthase O
, O
and O

dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O

imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibit O
KIT O
D816V O
, O
an O
imatini O
b-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O

of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
. O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O

Methylphenidate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
then O
OFC O
and O
mPFC O
DAT O
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O

, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O

editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O

sumatriptan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O
for O
rat O
5-HT1B O
receptors O
. O
LY O
344864 O
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F O
receptors O
, O
while O
sumatriptan O
acts O
via O
5-HT1B O
receptors O
. O
The O
fact O
that O
activation O
of O
5-HT1F O

receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O
trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile O
. O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
the O
human O
monocytic O
THP-1 O
line O
and O
their O
survival O
is O
followed O
. O
Respiratory O
burst O
is O
directly O
measured O
on O
the O
activated O
cells O
. O
We O
tested O
inhibitors O
of O
the O
cyclooxygenase O
(COX) O
or O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX O
pathway O
generates O
inflammatory O
prostaglandins O
O O
, O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
. O

found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 O
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O
NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O

ketamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine O
in O
female O
rats O
. O
In O
preclinical O
studies O
, O
the O
mammalian O
target O
of O
rapamycin O
(mTOR) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic O
elongation O
factor O
(eEF2) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine O
's O
rapid O
antidepressant O
actions O
. O
In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O

a O
low O
dose O
of O
ketamine O
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR O
or O
eEF2 O
. O

saxitoxin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
These O
illnesses O
are O
a O
result O
of O
saxitoxin's O
ability O
to O
bind O
to O
the O
voltage-gated O
sodium O
channel O
, O
blocking O
the O
passage O
of O
nerve O
impulses O
and O
leading O
to O
death O
via O
respiratory O
paralysis O
. O
Recent O
advances O
in O
saxitoxin O
research O
are O
discussed O
, O
including O
the O
molecular O
biology O
of O
toxin O
synthesis O
, O
new O
protein O
targets O
, O
association O
with O
metal-binding O
motifs O
and O
methods O
of O
detection O
. O
The O
eco-evolutionary O
role(s) O
PSTs O
may O
serve O
for O
phytoplankton O
species O
that O
produce O
them O
are O
also O
discussed O
. O

betaxolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
into O
cortical O
synaptosomes O
by O
direct O
interaction O
with O
Na(+) O
channels O
: O
comparison O
with O
other O
beta-adrenoceptor O
antagonists.Betaxolol O
, O
a O
beta(1)-adrenoceptor O
antagonist O
used O
for O
the O
treatment O
of O
glaucoma O
, O
is O
known O
to O
be O
neuroprotective O
in O
paradigms O
of O
ischaemia/excitotoxicity O
. O
In O
this O
study O
, O
we O
examined O
whether O
betaxolol O
and O
other O
beta-adrenoceptor O
antagonists O
interact O
directly O
with O
neurotoxin O

bi O
nding B
to O
sites O
1 O
a O
nd O
2 O
of O
the O
voltage-sensitive O
sodium O
channel O
(Na(+) O
channel) O
in O
rat O
cerebrocortical O
synaptosomes O
. O
Betaxolol O
inhibited O
specific O
[(3)H]-batrachotoxinin-A O
20-alpha-benzoate O
([(3)H]-BTX-B) O
binding O
to O
neurotoxin O
site O
2 O
in O
a O
concentration-dependent O
manner O
with O

mitiglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O

Kir6.2 O
/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O

VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O

antofine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O
by O

antofine O
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

VIG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
O O

GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O

rasagiline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
mediated O
toxicity O
in O
a O
dopaminergic O
cell O
line O
to O
provide O
a O
model O
of O
nigral O
toxicity O
in O
order O
to O
investigate O
the O
potential O
molecular O
mechanisms O
that O
mediate O
rasagiline O
protection O
. O
We O
demonstrate O
that O
rasagiline O
protects O
against O
cell O
death O
induced O
by O
the O
combination O
of O
free O
radicals O
generated O
by O
paraquat O
and O
either O
wild-type O
or O
A53T O
mutant O
alpha-synuclein O
over-expression O
. O
This O
protection O
was O
associated O
with O
a O
reduction O
in O
caspase O
3 O
activation O
, O
a O
reduction O
in O
superoxide O
generation O
and O
a O

trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential O
. O
Rasagiline O

terazosin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
common O
feature O
in O
symptomatic O
BPH O
and O
alpha1aARs O
are O
enriched O
in O
prostatic O
tissue O
, O
drugs O
that O
demonstrate O
high O
alpha1aAR O
selectivity O
have O
attracted O
attention O
. O
Tamsulosin O
, O
which O
has O
high O
affinity O
for O
alpha1aAR O
and O
alpha1dAR O
subtypes O
but O
not O
for O
alpha1bAR O
, O
shows O
efficacy O
similar O
to O
the O
nonsubtype O
selective O
agents O
terazosin O
and O
doxazosin O
. O
It O
is O
associated O
with O
fewer O
cardiovascular O
side O
effects O
, O
although O
it O
has O
some O

ejaculatory O
side O
effects O
. O
The O
nonsubtype O
selective O
agent O
alfuzosin O
also O
demonstrates O
efficacy O
and O
offers O
an O
enhanced O
side O
effect O
profile O
, O
particularly O
minimizing O
hypotension O
. O

N-ethylmaleimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
ACS5 O
. O
ACS1 O
was O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
O O
, O
inhibited O
ACS O
activity O
47% O
in O
MAM O

28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O

Viagra O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
tissue O
by O
inhibition O
of O
PDE5 O
that O
breaks O
down O
cGMP O
, O
the O
key O
pathway O
for O
the O
production O
of O
erectile O
function O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE O
(PDE6) O
, O
which O
produces O
visual O
changes O

through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O
well O

homomazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG O
) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

5-morpholino-7H-thieno[3,2-b]pyran-7-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
stage O
PI3K O
inhibitors O
. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O
while O
simultaneously O
exhibiting O
an O
increased O
potency O
toward O
PI3K O
. O
This O
work O
resulted O
in O
the O
discovery O
of O
the O
5-morpholino-7H-thieno[3,2-b]pyran-7-one O
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K O

inhibitors O
having O
improved O
potency O
toward O
PI3K O
O O
. O
The O
synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
these O
compounds O
are O
reported O
herein O

N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O

N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
O O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase O
and O
butyrylcholinesterase O
. O

aggregation O
results O
showed O
that O
all O
compounds O
exhibited O

BSO O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(B O
O) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O

this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O

resveratrol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
O O
. O

proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O

phillyrin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O

phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

thapsigargin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
17-phenyl O
trinor O
PGE2 O
, O
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089 O
. O
Also O
consistent O
with O
the O
involvement O
of O
Gq O
coupled O
EP1 O
receptors O
, O
the O
PGE1 O
stimulation O
is O
inhibited O
by O
the O
PKCI O
vector O
(encoding O
the O
PKC O
inhibitory O
domain) O
, O
the O
PKC O
inhibitor O
Go O
6976 O
, O
thapsigargin O
O O
, O
as O
well O
as O
the O
calmodulin O
antagonists O
W7 O
and O
W13 O

clopidogrel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
CHO O
cells O
, O
as O
in O
platelets O
, O
ADP O
and O
2MeS-ADP O
induced O
adenylyl O
cyclase O
downregulation O
, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel O
. O
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" O
platelet O
receptor O
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel O
binds O
in O
a O
covalent O
manner O
to O
this O
receptor O
, O
thus O
explaining O
how O
it O
blocks O
the O

aggregating O
effect O
of O
ADP O
on O
platelets O
. O

BPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treated O
with O
low O
doses O
of O
BPA O
range O
10(-9)-10(-6)M O
during O
the O
differentiation O
process O
, O
with O
DMSO O
as O
the O
solvent O
control O
and O
17-β-estrodiol O
(E2) O
as O
the O
estrogen-positive O
control O
. O
Our O
results O
showed O
that O
low O
dose O
BPA O
and O
E2 O
could O
influence O
the O
mammosphere O
area O
of O
iDMECs O
and O
upregulate O
the O
expression O
level O
of O
Oct4 O
and O
Nanog O
proteins O
, O
while O
only O
BPA O
could O
downregulate O
the O
expression O
of O

E-cadherin O
protein O
. O
Taken O
together O
, O
this O
study O
provides O
some O
insights O
into O
the O
effects O
of O
low O
dose O
BPA O
on O
the O
early O
differentiation O

hydroxylamines O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O

pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt O
b5 O
O O
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O

Na O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Block O
of O
human O
NaV1.5 O
sodium O
channels O
by O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
phenytoin O
Voltage-gated O
sodium O
(Na) O
channels O
are O
a O
critical O
component O
of O
electrically O
excitable O
cells O
. O
Phenytoin O
(diphenylhydantoin O
, O
DPH) O
is O
an O
established O
sodium O
channel O
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O

2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
pharmacology O
at O
AMPA O
and O
kainate O
preferring O
glutamate O
receptors O
of O
4-heteroarylmethylidene O
glutamate O
analogues O
2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
(1) O
is O
a O

potent O
AMPA O
receptor O
agonist O
with O
moderate O
affinity O
for O
native O
kainic O
acid O
(KA) O
receptors O
, O
whereas O
(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
(3) O
show O
high O
affinity O
for O
the O
GluR5 O
subtype O
of O
KA O
receptors O
and O
much O
lower O
affinity O
for O
the O
GluR2 O
subtype O
of O
AMPA O
receptors O
. O
As O

COC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT O
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O

t I
arget I
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O
VMAT2 O
as O

1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O

1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1 O
-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O

DEC O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
parasitaemia O
monitored O
. O
To O
investigate O
a O
role O
for O
inducible O
nitric O
oxide O
in O
DEC's O
activity O
, O
DEC O
and O
ivermectin O
were O
administered O
to O
microfilaraemic O
iNOS-/- O
mice O
and O
their O
background O
strain O
(129/SV) O
. O
Western O
blot O
analysis O
was O
used O
to O
determine O
any O
effect O
of O
DEC O
on O
the O
production O
of O
COX O
and O
inducible O
nitric-oxide O
synthase O
(iNOS) O
proteins O
. O
RESULTS O
: O
DEC O
administered O
alone O
to O

BALB/c O
mice O
resulted O
in O
a O
rapid O
and O
profound O
reduction O
in O
circulating O
microfilariae O
within O
five O
minutes O
of O
treatment O
. O
Microfilarial O
levels O
began O
to O
recover O
after O
24 O
hours O
and O

Vinblastine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mechanisms O
. O
In O
conclusion O
, O
the O
present O
study O
addresses O
for O
th O
e B
first O
time O
a O
central O
ro O
le B
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine O
in O
melanoma O
treatmen O
n O
(Rho O
A) O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms.Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site O
, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O

organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O

gefitinib O
acts O
as O
UNDEFINED O
for O
what O
entity O
? O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O
the O
F723A O
mutation O
greatly O
enhanced O
the O
gefitinib O
sensitivity O
of O
the O
wild-type O
EGFR O
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib O
sensitivity O
. O
Taken O
together O
, O

our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O
sensitivities O
caused O
by O
distinct O
NSCLC-associated O
EGFR O
mutations O
. O

adenylosuccinate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
O O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O

jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O

voltage-gated O
calcium O
channels O
(L-VGCCs O
) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O

RAD001 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
RAD001 O
, O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR O
( O
mammalian O
target O
of O
rapamycin O
) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O

placebo-controlled O
trial O
has O
examined O

auranofin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
with O
the O
inhibitory O
effect O
of O
auranofin O
on O
the O
homodimerization O
of O
TLR4 O
induced O
by O
an O
agonist O
. O
Furthermore O
, O
auranofin O
inhibited O
NF-kappaB O
activation O
induced O
by O
MyD88-dependent O
downstream O
signaling O
components O
of O
TLR4 O
, O
MyD88 O
, O
IKKbeta O
, O
and O
p65 O
. O
IRF3 O
activation O
induced O
by O
MyD88-independent O
signaling O
components O
, O
TRIF O
and O
TBK1 O
, O
was O
also O
downregulated O
by O
auranofin O
O O
. O
Our O

first O
demonstrate O
that O
auranofin O
suppresses O
the O
multiple O
steps O
in O
TLR4 O
signaling O
, O
especially O
the O
homodimerization O
of O
TLR4 O
. O
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 O
activity O
by O
auranofin O
may O
be O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O

conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O

isoprenaline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O

beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O

pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O

double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
make O
it O
an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO O
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial O
NO O
synthase O
heme O
domain O
(eNOS(HD)) O
using O
ultrafast O
transient O
spectroscopy O
. O
NO O
rebinding O
in O
HNS O
from O
Staphylococcus O
aureus O
(SA-HNS) O
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
(BA-HNS O
) O
or O
for O
eNOS(HD) O
in O
both O
oxidized O
and O
reduced O

forms O
in O
the O
presence O
of O
arginine O
. O
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O
barriers O
for O
NO O
recombination O
, O
we O
measured O

Fluoride O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
O O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O

treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 O
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O

cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O

ADP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Neuroprotective O
role O
of O
ATP-sensitive O
potassium O
channels O
in O
cerebral O
ischemia.ATP-sensitive O
potassium O
(K(ATP)) O
channels O
are O
weak O
, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity O
, O
thus O
modulating O
many O
cellular O
functions O
. O
An O
increase O
in O
the O
ADP/ATP O
ratio O
opens O
K(ATP) O
channels O
O O
, O
leading O
to O
membrane O
hyperpolarization O
. O
K(ATP) O
channels O
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain O
, O
including O
the O

and O
cortex O
. O
Brief O
hypoxia O
triggers O
membrane O
hyperpolarization O
in O
these O
central O
neurons O
. O
In O
vivo O
animal O
studies O

DEX O
acts O
as O
AGONIST O
for O
what O
entity O
? O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
O O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O

with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O

batimastat O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
gelatinase O
A O
(MMP-2) O
by O
batimastat O
and O
captopril O
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma.We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix O
metalloproteinase O
inhibitor O
, O
batimastat O
(BB-94) O
and O
the O
angiotensin-converting O
enzyme O
inhibitor O
, O
captopril O
, O
on O
metalloproteinase O
activity O
of O
murine O
Lewis-lung-carcinoma O
cells O
(3LL) O
in O
vitro O
, O
and O
on O

local O
growth O
and O
lung O
metastasis O
of O
the O
same O
tumor O
implanted O
intramuscularly O
in O
syngeneic O
C57BL/6 O
mice O
. O
The O
effect O
of O
BB-94 O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O
airway O
IL-13 O
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O
GM-CSF O
and O
Tregs O
were O
unaffected O
by O
the O
treatment O
. O
These O
findings O
suggest O
that O

the O
protection O
provided O
by O
PGE2 O
is O
a O
result O
of O
the O
modulation O
of O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
O O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O

ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O

2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O

rosuvastatin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short O
OATP2B1 O
variant O
towards O
substrates O
estrone O
sulfate O
and O
rosuvastatin O
are O
similar O
to O
the O
well-characterized O
full O
length O
variant O
. O
Transcriptional O
activity O
screening O
of O
the O
liver O
enriched O
OATP2B1 O
variant O
promoter O
identified O
hepatocyte O
nuclear O
factor O
4 O
alpha O

(HNF4α) O
as O
a O
novel O
transacting O
factor O
. O
With O
a O
combination O
of O
in O

venlafaxine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
only O
a O
moderate O
affinity O
for O
the O

5-HT O
transporter O
(Ki O
= O
74 O
nM) O
and O
a O
very O
low O
affinity O
for O
the O
norepinephrine O
transporter O
(Ki O
= O
1.26 O
microM) O
. O
The O
relatively O
low O
affinities O
of O
venlafaxine O
contrast O
with O
its O
potent O
in O
vivo O
5-HT O
and O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors O
) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O

nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O

Gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine O
-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O

clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K O
) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O

. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O

etomidate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O

potency O
from O
alpha2B- O
and O
alpha2C-receptors O
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O

delphinidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor I
(AhR O
)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O

HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O

Mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O

with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5) O
. O
We O
further O
probed O
the O
interaction O

5HHMF O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O

oxygenase-1 O
(HO-1 O
) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O

DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat O
brain O
AChE O
after O
dichlorvos O
O O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O

BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O

vitamin O
E O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
O O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O

caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O

Amitriptyline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O

induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA O
-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O

oxygen O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
mutation O
in O
the O
FAM36A O
gene O
, O
the O
human O
ortholog O
of O
COX20 O
, O
impairs O
cytochrome O
c O
oxidase O
assembly O
and O
is O
associated O
with O
ataxia O
and O
muscle O
hypotonia.The O
mitochondrial O
respiratory O
chain O
complex O
IV O
cytochrome B
c O
oxidase) O
is O
a O
multi-subunit O
enzyme O
that O
transfers O
electrons O
from O
cytochrome O
c O
to O
molecular O
oxygen O
O O
, O
yielding O
water O
. O
Its O
biogenesis O
requires O
concerted O
expression O
of O
mitochondria- O
and O
nuclear-encoded O
subunits O
and O
assembly O
factors O

In O
this O
report O
, O
we O
describe O
a O
homozygous O
missense O
mutation O
in O
FAM36A O
from O
a O
patient O
who O
displays O

dopamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase I
(phenylalanine O
hydroxylase I
, O
EC O
1.14.16.1 O
) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O

Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O

clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Agmatine O
: O
an O
endogenous O
clonidine-displacing O
substance O
in O
the O
brain.Clonidine O
, O
an O
antihypertensive O
drug O
, O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
. O
The O
endogenous O
ligand O
for O
imidazoline O
receptors O
may O
be O
a O
clonidine O
-displacing O
substance O
, O
a O
small O
molecule O
isolated O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O

(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O

dihydropyridine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O

(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O

carbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O
probes O
that O
are O
suitable O
for O

investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

anisomycin O
acts O
as O
NOT O
for O
what O
entity O
? O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O

UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O

ornithine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
O O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O

ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O

Tomudex O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
a O
decrease O
in O
E2F-1 O
expression O
. O
These O
results O
propose O
that O
cyclin O
E-cdk2 O
kinase O
can O
negatively O
regulate O
DNA O
replication O
. O
The O
studies O
with O
dThyd O
rescue O
from O
cyclin O
E-cdk2 O
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex O
indicate O
that O
increased O
cyclin O
E-cdk2 O
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate O
synthase O
and O
resultant O
dNTP O
pool O
imbalance O
. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O

exposure O
to O
Tomudex O
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1 O
, O
but O
did O
not O
prevent O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX O
-treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O

PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
three O
decades O
, O
acetaminophen O
(INN O
, O
paracetamol) O
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O

COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O

indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor O
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O
such O
as O
anti-cholinergic O
, O
local O
anaesthetic O
, O
alpha-adrenoceptor O
antagonistic O
and O

anti-serotonin O
activity O
. O
In O
addition O
, O
H1-receptor O
antagonists O
have O
been O
shown O
to O
have O
effects O
on O
mast O
cell O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O

determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
o O
cyclooxygenase-2 B
by O
lumiracoxi O
b.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O

5HHMF O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O

Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O

the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O

[-]-Hup O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effective O
treatment O
requires O
drugs O
that O
can O
simultaneously O
protect O
by O
reversible O
binding O
to O
the O
acetylcholinesterase O
(AChE) O
and O
blocking O
cascades O
of O
seizure O
related O
brain O
damage O
, O
inflammation O
, O
neuronal O
degeneration O
as O
well O
as O
promoting O
induction O
of O
neuroregeneration O
. O
[-]-Huperzine O
A O
[-]-Hup O
A) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE O
inhibitor O
that O
penetrates O
the O
blood-brain O
barrier O
. O
It O
also O
has O

several O
neuroprotective O
effects O
including O
modification O
of O
beta-amyloid O
peptide O
, O
reduction O
of O
oxidative O
stress O
, O
anti-inflammatory O
, O
anti-apoptotic O
and O
induction O
and O
regulation O
of O
nerve O
growth O
f B
actor O
O O
. O
Toxicities O
at O
higher O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
ERK O
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models O
. O
Further O
characterization O
of O
sorafenib O
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular O
endothelial O
growth O
factor O
receptor O
family O
(VEGFR-2 O
and O
VEGFR-3 O
) O
and O
platelet-derived O
growth O
factor O
receptor O
family O
(PDGFR-beta O
and O
Kit) O
, O
which O
play O
key O
roles O
in O

tumor O
progression O
and O
angiogenesis O
. O
Thus O
, O
sorafenib O
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism O
, O

Epi O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
caveolin-1 O
(Cav1) O
, O
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
β-catenin O
to O
the O
proximal O

WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O

CpG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O

noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O

FK778 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
preclinical O
transplant O
models O
. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 O
kinases O
. O
CP-690550 O
, O
a O
JAK3 O
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials O
FK778 O
, O
is O
a O
synthetic O
malononitrilamide O
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine O
synthesis O
, O
dihydroorotic O
acid O
dehydrogenase O
, O
and O
receptor-associated O
tyrosine O
kinases O
has O
completed O
phase O
II O
trials O
. O
FK778 O
also O
shows O

antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy O
. O
Fingolimod O
(FTY720) O
, O
a O
synthetic O
sphingosine O
phosphate O
receptor O
modulator O
that O

phenylacetic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O

COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O

a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O

oxymetazoline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
known O
to O
substantially O
influence O
the O
pharmacological O
characteristics O
of O
the O
alpha(2)-adrenoceptor) O
revealed O
marked O
differences O
between O
the O
rabbit O
and O
the O
human O
alpha(2A)-adrenoceptor O
. O
The O
sympathetic O
nerves O
of O
both O
the O
human O
atrial O
appendages O
and O
rabbit O
pulmonary O
artery O
are O
endowed O
with O
alpha(2A)-autoreceptors O
, O
at O
which O
, O
however O
, O
both O
rilmenidine O
and O
oxymetazoline O
exhibit O
different O
properties O
(antagonism O
and O
agonism O
, O
respectively) O
. O
The O

antagonistic O
property O
of O
rilmenidine O
at O
human O
alpha(2A)-adrenoceptors O
indicates O
that O
in O
contrast O
to O
the O
suggestion O
based O
on O
rabbit O
data O
, O
the O
hypotensive O
property O
of O
the O
drug O
in O
humans O
is O
not O

zinc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
α-CPP O
and O
β-CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco-2 O
cells O
versus O
iron O
sulphate O
, O
β-CN(1-25)4P O
being O
the O
most O
effective O
. O
In O
relation O
to O
zinc O
bioavailability O
, O
α-CPPs O
, O
β-CPPs O
, O
α(s1)-CN(64-74)4P O
and O
β-CN(1-25)4P O
increased O
zinc O
uptake O
. O
However O
, O

this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc O
sulphate O
. O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
o O
dasatinib B
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BC O
R-ABL.PURPOSE B
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O

intolerance O
. O
In O
vitro O
and O
in O

Genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O

and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O

aurothioglucose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
(TRR) O
inhibitors O
(aurothioglucose O
and O

Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O

propranolol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors O
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O

beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs O
/cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

Vegfrecine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enzyme O
assays O
, O
but O
platele O
t-derived O
growth O
factor I
recepto I
rs O
(PDGFRs) O
, O
fibroblast O
growth O
factor O
receptor O
(FGFR) O
, O
and O
epidermal O
growth O
factor O
receptor O
(EGFR) O
responded O
only O
weakly O
. O
Compound O
1 O
is O
a O
promising O
new O
selective O
VEGFR O
inhibitor O
for O
investigating O
new O
treatments O
of O
cancer O
and O
inflammatory O
disease O
s O
Isolated O
from O
the O
Culture O
Broth O
of O
Streptomyces O
sp.A O
new O
inhibitor O

of O
VEGF O
receptor O
tyrosine O
kinases O
, O
vegfrecine O
(1) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
Streptomyces O
sp O
. O
MK931-CF8 O
. O
The O
molecular O
structure O
of O
1 O
was O
determined O
by O
NMR O
and O
MS O
analysis O

DMBT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
angiogenesis O
and O
invasion O
b O
DMBT O
is O
mediated O
by O
downregulation O
of O
VEG O
F O
and O
MMP-9 O
through O
Akt O
pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells.Invasion O
, O
either O
directly O
or O
via O
metastasis O
formation O
, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients O
, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
( O
CBS O
) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O

. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O

8-methoxymethyl-3-isobutyl-1-methylxanthine O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O

, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O

(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O

Leucyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucyl-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles O
Leucyl-tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(2A) O
receptors O
in O
schizophrenic O
patients O
treated O
with O
flupentixol O
in O
comparison O
with O
risperidone O
and O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O

schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O
with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O

gefitinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates O
. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy O
, O
and O
epidermal O
growth O
factor O
receptor O
inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies O
. O
Epidermal O
growth O
factor O
receptor O
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib O
(Iressa O
, O
ZD1839) O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O

Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O

adenine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human O
adenine O
phosphoribosyltransferase O
Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
. O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O

oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N-terminally O

N-ethylmaleimide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC O
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O

KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O

acyl-CoAs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT O
, O
and O
lower O
activity O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
. O
Kinetic O
constants O
of O
the O
mutant O
CrAT O
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O
(Gly553) O

to O
methionine O
in O
carnitine O
octanoyltransferase O
(COT) O
decreased O
activity O
toward O
its O
natural O
substrates O
, O
medium- O
and O
long-chain O
acyl-CoAs O
, O
and O
increased O
activity O
toward O
short-chain O
acyl-CoAs O
. O
Another O
CrAT O

AuF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF-induced O
MAPK O
, O
JNK O
and O
p38(MAPK O
) O
phosphorylation O
, O
in O
correlation O
with O
preventing O

caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
specific O
processing O
to O
form O
the O
mature O
two-chain O
disulfide-linked O
active O
species O
that O
is O
secreted O
by O
the O
cell O
. O
A O
major O
part O
of O
this O
processing O
requires O
endoproteolytic O
cleavage O
at O
specific O
pairs O
of O
basic O
amino O
acid O
residues O
, O
an O
event O
necessary O
for O
the O
maturation O
of O
a O
variety O
of O
important O
biologically O
active O
proteins O
, O
such O
as O
insulin O
and O
nerve O
growth O
factor O
. O
Human O
type O
2 O
preprorelaxin O
was O
coexpressed O
in O
human O
kidney O
293 O
cells O
with O
the O
candidate O
prohormone O
convertase-processing O
enzymes O
mPC1 O
or O

mPC2 O
, O
both O
cloned O
from O
the O
mouse O
pituitary O

[3H]DHA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
demonstrated O
EGFP O
expression O
. O
beta2AR O
density O
measured O
with O
[3H]dihydroalprenolol O
([3H]DHA) O
increased O
either O
13- O
or O
77-fold O
in O
infected O
cells O
compared O
to O
mock O
infected O
controls O
depending O
on O
the O
culture O
conditions O
used O
. O
The O
[3H]DHA O
binding O
was O
to O
a O
single O
receptor O
population O
with O
a O
dissociation O
constant O
of O
0.42 O
nM O
, O
as O
would O
be O
expected O
for O
wild-type O
beta2AR O
O O
. O
Agonist O
competition O

with O
[3H]DHA O
showed O
the O
following O
rank O
order O
of O
potency O
: O
isoproterenol>epinephrine> O
norepinephrine O
, O
consistent O
with O
beta2AR O
interaction O
. O
Isoproterenol-stimulated O
cyclic O
AMP O
levels O
were O
5-fold O
higher O
in O
infected O
cells O

amprenavir O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR O
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
O O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O

exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O

procyanidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O
HLA-DR O
expression O
via O
the O
ubiquitin-proteasome O
pathway O
. O
Furthermore O
, O
the O
up-regulation O
of O
IL-12 O
and O
TNF-α O
was O
found O
in O
the O
procyanidin O
trimers-treated O
cells O
in O
the O
presence O
of O
OVA O
. O
These O
results O
suggest O
that O
apple O

polyphenols O
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O

PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
O O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O

EtOH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH O
+DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O

, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O

lithium O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
O O

Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O

LY294002 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K O
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
, O
resulted O
in O
the O
only O
PI3K O
vascular-targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
, O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O
This O
inhibitor O
has O
properties O
that O
impart O

more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
i O
ts B
en O
zymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O

decitabine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
improved O
. O
gamma-Globin O
gene O
promoter O
methylation O
decreased O
, O
and O
platelets O
and O
the O
proportion O
of O
megakaryocytes O
and O
erythroid O
cells O
in O
the O
marrow O
increased O
without O
a O
decrease O
in O
marrow O
cellularity O
, O
consistent O
with O
a O
DNA O
hypomethylating O
, O
noncytotoxic O
mechanism O
of O
action O
. O
Weekly O
subcutaneous O
decitabine O
produces O
cumulative O
increases O
in O
HbF O
and O
total O
hemoglobin O
through O
a O
noncytotoxic O
mechanism O
of O
action O
. O
Chronic O
dosing O

and O
sustained O
increases O
in O
hemoglobin O
F O
and O
total O
hemoglobin O
levels O
may O
be O
possible O
. O
Further O
studies O
in O
SSD O
and O
thalassemia O
are O
indicated O
. O

Nor-NOHA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O

When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O

polyphenols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
O O
. O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O
by O
products O
of O
lipid O
peroxidation O

clopidogrel O
acts O
as O
NOT O
for O
what O
entity O
? O
active O
metabolite O
formed O
in O
the O
liver O
. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently O
. O
Several O
purinergic O
receptors O
have O
been O
described O
on O
platelets; O
P2X O
(1) O
, O
a O
calcium O
channel O
, O
and O
P2Y1 O
a O
Gq-coupled O
seven-transmembrane O
domain O
receptor O
, O
have O
been O
found O
not O
to O
be O
antagonized O
by O
clopidogrel O
O O
. O
Another O
Gi O
(2)-coupled O
receptor O
(named O
P2Y12) O
has O
been O
recently O
cloned O
and O
stably O
expressed O

CHO O
cells O
. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP O
, O
a O
stable O
analogue O
of O

diclofenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
families O
with O
benign O
familial O
neonatal O
convulsions O
, O
a O
neonatal O
form O
of O
epilepsy O
. O
Enhancement O
of O
KCNQ2/Q3 O
potassium O
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 O
channel O
openers O
. O
Extracellular O
application O
of O

meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 O
K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O

S(+) O
isomer O
of O
MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O

In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O

Gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O

(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O

BRL O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta O
1-adrenoceptor O
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta O
2-adrenoceptor O
stimulation O
, O
and O
this O
response O
was O
totally O
abolished O
by O
pretreatment O
with O
N20 O
. O
Significant O
increases O
in O
systolic O
blood O

pressure O
and O
Doppler O
stroke O
distance O
occurred O
with O
BRL O
and O
SAL O
which O
were O
unaffected O
by O
pretreatment O
with O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O

the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O

dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
TDI-sensitized O
rats O
, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced O
. O
Histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI O
provocation O
. O
Pretreatment O
with O
dexamethasone O
significantly O
suppressed O
nasal O
allergy-like O
behaviors O
, O
up-regulation O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
induced O
by O
TDI O
in O
TDI-sensitized O

rats O
. O
CONCLUSIONS O
: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine O
through O
up-regulation O
of O
HDC O
gene O
expression O
and O
HDC O
activity O
in O
nasal O
mucosa O
plays O
an O
important O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O

to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O

Pulsatilla O
saponin O
D O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
SB365 O
Pulsatilla O
saponin O
D O
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O
cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT O
/mTO O
R O
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O

formate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O

[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
O O
: O

Agmatine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O
arginine O
decarboxylase O
, O
is O
present O
in O
brain O
. O
Agmatine O
, O
locally O
synthesized O
, O
is O
an O
endogenous O
agonist O
at O
imidazoline O
receptors O
O O
, O
a O

ligand O
at O
alpha O
2-adrenergic O
receptors O
and O
may O
act O
as O
a O
neurotransmitter O
. O

L-proline O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
increase O
in O
cell O
viability O
after O
freezing O
at O
-20 O
degrees O
C O
compared O
to O
the O
viability O
of O
cells O
harboring O
the O
wild-type O
PRO1 O
gene O
. O
These O
results O
suggest O
that O
the O
altered O
gamma-glutamyl O
kinase O
results O
in O
stabilization O
of O
the O
complex O
or O
has O
an O
indirect O
effect O
on O
gamma-glutamyl O
phosphate O
reductase O
activity O
, O
which O
leads O
to O
an O
increase O
in O
L-proline O
production O
in O
Saccharomyces O
cerevisiae O
. O
The O
approach O
described O
in O
this O
paper O
could O
be O
a O
practical O
method O
for O
breeding O
novel O

freeze-tolerant O
yeast O
strains O
. O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O

DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O

paraoxon O
acts O
as O
NOT O
for O
what O
entity O
? O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon O
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O
Using O
a O
well-studied O
reference O
chemical O
, O
this O
study O
highlights O
the O
potential O
challenges O
in O
developing O
quantitative O
AOPs O
to O
support O
chemical O
screening O
and O
prioritization O
strategies O
. O

phenylalanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
thoroughly O
validated O
biophysically O
by O
isothermal O
titration O
calorimetry O
(ITC) O
and O
NMR O
techniques O
and O
observed O
by O
X-ray O
crystallography O
to O
bind O
in O
a O
shallow O
surface O
pocket O
that O
is O
occupied O
in O
the O
native O
complex O
by O
the O
side O
chain O
of O
a O
phenylalanine O
from O
the O
conserved O
FxxA O
interaction O
motif O
found O
in O
BRCA2 O
. O
This O
represents O
the O
first O
report O
of O
fragments O
or O
any O
small O
molecule O
binding O
at O
this O
protein-protein O
interaction O
site O
. O

losartan O
acts O
as O
NOT O
for O
what O
entity O
? O
50 O
mmHg O
. O
Both O
drugs O
increased O
RBF O
and O
GFR; O
however O
, O
only O
losartan O
shifted O
FENa O
and O
FEH2O O
curves O
leftward O
. O
Human O
and O
rat O
renin O
and O
angiotensinogen O
genes O
were O
downregulated O
in O
dTGR O
and O
were O
increased O
by O
losartan O
and O
cilazapril O
treatments O
, O
whereas O
no O
changes O
in O
the O
expression O
of O
rat O
ACE O
and O
AT1A O
receptor O
genes O
were O
observed O
. O
Endothelial O
NO O
synthase O
expression O
was O
increased O
by O
cilazapril O
but O
not O
by O
losartan O
. O

Neither O
inducible O
NO O
synthase O
nor O
neural O
NO O
synthase O
gene O
expression O
was O
affected O
by O
drug O
treatments O
. O
Therefore O
, O

Phe O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cells O
. O
Amino O
acid O
sequence O
analysis O
identified O
6 O
sequences O
, O
all O
of O
which O
contained O
hydrophilic O
residues O
, O
and O
5 O
of O
these O
6 O
sequences O
included O
Tyr O
, O
Phe O
and O
Leu O
conservative O
residues O
. O
CONCLUSION O
: O
The O
peptide O
sequences O
containing O
Tyr O
, O
Phe O
conservative O
residues O
identified O
in O
this O
study O
can O
bind O
to O
cell O
surface O
IL-2Ralpha O
O O

GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
butyrylcholinesterase O
(BuChE) O
in O
plasma O
and O
liver O
. O
RESULTS O
: O
Following O
administration O
of O
the O
highest O
of O
the O
GAL O
doses O
used O
(2.5; O
5; O
10 O
mg/kg O
i.m.) O
, O
AChE O
activity O
decreased O
mainly O
in O
the O
frontal O
cortex O
, O
hippocampus O
and O
hypophysis O
. O
In O
the O
interaction O
of O
GAL O
and O
CAR O
, O
AChE O
inhibition O
was O
stronger O
but O
without O
any O
statistical O
significance O
. O
The O
peripheral O
inhibition O
of O
BuChE O
was O
found O
to O

be O
dose-dependent O
. O
Premedication O
by O
CAR O
led O
to O
a O
slight O
change O
in O
the O
values O
of O
the O
activities O
monitored O
. O
CONCLUSIONS O
: O
CAR O
in O
terms O
of O

topiramate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
is O
poorly O
understood O
. O
The O
drug O
has O
been O
reported O
to O
interact O
with O
various O
ion O
channel O
types O
, O
including O
AMPA/kainate O
receptors O
. O
In O
whole-cell O
voltage-clamp O
recordings O
from O
principal O
neurons O
of O
the O
rat O
basolateral O
amygdala O
, O
topiramate O
at O
low O
concentrations O
(IC50 O
, O
approximately O
0.5 O
microm) O
selectively O
inhibited O
pharmacologically O
isolated O
excitatory O
synaptic O
currents O
mediated O
by O
kainate O
receptors O
containing O
the O
GluR5 O
subunit O
. O
Topiramate O
also O

partially O
depressed O
predominantly O
AMPA-receptor-mediated O
EPSCs O
, O
but O
with O
lower O
efficacy O
. O
Topiramate O
did O
not O
alter O
the O
degree O
of O
facil O
itation O
in O
paired- O
pulse O
experiments O
, O
and O
it O
reduced O
the O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O

analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-but O
yl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O

adrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase I
( O
phenylalanine I
hydroxylase I
O O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O

Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O

ambenonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
O O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O

benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O

Tolbutamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx O
Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel I
K(ir)6.2 O
/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O

the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O

U50,488H O
acts O
as O
NOT O
for O
what O
entity O
? O
hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H O
treatment O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
mechanisms O
underlying O
this O
process O
. O
U50 O
, O
488H O
caused O
a O
significant O
down-regulation O
of O
the O
hkor O
, O
although O
etorphine O
did O
not O
. O
Neither O
U50,488H O
nor O
etorphine O
caused O
down-regulation O
of O
the O
rat O
kappa-opioid O
receptor O
O O
. O
Thus O
, O
similar O
to O
internalization O
, O
there O
are O
agonist O
and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid O

. O
Expression O
of O
the O
dominant O
negative O
mutants O
arrestin-2(319-418) O
or O
dynami O
n O
I-K44A O
significantly O
red O
uced O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
. O
Coexpression O
of O

NDP-MSH O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
MELANOTAN O
, O
[Nle(4) O
, O
D-Phe(7)]-alpha-MSH O
, O
on O
melanin O
synthesis O
in O
humans O
with O
MC1R O
variant O
alleles.MELANOTAN O
NDP-MSH) O
binds O
the O
MC1 O
receptor O
to O
significantly O
increase O
the O
eumelanin O
content O
of O
human O
skin O
cells O
. O
In O
this O
study O
of O
77 O
Caucasian O
individuals O
, O
we O
investigated O
the O
effects O
of O
MELANOTAN O
in O
individuals O
with O
variant O
MC1R O
genotypes O
, O
as O

it O
has O
been O
suggested O
through O
in O
vitro O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
O O
, O
in O
rats O

Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O

MDA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
effect O
of O
the O
R(-) O
and O
S(+) O
isomers O
of O
3,4-methylenedioxyamphetamine O
(MDA) O
and O
its O
N-methyl O
analog O
3,4-methylenedioxymethamphetamine O
(MDMA) O
on O
[3H]inositol O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A O
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O

(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
sign O
ificant O
ly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O

dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
O O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
measured O
the O
enzyme O
activity O
of O
thymidine O
kinase O
(TK) O
, O
thymidine O
phosphorylase O
(TP) O
and O
thymidilate O
synthase O
(TS) O
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102 O
. O
Antitumor O
activity O
of O
TAS-102 O
appears O
to O
be O
associated O
with O
TK O
, O
tumor O
growth O
and O
TS O
O O
. O
However O
, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK O
and O
TP O
ratio O
. O
There O
was O
a O
significant O

(p=0.04) O
between O
tumor O
growth O
inhibition O
and O
this O
ratio O
. O
These O
results O
suggested O
that O
the O
activation O

catecholamines O
acts O
as O
NOT O
for O
what O
entity O
? O
Epididymal O
tissue O
from O
wild-type O
mice O
responded O
in O
vitro O
to O
noradrenaline O
and O
isoprenaline O
with O
increased O
glycerol O
release O
, O
reduced O
IL-6 O
release O
, O
and O
increased O
cAMP O
accumulation O
. O
Qualitatively O
similar O
but O
significantly O
attenuated O
responses O
to O
the O
catecholamines O
were O
observed O
in O
tissue O
from O
ANXA1-null O
mice O
, O
an O
effect O
that O
was O
not O
associated O
with O
changes O
in O
beta-adrenoceptor O
mRNA O
expression O
. O
Lipopolysaccharide O
(LPS) O
also O
stimulated O

lipolysis O
in O
vitro O
, O
but O
its O
effects O
were O
muted O
by O
ANXA1 O
gene O
deletion O
. O
By O
contrast O
, O
LPS O
failed O
to O
influence O
IL-6 O
release O
from O
wild-type O
tissue O
but O
stimulated O

Met O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met790 O
side O
chain O
of O
the O
G719S O
/T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O

different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 O
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O

, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating O
Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1 O
/GluN2B I
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O

gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O

vinblastine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O

the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

phenoxybenzamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
alpha O
1A-adrenoceptor O
involvement O
. O
4 O
. O
The O
potency O
of O
RS-17053 O
(pKB/pA2's O
= O
7.72-8.46) O
was O
not O
affected O
by O
lowering O
temperature O
, O
changing O
experimental O
protocol O
or O
inducing O
myogenic O
tone O
via O
KCl O
or O
U46619 O
. O
5 O
. O
Selective O
protection O
of O
a O
putative O
alpha O
1A-adrenoceptor O
population O
against O
the O
irreversible O
action O
of O
phenoxybenzamine O
also O
failed O
to O
increase O
the O
potency O
of O

RS-17053 O
(pA2 O
= O
8.25 O
+/- O
0.06 O
against O
A61603) O
. O
6 O
. O
Combined O
concentration-ratio O
analysis O
demonstrated O
that O
tamsulosin O
, O
which O
does O
not O
discriminate O
between O
alpha O
1A- O
and O
alpha O
1L-adrenoceptors O
, O
and O
RS-17053 O
competed O

arsenic O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT O
, O
Camellia O
sinensis) O
leaves O
against O
arsenic O
(NaAsO2)-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O
The O
treatment O
with O
arsenic O
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
O O
, O
total O

, O
albumin O
, O
bilirubin O
, O
cholesterol O
, O
urea O
and O
creatinine) O
. O
But O
the O
co-administration O
of O
GT O
has O
in O
creased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters O
. O
Exposure O
of O
rats O
to O
arsenic O
caused O

alcohol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
mesolimbic O
pathway O
. O
The O
view O
that O
condensation O
products O
of O
dopamine O
and O
alcohol-derived O
aldehyde O
(tetrahydroisoquinolines) O
play O
a O
role O
remains O
controversial O
. O
There O
is O
, O
however O
, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol O
on O
the O
binding O
properties O
of O
opioid O
receptors O
, O
as O
well O
as O
modulation O
of O
opioid O
peptide O
synthesis O
and O
secretion O
(e.g O
. O
a O
suggested O
increase O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O

is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine I
transporter I
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA O
) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O

(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c O
) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O

serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC O
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O

Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

HFC O
acts O
as O
NOT O
for O
what O
entity O
? O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O

UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration O
, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state O
. O
In O
addition O
, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
Nav1.5 O
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil O
block O
, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state O
. O
We O
also O
tested O
whether O
mibefradil O
interacted O
with O
slow-inactivated O

state(s) O
. O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
D2 O
receptor O
occupancy O
at O
48 O
h O
correlated O
positively O
with O
clinical O
improvement O
after O
2 O
weeks O
of O
treatment O
. O
Therefore O
, O
if O
these O
results O
are O
confirmed O
, O
D2 O
receptor O
occupancy O
at O
the O
beginning O
of O
treatment O
with O
risperidone O
may O
be O
a O
predictor O
of O
subsequent O
clinical O
respons O
e O
: O
implications O
for O
the O
timing O
and O
magnitude O
of O
clinical O
response.The O
objective O
of O
the O
study O
is O
to O
investigate O
whether O
dopamine O
D2 O
receptor O
occupancy O
by O
risperidone O
and O
plasma O
levels O
over O
time O
can O
account O
for O
therapeutic O
efficacy O
and O
the O
latency O
period O

to O
response O
cy O
at O
48 O
h O
correlated O
positively O
with O
clinical O
improvement O
after O
2 O
weeks O
of O
treatment O
. O
Therefore O
, O
if O
these O
results O
are O
confirmed O
, O
D2 O
receptor O
occupancy O
at O
the O
beginning O
of O
treatment O
with O
risperidone O
may O
be O
a O
predictor O
of O
subsequent O
clinical O
respons O
e O
: O
implications O
for O
the O
timing O
and O
magnitude O
of O
clinical O
response.The O
objective O
of O
the O
study O
is O
to O
investigate O
whether O
dopamine O
D2 O
receptor O
occupancy O
by O
risperidone O
and O
plasma O
levels O
over O
time O
can O
account O
for O
therapeutic O
efficacy O
and O
the O
latency O
period O
to O
response O
. O

indole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42 O
) O
. O
Neoechinulin O
A O

treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O

[(125)I] O
RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
O O
, O
and O
HEK-hNET O
cells O

Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O

topiramate O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Selective O
antagonism O
o O
GluR5 B
kainate-receptor-mediated O
synaptic O
currents O
by O
topiramat O
e O
in O
rat O
basolateral O
amygdala O
neurons.Topiramate O
is O
a O
widely O
used O
antiepileptic O
agent O
whose O
mechanism O
of O
action O
is O
poorly O
understood O
. O
The O
drug O
has O
been O
reported O
to O
interact O
with O
various O
ion O
channel O
types O
, O
including O
AMPA/kainate O
receptors O
. O
In O
whole-cell O
voltage-clamp O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O

NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
-treated O
cells O
. O
However O
, O
atropine O
significantly O

inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O

imatinib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O

impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O

rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O

podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
5-HT O
signal O
in O
the O
CA3 O
region O
, O
but O
prolonged O
the O
clearance O
of O
5-HT O
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine O
. O
From O
these O
data O
, O
it O
is O
inferred O
that O
both O
the O
SERT O
and O
NET O
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O

, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O

corticosteroid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin O
releasing O
hormone O
(CRH) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
an O
d B
cortisol B
were O
measured O
every O
10 O
min O
from O
healthy O

males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGF O
R/PDGF O
R O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
used O
the O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves O
a O
1 O
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser O
-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O

roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O

quinoxalines O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
represents O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmune O
disease O
. O
Small O
molecules O
that O
block O
the O
protein-protein O
interactions O
of O
human O
IgG-human O
FcRn O
may O
lower O
pathogenic O
autoantibodies O
and O
provide O
effective O
treatment O
. O
A O
novel O
class O
of O
quinoxalines O
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG O
:FcRn O
protein-protein O
interaction O
through O
optimization O
of O
a O
hit O
derived O
from O
a O
virtual O
ligand-based O
screen O
. O

phenothiazines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4 O
/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O

a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES O
) O
and O
mediates O
its O
biological O
activity O
through O

binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O

Rapamycin O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome O
Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O

catalytic O
core O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O

of O
E-selectin O
O O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O

U0126 O
acts O
as O
NOT O
for O
what O
entity O
? O
beta-catenin O
are O
independent O
targets O
for O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK O
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O

Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O

N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4 O
-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
an O
d B
ext I
ension B
, O
can O
be O
replaced O
by O
achiral O

4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O

Ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP O
-IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O

correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O

manumycin O
A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O

and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

5-FU O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzyme O
expression O
profiles O
suggest O
the O
novel O
tumor-activated O
fluoropyrimidine O
carbamate O
capecitabine O
(Xeloda) O
might O
be O
effective O
against O
papillary O
thyroid O
cancers O
of O
children O
and O
young O
adults.PURPOSE O
: O
The O
fluoropyrimidine O
carbamate O
(capecitabine) O
is O
converted O
to O
5-fluorouracil O
5-FU) O
by O
thymidine O
phosphorylase O
( O
TP O
) O
inside O
target O
tissues O
. O
5-FU O
interferes O
with O
DNA O
synthesis O

by O
blocking O
thymidylate O
synthase O
(TS) O
but O
is O
inactivated O
by O
dihydropyrimidine O
dehydrogenase O
(DPD) O
. O
Favorable O
enzyme O
profiles O
(high O
TP O
and O
low O
DPD) O
generate O
high O
intratumor O
levels O
of O
5-FU O
that O
are O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
a O
putative O
hyaluronan-binding O
motif O
, O
and O
a O
potential O
transmembrane O
domain O
near O
the O
C-terminal O
. O
Lectin O
and O
Western O
blotting O
indicate O
an O
M(r) O
around O
400,000 O
before O
and O
230,000 O
after O
chondroitinase O
ABC O
digestion O
. O
Removal O
of O
N- O
and O
O-linked O
oligosaccharides O
reduces O
the O
M(r) O
to O
approximately O
160,000 O
, O
suggesting O
that O
approximately O
60% O
of O
the O
mass O
of O
SPACRCAN O
is O
carbohydrate O
. O
Finally O
, O
we O
demonstrate O
that O
SPACRCAN O
binds O

hyaluronan O
and O
propose O
that O
associations O
between O
SPACRCAN O
and O
hyaluronan O
may O
be O
involved O
in O
organization O
of O
the O
insoluble O
interphotoreceptor O
matrix O
, O
particularly O
as O
SPACRCAN O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O

well O
as O
the O
calmodulin O
-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O

V(5+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

berberine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Z'-factor O
. O
Additionally O
, O
different O
extracts O
of O
Rhizoma O
Coptis O
and O
berberine O
were O
tested O
by O
the O
developed O
method O
. O
The O
results O
suggested O
that O
both O
the O
EtOAc O
extract O
and O
berberine O
were O
able O
to O
activate O
PPARα/β/γ O
, O
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs O
besides O
berberine O
O O
. O
In O
conclusion O
, O
the O
developed O
HTS O
assay O
is O
a O
simple O
, O
rapid O
, O
stable O
, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs O
natural O
agonists O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
O O
, O
while O
the O

of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O

(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AMPA O
and O
kainate O
preferring O
glutamate O
receptors O
of O
4-heteroarylmethylidene O
glutamate O
analogues.2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
(1) O
is O
a O
potent O
AMPA O
receptor O
agonist O
with O
moderate O
affinity O
for O
native O

kainic O
acid O
(KA) O
receptors O
, O
whereas O
(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
(3) O
show O
high O
affinity O
for O
the O
GluR5 O
subtype O
of O
KA O
receptors O
and O
much O
lower O
affinity O
for O
the O
GluR2 O
subtype O
of O
AMPA O
receptors O
O O
. O
As O
an O
attempt O
to O
deve B
lop O
new O
pharmac O
ological O
tools O
for O
studies O
of O
GluR5 O
receptors O
, O
(S)-E-4-(2-thiazolylmethylene)glutamic O
acid O
(4a) O
was O
designed O
as O
a O

hybrid O
between O
1 O
and O
3 O
. O
4a O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
Sitagliptin O
, O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4 O
) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O

excursion O
. O
In O
large O
, O
well O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR O
tyrosine O
kinase O
inhibitors O
sunitinib O
and/or O
sorafenib O
O O
. O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O

progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl-tRNA O
synthetase O
(MetRS) O
that O
charges O
the O
Met O
surrogate O
azidonorleucine O
(Anl) O
to O
tRNA(Met) O
. O
Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N- O
and O
C-terminal O
fragments O
of O
the O
bisected O
MetRS O
O O
. O
Anl-labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper-catalyzed O
or O

azide-alkyne O
cycloaddition O
. O
Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl O
to O
bacterial O
cells O
in O
which O
the O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O

determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O
transcriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE O
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O

manage O
inflammatory O
diseases O
. O

cortisone O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Longer O
HSD11B2 O
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes O
Type O
2 O
11β-hydroxysteroid O
dehydrogenase O
encoded O
by O
the O
HSD11B2 O
gene O
converts O
cortisol O
to O
inactive O
cortisone O
O O
, O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O

variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
(Cys226 O
, O
Cys270) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 O
O O
. O
Such O
model O
of O
Nox4 O
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O

molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O

dexamethasone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
regulatory O
mechanism O
of O
histamine O
synthesis O
by O
HDC O
remains O
to O
be O
elucidated O
. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine O
content O
, O
HDC O
activity O
and O
HDC O
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O
by O
the O
exposure O
to O
toluene O
diisocyanate O
(TDI) O
and O
to O
investigate O
the O
effect O
of O
dexamethasone O
on O
the O
above O
mentioned O
allergic O
parameters O
. O
METHODS O
: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI O

and O
the O
nasal O
allergy-like O
behaviors O
were O
scor O
ed I
d I
uring O
a O
10 O
minute O

prostaglandins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Involvement O
o O
EP1 B
and O
EP2 O
receptors O
in O
the O
regulation O
of O
the O
Na,K-ATPase O
by O
prostaglandin O
s O
in O
MDCK O
cells.Prostaglandins O
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney O
. O
In O
MDCK O
cells O
, O
which O
model O
distal O
tubule O
cells O
, O
the O
transcription O
of O
the O
Na,K-ATPase O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O

JTH-601 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
order O
in O
rat O
SMA O
was O
: O
A61603 O
>> O
SKF89748-A O
> O
cirazoline O
> O
noradrenaline O
> O
ST-587 O
> O
methoxamine O
. O
Prazosin O
antagonized O
all O
agonists O
with O
a O
low O
potency O
(pA2 O
: O
8.29-8.80) O
indicating O
the O
involvement O
of O
alpha O
1L-rather O
than O
alpha O
1A-adrenoceptors O
. O
3 O
. O
The O
putative O
alpha O
1L-adrenoceptor O
antagonist O
JTH-601 O
O O
, O
but O
not O
the O

1B-adrenoceptor O
antagonist O
chloroethylclonidine O
(10 O
microM) O
antagonized O
noradrenaline-induced O
contractions O
of O
SMA O
. O
The O
potency O
of O
the O
selective O
alpha O
1D-adrenoceptor O
antagonist O
BMY O
7378 O
against O
noradrenaline O
(pA2 O
= O
6.16 O
+/- O
0.13) O
and O
of O
the O
selective O
alpha O
1A-adrenoceptor O

mimosine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
MIP-2 O
, O
a O
C-X-C O
chemokine O
and O
MCP-1 O
, O
a O
C-C O
chemokine O
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst O
. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response O
. O
MCP-1 O
and O
MIP-2 O
was O
tested O
after O
1 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
days O
post O
inoculation O
, O
before O
and O
after O
mimosine O
treatment O
. O
The O
inflammatory O
index O
was O
calculated O
by O

counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts O
, O
while O
expression O
of O
MIP-2 O
and O
MCP-1 O
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
agains O
t O
SR O
C O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O

imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O

5HHMF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O

in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
O O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O

LY O
344864 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
effects O
of O
sumatriptan O
with O
those O
of O
a O
selective O
5-HT1F O
receptor O
agonist O
(LY O
344864) O
on O
c-fos O
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis O
. O
c-fos O
expression O
was O
induced O
in O
urethane-anaesthetized O
rats O
by O
intracisternal O
capsaicin O
administration O
. O
Sumatriptan O
and O
LY O
344864 O
decreased O
the O
number O
of O
capsaicin-induced O
c-fos O
-like O
immunoreactive O
cells O
within O
trigeminal O

nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O

MPEP O
acts O
as O
PART-OF O
for O
what O
entity O
? O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 O

PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O

microtubule-associated O
protein O
2 O
O O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O
gene O
expression O
are O
likely O
responsible O
for O
the O
inhibitory O
effects O
of O

V(5+) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
O O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O

levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O

loperamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH O
secretion O
was O
significantly O
lower O
after O
loperamide O
. O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH O
on O
ACTH O
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O

interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O
mechanisms O
, O

cDDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
malignancies O
including O
testicular O
, O
ovarian O
, O
cervical O
, O
bladder O
, O
lung O
, O
head O
, O
and O
neck O
cancers O
. O
Its O
use O
is O
limited O
by O
the O
development O
of O
resistance O
, O
often O
rationalized O
via O
effects O
on O
cellular O
uptake O
. O
It O
has O
been O
claimed O
that O
hCTR1 O
, O
the O
human O
high O
affinity O
copper O
transporter O
, O
is O
the O
major O
entry O
pathway O
for O
cDDP O
and O
related O
drugs O
via O
a O
mechanism O
that O
mimics O
copper O
. O
This O
is O
an O
unexpected O
prop I
erty B
o O
f O
hCTR1 O
, O
a O
highly O
selective O
copper O
(I) O

transporter O
. O
We O
compared O
the O
uptake O
rates O
of O
copper O
with O
cDDP O
(and O
several O

PMA O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O
surface O
plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O
by O
PMA O
O O
. O
The O
novel O
pattern O
of O
behavior O
of O
I3A O
makes O
it O
of O
great O
interest O
for O
further O
evaluation O

NH(2) O
acts O
as O
PART-OF O
for O
what O
entity O
? O
to O
cell O
death O
. O
The O
MB-like O
aggregates O
were O
deposited O
around O
centrosomes O
and O
disrupted O
the O
microtubular O
array O
. O
Coexpression O
of O
K8 O
with O
K18 O
restored O
the O
normal O
fibrous O
pattern O
of O
keratin O
distribution O
and O
reduced O
the O
toxicity O
of O
K18 O
. O
In O
contrast O
, O
an O
NH(2)-terminal O
deletion O
mutant O
of O
K8 O
promoted O
the O
formation O
of O
intracellular O
aggregates O
even O
in O
the O
absence O
of O
K18 O
overexpression O
. O
Deregulated O
expression O
of O
K18 O
, O
or O
an O
imbalance O
between O
K8 O
and O
K18 O

, O
may O
thus O
be O
an O
important O
determinant O
of O
MB O
formation O
, O
which O
compromises O
the O
function O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15 O
) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O

Nor-NOHA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O

release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O

antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His O
34) O
, O
h2 O
(Cys59-Asp71) O

, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O

DHT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O

methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O

mesalamine O
acts O
as O
NOT O
for O
what O
entity O
? O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction) O
. O
At O
a O
dose O
of O
100 O
mg/kg O
, O
ATB-429 O
reversed O
the O
allodynic O
response O
caused O
by O
CRD O
in O
postcolitic O
rats O
. O
Colonic O
cyclooxygenase-2 O
and O
interkeukin-1beta O
mRNA O
and O
spinal O
c-FOS O
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429 O
, O
but O
not O
by O
mesalamine O
O O
. O
ATB-429 O
, O
but O

mesalamine O
, O
increased O
blood O
concentrations O
of O
H(2)S O
in O
both O
healthy O
and O
postcolitic O
rats O
. O
Taken O
together O
, O
these O
data O
suggest O
that O
ATB-429 O
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O

cycloheximide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
5-HT1A-selective O
agonist O
, O
8-hydroxy-2-(di-n-propylamino)tetralin O
, O
was O
inactive O
. O
The O
memory-improving O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
was O
potentiated O
by O
a O
selective O
5-HT2 O
antagonist O
, O
ritanserin O
. O
These O
results O
suggest O
that O
the O
beneficial O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
may O
be O
related O
not O
only O
to O

cholinergic O
but O
also O
serotonergic O
neuronal O
systems O
(5-HT2 O
receptors O
) O
. O

flecainide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O
patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ O
I(Na) O
was O
more O
sensitive O
to O
flecainide O
, O
and O
flecainide O
preferentially O
inhibited O
late O
I(Na) O

(mean O
current O
between O
20 O
and O
23.5 O
ms O
after O
depolarization) O
compared O
with O
peak O
I(Na) O
. O
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) O
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O
+/- O
2 O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
O O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O

, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O

candoxatril O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
acute O
and O
chronic O
(10 O
days O
treatment) O
hemodynamic O
and O
hormonal O
effects O
of O
candoxatril O
(150 O
mg O
twice O
daily) O
in O
12 O
patients O
with O
moderately O
severe O
congestive O
heart O
failure O
were O
investigated O
in O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
study O
. O
On O
study O
day O
1 O
, O
candoxatril O
acutely O
increased O
plasma O
ANP O
levels O
, O
suppressed O
aldosterone O
and O
decreased O
right O
atrial O
and O
pulmonary O
capillary O
wedge O
pressures O
. O
After O
10 O
days O
of O
treatment O
, O
basal O

ANP O
was O
increased O
and O
basal O
aldosterone O
was O
decreased O
. O
Body O
weight O
was O
reduced O
, O
most O
likely O
refl O
ecti B
ng O
chronic O
natriuretic O
or O
diuretic O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatas O
-Sulfatas O
e O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamat O

e.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O

DRF O
2655 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
DRF O
2655 O
: O
a O
unique O
molecule O
that O
reduces O
body O
weight O
and O
ameliorates O
metabolic O
abnormalities.OBJECTIVE O
: O
Preclinical O
evaluation O
of O
DRF O
2655 O
, O
a O
peroxisome O
proliferator-activated O
receptor O
alpha O
(PPARalpha) O
and O
PPARgamma O
agonist O
, O
as O
a O
body-weight O
lowering O
, O
hypolipidemic O
and O
euglycemic O
agent O
. O
RESEARCH O
METHODS O
AND O
PROCEDURES O
: O
DRF O
2655 O
was O
studied O
in O
different O
genetic O
, O
normal O
, O

and O
hyperlipidemic O
animal O
models O
. O
HEK O
293 O
cells O
were O
used O
to O
conduct O
the O

cucurbitacin O
I O
acts O
as O
NOT O
for O
what O
entity O
? O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2 O
-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O

and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O

Crocin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O

cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O

aspartate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase O
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O

now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA O

(+)- O
and O
(-)- O
tamsulosin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
O O
. O
RS O
17053 O
showed O

affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O

VK2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c O
) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O

an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O

desoxypeganine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O

=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine O
>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O

TT-B O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
TT-B O
and O
anti-epidermal O
growth O
factor O
receptor O
(anti-EGFR) O
were O
antagonistic O
to O
each O
other O
in O
inhibiting O
the O
cell O
cycle O
progression O
of O
SC-6 O
from O
G0/G1 O
to O
S O
, O
suggesting O
that O
the O
two O
compounds O
share O
the O
same O
target O
, O
EGFR O
. O
The O
kinase O
activity O
of O
EGFR O
was O
little O
inhibited O
by O
TT-B O
in O
a O
cell-free O
system O
. O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
O O
. O
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase O

phenolic O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
COX-2 O
, O
supported O
by O
inhibition O
of O
paw O
edema O
and O
vascular O
permeability O
. O
Docking O
studies O
were O
also O
carried O
out O
to O
determine O
the O
structural O
features O
which O
sway O
the O
anti-inflammatory O
activity O
of O
the O
tested O
compounds O
. O
The O
keto O
and O
phenolic O
-OH O
are O
major O
factors O
that O
are O
prominently O
involved O
in O
interaction O
with O
COX-2 O
active O
site O
. O

Kynurenic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Tissue O
expression O
and O
translational O
control O
of O
rat O
kynurenine O
aminotransferase/glutamine O
transaminase O
K O
mRNAs O
Kynurenic O
acid O
(KA) O
is O
an O
endogenous O
glutamate O
receptor O
antagonist O
at O
the O
level O
of O
the O
different O
ionotropic O
glutamate O
receptors O
. O
One O
of O
the O
enzymes O
responsible O
for O
the O
production O
of O
KA O
, O
kynurenine O
aminotransferase O
I O
(KATI) O
, O
also O
catalyses O
the O
reversible O
transamination O
of O
glutamine O
to O

oxoglutaramic O
acid O
(GTK O
, O
EC O

SoRI-20041 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O

("DAT-mediated O
DA O
release") O
in O
a O
dose-dependent O
manner O
. O
SoRI-20041 O
, O
which O
does O
not O
alter O
DAT O
-mediated O
DA O
release O
measured O
with O
[(3)H]DA O
, O
reversed O
the O
effect O
of O
SoRI-20040 O
. O
SoRI-20040 O
and O
SoRI-9804 O
also O
partially O
inhibited O
DAT-mediated O
DA O
release O
induced O
by O
DA O
or O
(+/-)-3,4-methylenedioxyamphetamine O
, O
demonstrating O
that O
the O
observed O
partial O
inhibition O
is O
not O
specific O
for O
a O
particular O

Pelargonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activit O
1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O

HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O

erythro-9-(2-hydroxy-3-nonyl)adenine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O

, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
O O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O

[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
o O
β-ionone B
in O
SGC-7901 B
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3 O
K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O

7KC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
O O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O

caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O

[3H]-quinuclinidyl O
benzilate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O

benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremor O
ine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O

batimastat O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
gelatinase O
A O
(MMP- O
2) O
by O
batimasta O
t O
and O
captopril O
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma.We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix O
metalloproteinase O
inhibitor O
, O
batimastat O
(BB-94) O
and O
the O
angiotensin-converting O
enzyme O
inhibitor O
, O
captopril O
, O
on O
metalloproteinase O
activity O
of O
murine O

Neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Regulation O
of O
these O
sign O
alling B
pat B
hways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O
further O
studies O
neoechinulin O
A O
have O
a O
potential O
to O
be O
developed O
as O
a O
modulator O
of O
neuroinflammatory O
process O
in O
A O
β O
oligomer-induced O
microglia O
activation O
and O
thereby O
protects O
PC-12 O
cells O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O

aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O

N(5) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
N5-substituted O
tetrahydrobiopterin O
derivatives O
on O
phenylalanine O
hydroxylase O
, O
dihydropteridine O
reductase O
and O
nitric O
oxide O
synthase.Tetrahydrobiopterin O
[(6R)-5,6,7,8-tetrahydro-L-biopterin O
, O
H(4)biopterin] O
is O
one O
of O
several O
cofactors O
of O
nitric O
oxide O
synthases O
(EC O
1.14.13.39) O
. O
Here O
we O

compared O
the O
action O
of O
N(5)-substituted O
derivatives O
on O
recombinant O
rat O
neuronal O
nitric O
oxide O
synthase O
with O
their O
effects O
on O
dihydropteridine O
re O
ductase B
(EC O
1.6.99.7) O
and O
p O
henylalanine B
hydroxylase O
(EC O
1.14.16.1),the O
well-studied O
classical O
H(4)biopterin-dependent O
reactions O
. O
H(4)biopterin O
substituted O
at O
N(5) O
with O
methyl O
, O
hydroxymethyl O
, O
formyl O
and O
acetyl O
groups O
were O
used O
. O
Substitution O
at O

N(5) O
occurs O
at O
a O
position O
critical O

Tomudex O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(ZD1694) O
is O
a O
specific O
antifolate-based O
thymidylate O
synthase O
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies O
. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate O
synthase O
by O
Tomudex O
O O
. O
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex O
, O
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells O
, O
not O
expressing O

and O
p2 O
1(WAF1) O
, O
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O
S O
phase O
of O
the O
cell O
cycle O
with O

DZN O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax O
Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
O O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O

of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O

human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O

monomethylarsonate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
it O
adopts O
the O
canonical O
GST O
fold O
. O
A O
cysteine O
residue O
in O
place O
of O
the O
catalytic O
tyrosine O
or O
serine O
residues O
found O
in O
other O
GSTs O
was O
shown O
to O
form O
a O
mixed O
disulfide O
with O
glutathione O
. O
Omega O
class O
GSTs O
have O
dehydroascorbate O
reductase O
and O
thioltransferase O
activities O
and O
also O
catalyze O
the O
reduction O
of O
monomethylarsonate O
O O
, O
an O
intermediate O
in O
the O
pathway O
of O
arsenic O
biotransformation O

Other O
diverse O
actions O
of O
human O
GSTO1-1 O
include O
modulation O
of O
ryanodine O
receptors O
and O
interaction O
with O
cytokine O
release O
inhibitory O
drugs O
. O
In O
addition O
, O
GSTO1 O
has O
been O

Felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA O
receptors O
compose O
d O
of B
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivit O
B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O

NMDA O
receptor O
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O
subtype O
selectivity O
, O
we O
examined O

choline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
choline O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase O
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expre O
ssed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met O
and O

choline O
O O
. O
BHMT O
is O
also O
found O
in O
rat O
kidney O
, O
albeit O
in O
substantially O
lower O
amounts O
, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT O
expression O
is O
regulated O
by O
dietary O
Met O
or O
choline O
. O
Similarly O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
O O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O

its O
complexes O
with O
the O
inh O
ibitors B
. O
In O
addition O
, O
th O
e B
molecular O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues O
Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O

a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O

Prexige O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
No O
influence O
of O
moderate O
hepatic O
impairment O
on O
the O
pharmacokinetics O
of O
lumiracoxib O
, O
an O
oral O
COX-2 O
selective O
inhibitor.The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
hepatic O
impairment O
on O
the O
pharmacokinetics O
(PK) O
of O
the O
novel O
cyclooxygenase-2 O
COX-2) O
selective O
inhibitor O
lumiracoxib O
(Prexige O
) O
, O
so O
that O
dose O
recommendations O
for O
clinical O
use O
can O
be O
provided O
. O
This O
was O
an O
open-label O

, O
single O
dose O
, O
case-controlled O
study O
in O
which O
eight O
subjects O
with O
liver O
cirrhosis O
classed O
as O
moderate O
hepatic O
impairment O
(Child-Pugh O
score O
: O
7-9) O
and O
eight O
demographically-matched O

phosphatidylinositol-4,5-bisphosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O

that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O

SB365 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
togeth O
er O
wi I
th O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cance O
R O
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O

from O
the O
root O
of O
P O
. O
koreana O
inhibits O
the O
progression O

carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
upregulated O
and O
nerve O
growth O
factor-beta O
(NGF-beta) O
downregulated O
in O
the O
shunt O
group O
. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
increased O
and O
mRNA O
of O
NGF-beta O
decreased O
in O
the O
shunt O
group O
. O
Treatment O
with O
carvedilol O
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
O O
, O
BNP O
, O
and O
NGF-beta O
to O
the O
baseline O
values O

Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol O
again O
normalized O
the O
labeling O
. O
CONCLUSION O
: O
HIF-1alpha O
and O

leucyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
o O
leucyl-tRNA B
synthetas O
e O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles.Leucyl-tRNA O
synthetase O
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O

tryptophan O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ligand O
precursors O
and O
type O
II O
GnRH O
receptor O
genes O
are O
functionally O
inactivated.The O
decapeptide O
sequence O
of O
GnRH-II O
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date O
. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II O
decapeptide O
possessing O
arginine O
(codon O
: O
CGG) O
rath O
er I
than I
tryptophan O
(TGG) O
at O
position O
three O
in O
the O
mature O
peptide O
. O
This O
substitution O
is O
unique O
. O

We O
confirmed O
the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine O
prepro-GnRH-II O
gene O
. O
Bovine O
GnRH-II O
peptide O
was O
synthesized O
and O
pharmacologically O
characterized O
. O
It O
did O

glucuronic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP O
glucuronic O
acid O
than O
the O
other O
UGTs O
O O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O

microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O

loperamide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
to O
nanoparticles O
made O
of O
human O
serum O
albumin O
(HSA-NP) O
. O
Loperamide O
, O
which O
does O
not O
cross O
the O
blood-brain O
barrier O
but O
exerts O
antinociceptive O
effects O
after O
direct O
injection O
into O
the O
brain O
, O
was O
used O
as O
model O
drug O
. O
Apolipoprotein O
E O
was O
chemically O
bound O
via O
linkers O
to O
loperamide-loaded O
HSA O
-NP O
. O
This O
preparation O
induced O
antinociceptive O
effects O
in O
the O
tail-flick O
test O
in O
ICR O
mice O
after O
i.v O
. O
injection O
. O
In O
contrast O
, O
nanoparticles O
linked O

to O
apolipoprotein O
E O
variants O
that O
do O
not O
recognize O
lipoprotein O
receptors O
failed O
to O
induce O
these O
effects O
. O
These O
results O
indicate O
that O

ANE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O

steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O

clarithromycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 O
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O

humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O

guggulsterone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
O O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O

ibuprofen-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O

, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O

(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
O O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O

not O
inhibit O
either O

4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O

(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
] O
, O
100 O
microM) O
, O
PDE5 O

and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O

CysLTs O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O

antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O

cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O

mifepristone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vitro O
antiprogestational/antiglucocorticoid O
activity O
and O
progestin O
an O
glucocorticoid B
receptor O
binding O
of O
the O
putative O
metabolites O
and O
synthetic O
derivatives O
of O
CDB-2914 O
, O
CDB-4124 O
, O
and O
mifepriston O
e.In O
determining O
the O
biological O
profiles O
of O
various O
antiprogestins O
, O
it O
is O
important O
to O
assess O
the O
hormonal O
and O
antihormonal O
activity O
, O
selectivity O
, O
and O
potency O
of O
their O
proximal O
metabolites O
. O

The O
early O
metabolism O
of O
mifepristone O
is O
characterized O

bromfenac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran O
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated O
rabbits O
, O
and O
a O
22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated O
rabbits O
. O
CONCLUSIONS O
: O
Ketorolac O
is O
relatively O
COX-1 O
selective O
while O
bromfenac O
is O
potently O
selective O
for O
COX-2 O
over O
COX-1 O
O O

In O
the O
animal O
model O
, O
both O
ketorolac O
0.4% O
and O
bromfenac O
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes O
. O
Only O
bromfenac O
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye O
, O
suggesting O
possible O
systemic O
absorption O
of O
this O
drug O
. O

sodium O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
aspirin.The O
transcription O
factor O
nuclear O
factor-kappa O
B O
(NF-kappa O
B) O
is O
critical O
for O
the O
inducible O
expression O
of O
multiple O
cellular O
and O
viral O
genes O
involved O
in O
inflammation O
and O
infection O
including O
interleukin-1 O
(IL-1) O
, O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
O O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O

of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O

temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O

Sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
(Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE O
(PDE6 O
) O
, O
which O
produces O
visual O
changes O
through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O
well O
documented O
in O
the O
majority O
of O
men O
with O
ED O

irrespective O
of O
aetiology O
. O
The O
aetiology O
of O
ED O
, O
also O
, O
does O

Sodium O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B O
-dependent O
transcription O
from O
the O
Ig O
kappa O
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O

T O
cells O
. O

Wogonoside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O

signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O

but O
none O
in O
SR O

glyburide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
O O
, O
and O
SR-BI-mediated O
lipid O

is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O

Ifenprodil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance O
. O
Ifenprodil O
, O
known O
as O
the O
GluNR2B O
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O
We O
had O
previously O
reported O
a O
fluorescein O
conjugate O
that O
was O
shown O
(by O

confocal O
microscopy O
imaging O
of O
DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
Gl O
uN2B O
. O
To O

DMA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive O
electrodes O
. O
5-(N,N-dimethyl)-amiloride O
(50 O
microM; O
DMA) O
, O
a O
concentration O
that O
selectively O
inhibits O
the O
NHE O
isoforms O
NHE1 O
and O
NHE2 O
, O
but O
not O
NHE3 O
, O
did O
not O
affect O
DBS O
. O
Nevertheless O
, O
3 O
mM O
DMA O
, O
a O
higher O
concentration O
that O
inhibits O
NHE1 O
, O
NHE2 O
, O
and O
NHE3 O
O O
, O
significantly O
increased O
DBS O
. O
Moreover O

S1611 O
and O
S3226 O
, O
both O
specific O
inhibitors O
of O
NHE3 O
only O
, O
or O
perfusion O
with O
Na+-free O
solutions O
, O
dose O
dependently O
increased O
DBS O
, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive O
electrode O
, O
without O
affec O
ting O
intracellular O
pH O
. O
Coperfusion O

NTG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
genes O
is O
hypoxia-inducible O
factor O
1 O
(HIF-1) O
. O
Nitric O
oxide O
(NO) O
mediates O
a O
variety O
of O
biological O
effects O
including O
relaxation O
of O
blood O
vessels O
and O
cytotoxicity O
of O
activated O
macrophages O
. O
We O
investigated O
the O
effect O
of O
the O
clinically O
used O
nitrates O
nitroglycerin O
NTG) O
, O
isosorbide O
dinitrate O
(ISDN) O
, O
and O
sodium O
nitroprusside O
(SNP) O
on O
HIF-1 O
-mediated O
transcriptional O
responses O
to O
hypoxia O
. O
We O
demonstrate O
that O
among O

the O
three O
nitrates O
, O
only O
SNP O
inhibits O
HIF-1 O
activation O
in O
response O
to O
hypoxia O
. O
In O
contrast O
, O
NTG O
or O
ISDN O
does O
not O
affect O
HIF-1 O
activity O
. O
SNP O
inhibits O
the O
accumulation O

fenoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Relative O
myotoxic O
and O
haemodynamic O
effects O
of O
the O
beta-agonists O
fenoterol O
and O
clenbuterol O
measured O
in O
conscious O
unrestrained O
rats.The O
beta(2)-adrenoceptor O
(beta(2)-AR) O
agonists O
clenbuterol O
and O
fenoterol O
have O
similar O
beneficial O
effects O
in O
animal O
models O
of O
heart O
failure O
. O
However O
, O
large O
doses O
of O
clenbuterol O
can O
induce O
cardiomyocyte O
death O
, O
and O
it O
is O
not O
known O
which O
of O
these O
agents O
has O

the O
most O
favourable O
therapeutic O
profile O
. O
We O
have O
investigated O

rapamycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
showed O
that O
rapamycin O
shares O
all O
the O
proteasome O
targeting O
properties O
not O
only O
with O
other O
two-domain O
, O
closed-ring O
analogs O
(rapalogs) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco-rapamycin O
. O
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin O
that O
does O
not O
affect O
mTOR O
O O
. O
We O
hypothesize O
that O
the O
rapamycin O
and O
related O
compounds O
bind O
to O
the O
α O
face O
and O
allosterically O
impact O
the O
proteasome O
function O
. O
The O

of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin O
and O
for O
design O
of O

Thiazolidinediones O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells O
Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin O
-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O

vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O

5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O

5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O

(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O

arachidonic O
acid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
O O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O

a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

etomidate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
from O
alpha2B- O
and O
alpha2C-receptors O
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors O

O O
, O
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated O
increase O
in O
blood O
pressure O
. O
This O
effect O
of O
etomidate O
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate O

risperidone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O

evaluated O
and O
compared O
to O
that O
of O
al O
pha B
1-adrenoceptor O
su O
btype-discriminating B
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O

MXF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo O
II O
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O

inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
platelet O
function O
was O
not O
achieved O
. O
Our O
data O
may O
explain O
acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O
gastrointestinal O
safety O
profile O
compared O
with O
NSAIDs O
. O
In O
view O
of O
its O
substantial O
COX-2 O
inhibition O
, O
recently O
defined O
cardiovascular O
warnings O
for O
use O
of O
COX-2 O
inhibitors O
should O
also O
be O
considered O
for O
acetaminophen O
O O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
o O
nitric-oxide B
synthas O
e O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O

, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH O
) O
, O

superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O

amiloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
tear O
fluid O
was O
strongly O
inhibited O
. O
Corneas O
were O
covered O
with O
a O
continuous O
epithelium O
until O
the O
end O
of O
the O
experiment O
. O
The O
number O
of O
inflammatory O
cells O
was O
significantly O
decreased O
. O
Corneal O
vascularization O
was O
reduced O
by O
50% O
. O
In O
conclusion O
, O
early O
application O
of O
amiloride O
inhibited O
u-PA O
activity O
in O
UVB-irradiated O
corneas O
as O
well O
as O
in O
tear O
fluid O
and O
diminished O
the O
development O
of O
corneal O
pathology O
. O

indoramin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O

, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
O O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperido O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O

carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
B O
, O
c-ju O
n O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O

(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
O O

L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O

NaF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK O
-dependent O
mitochondrial O
pathway O
. O

minocycline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O
Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O
MMP-9 O
activity O
at O
5 O
mg/kg/day O
(P<0.001) O
, O
while O
minocycline O
had O
an O

effect O
at O
a O
lower O
dose O
, O
1 O
mg/kg/day O
(P<0.02) O
. O
The O
inhibition O
of O
cerebral O
MMP-9 O
mRNA O
and O
activity O
were O
highly O
correlated O
with O
drug O
levels O
in O
the O
brain O
tissue O
. O
We O
also O
assessed O
the O
potential O
relevant O
signaling O
pathway O

mexiletine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
A O
novel O
SCN5A O
arrhythmia O
mutation O
M1766L O
O O
, O
with O
expression O
defect O
rescued O
by O
mexiletin O
e.OBJECTIVE O
: O
Mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
, O
SCN5A O
, O
cause O
congenital O
long O
QT O
syndrome O
(LQT3) O
, O
Brugada O
syndrome O
, O
idiopathic O
ventricular O
fibrillation O
, O
and O
conduction O
disease O
by O
distinct O
cellular O
and O
clinical O
electrophysiological O
phenotypes O

METHODS O
: O
Postmortem O
molecular O
analysis O
of O
SCN5A O

Xyzal O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Compared O
pharmacological O
characteristics O
in O
humans O
of O
racemic O
cetirizine O
and O
levocetirizine O
, O
two O
histamine O
H1-receptor O
antagonists.The O
potent O
histamine O
H(1)-receptor O
antagonist O
cetirizine O
(Zyrtec) O
is O
a O
racemic O
mixture O
of O
levocetirizine O
(now O
available O
under O
the O
trademark O
Xyzal O
and O
dextrocetirizine O
. O
In O
this O
Commentary O
, O
we O
examine O
some O
biological O
properties O
of O
cetirizine O
and O
levocetirizine O
, O
namely O

enantioselectivity O
in O
pharmacological O
activity O
and O
pharmacokinetic O
properties O
, O
with O
emphasis O
on O
the O
possibility O
of O
racemization O
, O
the O
compared O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
suppress O
DA O
uptake O
in O
the O
DAT O
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O

efflux O
in O
these O
cells O
. O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
O O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O

55,940 O
binding O
in O
both O
mutants O
. O
The O

Doxycycline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
effect O
of O
tetracyclines O
on O
cerebral O
matrix O
metalloproteinase-9 O
after O
vascular O
endothelial O
growth O
factor O
hyperstimulation.Brain O
arteriovenous O
malformations O
(BAVMs) O
are O
a O
potentially O
life-threatening O
disorder O
. O
Matrix O
metalloproteinase O
(MMP)-9 O
activity O
was O
greatly O
increased O
in O
BAVM O
tissue O
specimens O
. O
Doxycycline O
was O
shown O
to O
decrease O
cerebral O
MMP-9 O
activities O
and O
angiogenesis O
induced O
by O
vascular O
endo O
thelial B
growth O
factor O

(VEGF) O
. O
In O
th O
e B
present O
study O
, O
we O
determined O
the O
dose-response O
effects O
of O
doxycycline O
and O
minocycline O
on O
cerebral O
MMP-9 O
using O
our O
mouse O
model O
with O
VEGF O
focal O
hyperstimulation O
delivered O
with O
adenoviral O
vector O
(AdVEGF) O
in O
the O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O

(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazi O
de O
were O
inhibited O
by O
thapsigargin O
or O

1,3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O

inhibitor O
(1,3-isobutyl-1-methylxanthine O
O O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O

microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM O
; O
cGMP O
, O
10 O

thiazolidinediones O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
extends O
the O
HOMA2 O
model O
, O
enabling O
the O
modeling O
of O
physiology O
and O
treatment O
effects O
, O
to O
present O
equations O
of O
the O
HOMA2 O
and O
iHOMA2 O
models O
, O
and O
to O
exemplify O
iHOMA2 O
in O
two O
widely O
differing O
scenarios O
: O
changes O
in O
insulin O
sensitivity O
with O
thiazolidinediones O
and O
changes O
in O
renal O
threshold O
with O
sodium O
glucose O
transporter O
(SGLT2) O
inhibition.RESEARCH O
DESIGN O
AND O
METHODSiHOMA2 O

enables O
a O
user O
of O
the O
available O
software O
to O
examine O
and O
modify O
the O
mathematical O
functions O
describing O
the O
organs O
and O
tissues O
involved O
in O
the O
glucose O
and O
hormonal O
compartments O
. O
We O
exemplify O
this O
with O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Characterization O
of O
insulin-like O
growth O
factor-binding O
protein-related O
proteins O
(IGFBP-rPs) O
1 O
, O
2 O
, O
and O
3 O
in O
human O
prostate O
epithelial O
cells O
: O
potential O
roles O
for O
IGFBP-rP1 O
and O
2 O
in O
senescence O
of O
the O
prostatic O
epithelium.Insulin-like O
growth O
factor I
(IGF)-binding O
protein I
(IGFBP)-related O
proteins O
IGFBP-rPs) O
are O
newly O
described O
cysteine O

-rich O
proteins O
that O
share O
significant O
aminoterminal O
structural O
similarity O
with O
the O
conventional O
IGFBPs O
and O
are O
involved O
in O
a O
diversity O
of O
biological O
functions O
, O
including O
growth O
regulation O
. O
IGFBP-rP1 O
(MAC25/Angiomodulin/prostacyclin-stimulating O
factor) O
is O
a O
potential O
tumor-suppressor O
gene O
that O
is O
differentially O
expressed O
in O

N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O

mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 O
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide O
) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O

assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O

Plerixafor O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O

results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clini O
cal O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O

expression O
of O
CXCL-8 O
, O
VEGF O
O O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O

microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
O O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O

alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O

salmeterol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
potential O
therapy O
for O
muscle O
wasting O
and O
weakness O
, O
but O
their O
use O
may O
be O
limited O
by O
adverse O
effects O
on O
the O
heart O
, O
mediated O
in O
part O
, O
by O
beta(1)-adrenoceptor O
activation O
. O
Two O
beta(2)-agonists O
, O
formoterol O
and O
salmeterol O
, O
are O
approved O
for O
treating O
asthma O
and O
have O
an O
extended O
duration O
of O
action O
and O
increased O
safety O
, O
associated O
with O
greater O
beta(2)-adrenoceptor O
selectivity O
. O
The O
pharmacological O
profiles O
of O
formoterol O
and O
salmeterol O
and O
their O
effects O
on O

skeletal O
and O
cardiac O
muscle O
mass O
were O
investigated O
in O
12-week-old O
, O
mal O
e B
F344 I
rats I
. O
Formoter B
ol O
and O
salmeterol O
were O
each O
administered O

procaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
a O
more O
potent O
reinforcer O
. O
Drug O
effects O
on O
behavior O
were O
related O
to O
DAT O
occupancy O
in O
monkey O
striatum O
during O
neuroimaging O
with O
positron O
emission O
tomography O
(PET) O
. O
DAT O
occupancy O
was O
determined O
by O
displacement O
of O
8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane O
(FECNT) O
. O
DAT O
occupancy O
was O
between O
66 O
and O
82% O

and O
<10-41% O
for O
doses O
of O
dimethocaine O
and O
procaine O
that O
maintained O
maximum O
response O
rates O
, O
respectively O
. O
Finally O
, O
in O
vivo O
microdialysis O
in O
awake O
subjects O
determined O
drug-induced O
changes O
in O
extracellular O
DA O
in O
the O
caudate O
nucleus O
. O
There O
was O
close O
correspondence O
between O
peak O
increases O
in O
DA O

dexmedetomidine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
the O
type O
such O
as O
dexmedetomidine O
. O
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate O
with O
alpha2-adrenoceptors O
in O
mice O
lacking O
individual O
alpha2-adrenoceptor O
subtypes O
(alpha2-KO) O
. O
METHODS O
: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate O
and O
the O
alpha2-agonist O
, O
dexmedetomidine O
, O
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor O
subtypes O
. O
Inhibition O
of O
binding O
of O
the O

alpha2-receptor O
antagonist O
[3H]RX821002 O
to O
recombinant O
alpha2-receptors O
by O
etomidate O
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro O
. O
RESULTS O
: O
In O
vivo O
, O
loss O
an O
d B
recovery O
of O
the O
righting O
reflex O
required O
similar O

2-hydroxy-3-methylanthraquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2-hydroxy-3-methylanthraquinone O
from O
H O
. O
diffusa O
. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone O
decreased O
phosphorylation-ERK1/2 O
(p-ERK1/2) O
, O
and O
increased O
p-p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 O
in O
U937 O
cells O
. O

Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
O O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 O
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O
Taken O
together O
, O
our O
study O
for O
the O

time O
suggests O
that O
2-hydroxy-3-methylanthraquinone O
is O
able O

PhIP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
O O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O

t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O

letrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O
hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
non-steroidal O
aromatase O
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site O
. O

Exemestane O
is O
a O
mechanism-based O
steroidal O
inhibitor O
that O
mimics O
the O
substrate O
, O
is O
converted O
by O
the O
enzyme O
to O
a O
reactive O
intermediate O
, O
and O
results O
in O
inactivation O
of O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O

imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
an O
alys O
is O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O

GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O

acyl O
glucuronides O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O

to O
acyl O
glucuronides O
O O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O

PGE1 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O

17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pat O
hway B
in O
human O
gastric O

adenocar O
cinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O

mitoxantrone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
O O
, O

4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
( O
less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O

recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O

LY O
53857 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
in O
mice O
were O
studied O
. O
Clomipramine O
at O
doses O
ranging O
5 O
- O
20 O
mg/kg O
elicited O
significant O
hyperglycemia O
in O
mice O
. O
Hyperglycemia O
elicited O
by O
clomipramine O
was O
not O
reduced O
by O
pretreatment O
with O
the O
5-hydroxytryptamine O
(5-HT) O
depleter O
p-chlorophenylalanine O
. O
The O
5-HT(1/2/5/7)-receptor O
antagonist O
methysergide O
and O
the O

5-HT(2A/2B/2C)-receptor O
antagonist O
LY O
53857 O
enhanced O
clomipramine-induced O
hyperglycemia O
, O
while O
the O
5-HT(1A/1B)-receptor O
antagonist O
(-)-propranolol O
and O
the O
5-HT O
(3/4)-receptor O
antagonis O
t O
tropisetron O
did O
not O
affect O
it O
. O
The O
5-HT(2B/2C)-receptor O
antagonist O
SB O
206553 O
facilitated O
hyperglycemia O
induced O
by O
clomipramine O
, O
although O
the O

5-HT(2A)-receptor O
antagonist O
ketanserin O
was O
without O
effect O
. O
Clomipramine-induced O
hyperglycemia O
was O

sulindac O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O

NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O

ORF O
17583 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Effects O
of O
ORF O
17583 O
, O
other O
histamine O
H2-receptor O
antagonists O
and O
omeprazole O
on O
gastric O
acid O
secretory O
states O
in O
rats O
and O
dogs O
ORF O
17583 O
, O
a O
histamine O
H2-receptor O
antagonist O
, O
inhibited O
gastric O
acid O
secretion O
in O
pylorus-ligated O
rats O
(ED50 O
= O
4.9 O
mg/kg O
intraduodenal; O
3.4 O
mg/kg O
p.o.; O
and O
0.21 O
mg/kg O
i.p.) O
and O
in O
total O
gastric O

fistula O
or O
Heidenhain O
pouch O
dogs O
stimulated O
by O
betazole O
(ED50 O
= O
0.12 O
mg/kg O
p.o O
. O

palinurin O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Evidence O
for O
a O
new O
binding O
mode O
t O
GSK-3 B
O O
: O
allosteric O
regulation O
by O
the O
marine O
compound O
palinuri O
n.Glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
is O
widely O
recognised O
as O
a O
relevant O
player O
in O
the O
pathogenesis O
of O
several O
highly O
prevalent O
disorders O
such O
as O
Alzheimer's O
disease O
, O
mood O
disorders O
, O
diabetes O
and O
cancer O
. O
Therefore O
, O
this O
enzyme O
constitutes O
a O
highly O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O

, O
we O
recorded O
steady-state O
currents O
from O
cell-a O
ttached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O

MET O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET O
) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O

(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O

Ala O
acts O
as O
PART-OF O
for O
what O
entity O
? O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O

Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR O
) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O

[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O

GW572016 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
erlotinib O
(Tarceva O
, O
OSI-774) O
, O
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab O
(IMC-225 O
, O
Erbitux) O
. O
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033 O
, O
an O
irreversible O
pan-erbB O
tyrosine O
kinase O
inhibitor O
, O
and O
PKI166 O
and O
GW572016 O
, O
both O
examples O
of O
dual O
kinase O
inhibitors O
(inhibiting O
epidermal O
growth O
factor O
receptor O
and O

Her2) O
. O
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy O
, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy O
. O
However O
, O
serious O
clinical O
challenges O

OMT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O

ischemia O
. O

nizatidine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
o O
nizatidine B
, O
a O
selective O
histamine B
H2-recepto O
r O
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs.Nizatidine O
(LY139037) O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O

Meclofenamic O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
ac O
tion B
pote B
ntials B
, O
whereas O
in O
vivo O
diclofenac O
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O
mg/kg) O
. O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy O
, O
migraine O
, O
or O
neuropathic O
pai O
3 O
potassium O
channel O
openers O
, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties.The O

voltage-dependent O
M-type O
potassium O
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing O
. O
The O
KCNQ2/Q3 O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase O
O O
, O
and O
glutamate O

, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O

D-amphetamine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Polymorphisms O
i O
dopamine B
transporter B
(SLC6A3) O
are O
associated O
with O
stimulant O
effects O
of O
D-amphetamin O
e O
: O
an O
exploratory O
pharmacogenetic O
study O
using O
healthy O
volunteers.Individuals O
vary O
in O
their O
subjective O
responses O
to O
stimulant O
drugs O
, O
and O
these O
differences O
are O
believed O
to O
be O
partially O
genetic O
in O
origin O
. O
We O
evaluated O
associations O
between O
mood O
, O
cognitive O
and O
cardiovascular O

carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
mRNA O
of O
NGF-beta O
decreased O
in O
the O
shunt O
group O
. O
Treatment O
with O
carvedilol O
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
BNP O
, O
and O
NGF-beta O
to O
the O
baseline O
values O
. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol O
again O
normalized O
the O
labeling O
. O

CONCLUSION O
: O
HIF-1alpha O
and O
VEGF O
mRNA O
and O
protein O
expression O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure O
. O
Treatment O
with O
carvedilol O
is O
associated O
with O
a O
reversal O
of O
abnormal O

BH(4) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
fructose-fed O
rats O
was O
reversed O
with O
BH(4) O
treatment O
. O
The O
BH(4) O
treatment O
was O
associated O
with O
a O
2-fold O
increase O
in O
eNOS O
activity O
as O
well O
as O
a O
70% O
reduction O
in O
endothelial O
O(2)(-) O
production O
compared O
with O
those O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
also O
partially O
improved O
the O
insulin O
sensitivity O
and O
blood O
pressure O
, O
as O
well O
as O
the O
serum O
triglyceride O
concentration O

, O
in O
the O
fructose-fed O
rats O
. O
Moreover O
, O
BH(4) O
treatment O
of O
the O
fructose-fed O
rats O
markedly O
reduced O
the O
lipid O
peroxide O
content O
of O
both O
aortic O
and O
cardiac O
tissues O
and O
inhibited O

Diclofenac-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O

0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O

values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
O O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O

calcium O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
the O
mutants O
by O
CTRC O
was O
unchanged O
and O
processing O
of O
the O
activation O
peptide O
was O
increased O
only O
in O
the O
D19A O
mutant O
by O
4-fold O
. O
Surprisingly O
, O
however O
, O
this O
increased O
processing O
had O
only O
a O
minimal O
effect O
on O
autoactivation O
. O
The O
tetra-aspartate O
motif O
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium O
(KD O
~1.6 O
mM) O
, O
which O
stimulates O
autoactivation O
. O
Unexpectedly O
, O
calcium O
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O

peptide O
mutations O
. O
Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G O
and O
K23_I24insIDK O
was O
not O
stimulated O
by O
calcium O
. O
Finally O
, O
the O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
development O
of O
Mn O
toxicity O
. O
Of O
the O
other O
Parkinson-linked O
genes O
, O
mutations O
in O
LRRK2 O
, O
an O
autosomal O
dominant O
gene O
, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism O
. O
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock-down O
on O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT O
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O

potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O

S-adenosylhomocysteine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(MAT) O
was O
significantly O
elevated O
(205% O
, O
p<0.0001) O
in O
the O
dwarf O
mice O
, O
as O
were O
cystathionine O
synthase O
(50% O
, O
p<0.01) O
, O
cystathionase O
(83% O
, O
p<0.001) O
, O
and O
glycine O
N-methyltransferase O
(GNMT O
, O
91% O
, O
p<0.001) O
activities O
. O
Even O
though O
the O
activities O
of O
MAT O
and O
GNMT O
were O
elevated O

, O
the O
concentration O
of O
liver O
S-adenosylmethionine O
was O
decreased O
(24% O
, O
p<0.001) O
and O
S-adenosylhomocysteine O
increased O
(113% O
, O
p<0.001) O
in O
the O
dwarf O
mice O
. O
These O
data O
indicate O
that O
dwarf O
mice O
, O
compared O
to O
wild O
type O
mice O
, O
have O
a O
markedly O
different O
metabolism O
of O
methionine O
. O
Altered O
methionine O
metabolism O
may O
partially O
explain O
earlier O
reports O

norepinephrine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
macrophage O
cell O
line O
(RAW O
264.7) O
. O
Thus O
, O
it O
can O
be O
suggested O
that O
the O
inhibitory O
action O
of O
ginseng O
saponins O
against O
the O
immobilization O
stress-induced O
increase O
of O
plasma O
IL-6 O
level O
would O
be O
in O
periphery; O
at O
least O
in O
part O
, O
mediated O
by O
blocking O
norepinephrine- O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
rather O
than O
in O
the O
brain O
. O
Ginseng O
saponins O

might O
be O
proposed O
as O
a O
possible O
candidate O
in O
the O
research O
or O
therapeutic O
modulation O
of O
stress-related O
disorders O
. O

dfbp O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O

(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC O
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O

17-phenyl O
trinor O
PGE2 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
beta1 O
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2 O
. O
To O
identify O
the O
EP O
receptors O
that O
mediate O
transcriptional O
regulation O
, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct O
, O
pHbeta1-1141 O
Luc O
. O
The O
involvement O
of O
EP1 O
and O
EP2 O
receptors O
is O
indicated O
by O
studies O
with O
the O
EP1 O
selective O
agonist O
17-phenyl O
trinor O
PGE2 O
O O
, O
and O
the O
EP2 O
selective O
agonist O
butaprost O

stimulate) O
, O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 O
(EP1 O
specific) O
and O
AH O
6809 O
(EP1 O
and O
EP2 O
spec O
ific O
) O
. O
Consistent O
with O
the O
involvement O
of O

MAC13243 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
MAC13243 O
and O
the O
thiourea O
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA O
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
O O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O

LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

RS-17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
1A-adrenoceptor O
population O
against O
the O
irreversible O
action O
of O
phenoxybenzamine O
also O
failed O
to O
increase O
the O
potency O
of O
RS-17053 O
(pA2 O
= O
8.25 O
+/- O
0.06 O
against O
A61603) O
. O
6 O
. O
Combined O
concentration-ratio O
analysis O
demonstrated O
that O
tamsulosin O
, O
which O
does O
not O
discriminate O
between O
alpha O
1A- O
and O
alpha O
1L-adrenoceptors O
, O
and O
RS-17053 O
competed O
for O
binding O
at O
the O
same O
site O
in O
the O
SMA O
. O
7 O
. O

In O
summary O
, O
data O
obtained O
in O
our O
experiments O
in O
rat O
SMA O
indicate O
that O
the O
alpha O
1-adrenoceptor O
mediating O
noradrenaline-induced O
contraction O
displays O
a O
distinct O
alpha O
1L-adrenoceptor O
pharmacology O
. O
This O
study O
does O

Docetaxel O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
patients O
with O
metastatic O
lesion O
initially O
respond O
to O
androgen O
ablation O
therapy O
, O
almost O
patients O
develop O
to O
hormone-refractory O
states O
. O
The O
optimal O
treatment O
for O
men O
with O
hormone O
refractory O
prostate O
cancer O
(HRPC) O
has O
not O
been O
established O
. O
Docetaxel O
is O
a O
semisynthetic O
taxane O
that O
inhibit O
tumor O
growth O
by O
induction O
of O
microtubule O
stabilization O
and O
promotion O
of O
bcl-2 O
inactivation O
, O
which O
induce O
apoptosis O
. O
Docetaxel O
as O
single O
agent O
has O
significant O
anti-tumor O
effect O
in O

HRPC O
patie O
nts O
. O
Docetaxel O
combined O
with O
estramustine O
or O
other O
antimicrotubular O
agents O
have O
shown O
further O
significant O
cytotoxicity O
in O
HRPC O
patients O
. O

Trichostatin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Induction O
of O
the O
liver O
cancer-down-regulated O
long O
noncoding O
RNA O
uc002mbe.2 O
mediates O
trichostatin-induced O
apoptosis O
of O
liver O
cancer O
cells.Differential O
expression O
of O
long O
non-coding O
RNAs O
(lncRNAs) O
plays O
critical O
roles O
in O
hepatocarcinogenesis O
. O
Considerable O
attention O
has O
focused O
on O
the O
antitumor O
effect O
of O
histone O
deacetylase O
inhibitor O
(Trichostatin O
A O
O O
, O
TSA) O
as O
well O
as O
the O
coding O
gene O

apoptosis O
of O
cancer O
cells O
. O
However O
, O
it O
is O
not O
known O
whether O
lncRNA O
has O
a O
role O
in O
TSA-induced O
apoptosis O
of O
human O
hepatocellular O
carcinoma O
(HCC) O
cells O
. O
The O
global O
expression O
of O
lncRNAs O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O

, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A O
; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
O O
, O
AP-1 O
, O
and O
C/EBPbeta O

not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O

organophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O

The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KIT O
D816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O

KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
localization O
, O
gene O
structure O
, O
and O
expression O
pattern O
of O
DDAH1 O
: O
comparison O
with O
DDAH2 O
and O
implications O
for O
evolutionary O
origins.Endogenously O
produced O
asymmetrically O
methylated O
arginine O
residues O
are O
competitive O
inhibitors O
of O
all O
three O
isoforms O
of O
nitric O
oxide O
synthase O
(NOS) O
. O
The O
enzyme O
dimethylarg O
inine O
dimethylaminohydrolase O
(DDAH) O
spec O
ifically O
hydrolyzes O
these O
asymmetrically O
methylated O
arginine O
residues O

to O
citrulline O
and O
methylamines O
. O
Previously O
we O
have O
proposed O
that O
regulation O
of O
asymmetric O
methylarginine O
concentration O
by O
DDAH O
may O
provide O
a O
novel O
mechanism O
for O
the O
regulation O
of O
NOS O
activity O
in O
vivo O
. O
Recently O
we O
reported O
the O
cloning O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
O O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O

other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O

pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺-driven O
N-terminal O
to O
C-terminal O
tertiary O
interaction O
in O
PrP(C) O
O O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O

the O
type O
of O
mutation O
and O
the O
apparent O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
UDP-glucuronosyltransferases O
and O
liver O
microsomes.Abstract O
1 O
. O
UDP-glucuronosyltransferases O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
HFC) O
for O
several O

UGTs O
O O
. O
3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
st B
udied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O

tyrosine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
this O
binding O
was O
competitively O
abrogated O
by O
the O
LRP-1 O
antagonist O
, O
the O
receptor-associated O
protein O
. O
In O
mouse O
embryonic O
fibroblasts O
(PEA-13) O
lacking O
LRP-1 O
, O
tPA O
failed O
to O
induce O
MMP-9 O
expression O
. O
Furthermore O
, O
tPA O
induced O
rapid O
tyrosine O
phosphorylation O
on O
the O
beta O
subunit O
of O
LRP-1 O
, O
which O
was O
followed O
by O
the O
activation O
of O
Mek1 O
and O
its O
downstream O
Erk-1 O
and O
-2 O
O O

Blockade O
of O
Erk-1/2 O
activation O
by O
the O
Mek1 O
inhibitor O
abolished O
MMP-9 O
induction O
by O
tPA O
in O
NRK-49F O
cells O
. O
Conversely O
, O
overexpression O
of O
constitutively O
activated O
Mek1 O
induced O
Erk-1/2 O
phosphorylation O
and O
MMP-9 O
expression O
. O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O

MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O

2'-cytidine O
monophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine I
pancreatic I
ribonuclease I
A I
RNase B
A) I
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O

2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O

Crocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O

3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
CPT1B O
) O
. O
Their O
deduced O
amino O
acid O
sequences O
show O
a O
high O
degree O
of O
conservation O
compared O
with O
orthologues O
from O
other O
mammalian O
species O
, O
with O
the O
notable O
exception O
of O
the O
N-terminus O
of O
ovine O
M-CPT O
1 O
. O
These O
differences O
were O
also O
present O
in O
bovine O
M-CPT O
1 O
, O
whose O
N O
-terminal O
sequence O
we O
determined O
. O
In O
addition O
, O
the O
5'-end O
of O
the O
sheep O
CPT1B O
cDNA O
suggested O
a O
different O
promoter O
architecture O
when O
compared O
with O
previously O
characterized O
CPT1B O
genes O
. O
Northern O
blotting O
revealed O
differences O
in O
tissue O
distribution O
for O

both O
CPT1A O
and O
CPT1B O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK O
) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O

pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O

Mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O
, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O

use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential O
, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O

Tamoxifen O
acts O
as O
NOT O
for O
what O
entity O
? O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER O
-positive O
cancers O
. O
Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O

epidemiologic O
models O
, O
(b) O
biomarkers O
predictive O
of O
response O
to O
specific O

prostacyclin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
O O
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue O
factor O
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O

endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O

DEX O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma O
/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O

+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O

SiO(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 O
and O
caspase-9 O
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O

in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

estrogen O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα O
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
, O
suggesting O
that O
the O
compound O
has O
no O
endocrine O

disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test O
, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O

crizotinib O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
for O
anticancer O
therapy O
. O
Recently O
, O
several O
molecularly O
distinct O
phenotypes O
of O
NSCLC O
based O
on O
specific O
and O
mutually O
exclusive O
genetic O
derangements O
have O
been O
described O
. O
Few O
targets O
like O
epidermal O
growth O
factor O
receptor O
(EGFR) O
mutations O
and O
anaplastic O
lymphoma O
kinase O
(ALK) O
gene O
rearrangements O
have O
successfully O
been O
targeted O
with O
EGFR O
tyrosine O
kinase O
inhibitors O
(TKIs) O
and O
crizotinib O
O O
, O
respectively O
. O
Many O

inhibitors O
of O
specific O
driver O
mutations O
involving O
genes O
like O
ROS O
, O
c-MET O
, O
FGFR O
, O
mTOR O
, O
IGFR O
an I
d I
RET B
are I
currently I
under I
d I
evelopment I
. O
However O
, O
efforts O
to O
target O
some O
mutated O
genes O
like O

L-proline O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
gamma-glutamyl O
phosphate O
reductase O
, O
both O
of O
which O
catalyze O
the O
first O
two O
steps O
of O
L-proline O
synthesis O
from O
L-glutamate O
and O
which O
together O
may O
form O
a O
complex O
in O
vivo O
. O
When O
cultured O
in O
liquid O
minimal O
medium O
, O
yeast O
cells O
expressing O
the O
mutated O
gamma-glutamyl O
kinase O
were O
found O
to O
accumulate O
intracellular O
L-proline O
and O
showed O
a O
prominent O
increase O
in O
cell O
viability O
after O
freezing O
at O
-20 O
degrees O
C O
compared O
to O
the O
viability O
of O
cells O
harboring O
the O

wild-type O
PRO1 O
gene O
. O
These O
results O
suggest O
that O
the O
altered O
gamma-glutamyl O
kinase O
results O
in O
stabilization O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC O
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O

3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O

replaced O
with O
a O

putrescine O
acts O
as O
NOT O
for O
what O
entity O
? O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O

damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

Tomudex O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases O
. O
The O
changes O
in O
cyclin O
and O
cdk O
protein O
expression O
and O
their O
kinase O
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells O
. O
Tomudex O
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) O
expression O
, O
with O
an O
increase O
in O
cyclin O
E O
and O
cdk2 O
protein O
expression O
and O
kinase O
activities O
24 O
h O
after O
a O
2-h O
exposure O
. O
Although O
cyclin O
A O
protein O
expression O
was O
markedly O
increased O
, O

cyclin O
A O
kinase O
activity O
was O
only O
slightly O
increased O
. O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
Sitagliptin O
, O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O

post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
intra- O
and O
extrace O
llular O
pH O
, O
our O
resu O
lts B
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
stud O
e O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O

indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O

R(-) O
and O
S(+) O
isomers O
of O
MDMA O
acts O
as O
NOT O
for O
what O
entity O
? O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O

S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O

cGMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cloning O
and O
characterization O
of O
a O
nove O
human O
phosphodiesterase O
that O
hydrolyzes O
both O
cAMP O
and O
cGM O
P O
(PDE10A).cDNA O
encoding O
a O
novel O
phosphodiesterase O
(PDE) O
was O
isolated O
from O
a O
human O
fetal O
lung O
cDNA O
library O
and O
designated O
PDE10A O
. O
The O
deduced O
amino O
acid O
sequence O
contains O
779 O
amino O
acids O
, O
including O
a O
putative O
cGMP O
binding O
sequence O
in O
the O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
, O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O

, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O
core O
of O
SUR O
with O
the O
K(IR) O
pore O
. O

methyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Methyl O
transfer O
in O
glycine O
N-methyltransferase O
. O
A O
theoretical O
study.Density O
functional O
theory O
calculations O
using O
the O
hybrid O
functional O
B3LYP O
have O
been O
performed O
to O
study O
the O
methyl O
transfer O
step O
in O
glycine O
N-methyltransferase O
(GNMT O
) O
. O
This O
enzyme O
catalyzes O
the O
S-adenosyl-L-methionine O
(SAM)-dependent O
methylation O
of O
glycine O
to O
form O
sarcosine O
. O
The O
starting O
point O
for O
the O
calculations O
is O
the O
recent O
X-ray O
crystal O
structure O
of O

GNMT O
complexed O
with O
SAM O
and O
acetate O
. O
Several O
quantum O
chemical O
models O

FLX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
haloperidol.RATIONALE O
: O
Flupentixol O
(FLX) O
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades O
. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine O
D(2) O
, O
D(1) O
and O
5-HT(2A) O
receptors O
and O
recently O
, O
FLX O
showed O
to O
be O
not O
inferior O
to O
risperidone O
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology O
, O
which O
was O
implicated O
with O
flupentixol's O
interaction O

with O
5-HT(2A) O
and/or O
D(1) O
receptors O
. O
OBJECTIVES O
: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13 O
, O
5.7 O
+/- O
1.4 O
m O
g/day) O
in O
comparison O
with O
risperidone O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
such O
as O
substance O
P O
. O
Within O
the O
class O
of O
AII O
blockers O
, O
eprosartan O
differs O
from O
other O
currently O
available O
agents O
in O
terms O
of O
chemical O
structure O
, O
as O
it O
is O
a O
non-biphenyl O
, O
non-tetrazole O
, O
non-peptide O
antagonist O
with O
a O
dual O
pharmacological O
mode O
of O
action O
. O
Eprosartan O
acts O
at O
vascular O
AT(1) O
receptors O
(postsynaptically) O
and O
at O
presynaptic O
AT(1) O
receptors O
, O
where O
it O
inhibits O
sympathetically O
stimulated O

noradrenaline O
release O
. O
Its O
lack O
of O
metabolism O
by O
cytochrome O
P450 O
enzymes O
confers O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
and O
may O
be O
of O
importance O
when O
treating O
elderly O

17-HDHA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA/DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin O
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
O O
, O
increased O
adiponectin O

and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA O
and O
protectin O
D1 O
contributes O
to O
adipose O

MAC13243 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
, O
as O
a O
likely O
inhibitor O
of O
the O
bacterial O
lipoprotein O
targeting O
chaperone O
, O
LolA O
O O
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O

Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
acti O
n-like O
protein O
, O
MreB O
. O
Herein O
, O
we O

alcohol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs O
) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O

an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
e O
thanol B
O O
. O
In O
addition O
, O

N-hydroxy-4-aminobiphenyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O

immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O

fisetin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O

S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O

BDZs O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
( O
GABA(A)R B
) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O

inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
( O
NOS O
) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O

determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O

, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE O
) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O

However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O

tetrahydrobiopterin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
TPH O
mRNA O
in O
median O
raphe O
nucleus O
(MRN) O
and O
dorsal O
raphe O
nucleus O
(DRN) O
, O
respectively O
, O
without O
significantly O
altering O
TPH O
mRNA O
levels O
in O
the O
pineal O
gland O
. O
In O
contrast O
, O
there O
was O
little O
change O
in O
mRNA O
levels O
for O
GTP O
cyclohydrolase O
I O
(GTPCH) O
, O
the O
rate O
limiting O
enzyme O
in O
synthesis O
of O
the O
tetrahydrobiopterin O
(BH4) O
, O
the O
obligate O
cofactor O
for O
TPH O
. O
This O
is O
the O
first O
study O
to O
reveal O

stress-elicited O
activation O
of O
TPH O
gene O
expression O
. O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
an O
d O
tyrosine B
kinase I
s O
VEGFR/PDGFR B
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O

(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O

activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O

dismutase O
(SOD) O
, O
and O
catalase O
(CAT O
)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

Pranlukast O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mRNA O
in O
eosinophils O
, O
lymphocytes O
, O
and O
mast O
cells O
in O
sensitized O
and O
allergen-stimulated O
lung O
tissues O
. O
CysLTR1 O
mRNA O
was O
detected O
in O
macrophages O
, O
smooth O
muscle O
cells O
, O
eosinophils O
, O
and O
mast O
cells O
, O
but O
was O
less O
expressed O
in O
lymphocytes O
. O
Pranlukast-induced O
inhibition O
of O
IL-5 O
mRNA O
expression O
was O
noted O
in O
various O
cells O
, O
irrespective O
of O
their O
CysLTR1 O
mRNA O
expression O
status O
. O
In O
addition O

, O
cysteinyl O
leukotrienes O
per O
se O
failed O
to O
upregulate O
the O
IL-5 O
production O
. O
CONCLUSION O
: O
Our O
results O
indicate O
that O
pranlukast O
inhibits O
IL-5 O
synthesis O
via O
a O
mechanism O
distinct O
from O
CysLTR1 O
antagonism O
. O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 O
inhibitors O
has O
not O
been O
clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 O
inhibitors O
celecoxib O
and O
rofecoxib O
O O
. O
METHODS O
: O
A O
search O
was O
performed O
in O
the O
US O
Food O
and O
Drug O
Administration's O

Adverse O
Event O
Reporting O
System O
(AERS) O
to O
identify O
cases O
of O
rena O
l I
fail I
ure O
submitted O
to O
the O
FDA O
. O
A O
MEDLINE O
search O
of O
the O
English O
language O
literature O

pyridostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O

=tacrine>pyridostigmine O
=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

UDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
O O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O

, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O

cocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vivo O
comparison O
of O
the O
reinforcing O
and O
dopamine O
transporter O
effects O
of O
local O
anesthetics O
in O
rhesus O
monkeys.Dopaminergic O
mechanisms O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
reinforcing O
effects O
of O
cocaine O
. O
Similar O
to O
cocaine O
, O
other O
local O
anesthetics O
bind O
to O
the O
dopamine O
transporter O
(DAT O
) O
and O
inhibit O
DA O
uptake O
in O
rodent O
and O
monkey O
brain O
. O
Additionally O
, O
local O
anesthetics O
are O
self-administered O
in O
rhesus O
monkeys O
, O

indicative O
of O
abuse O
liability O
. O
The O
present O
study O
examined O
the O
reinforcing O
and O
DAT O
effects O
of O
the O
local O
anesthetics O

DEX O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX O
-treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O

low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O

CT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
PSAC O
, O
125 O
to O
4,000 O
U/mL O
RP O
, O
or O
0.31 O
to O
10 O
microg/mL O
TP O
. O
Ten O
IU/mL O
urokinase O
was O
also O
incubated O
with O
pooled O
plasma O
of O
stroke O
patients O
, O
that O
was O
previously O
oxidized O
with O
the O
singlet O
oxygen O
(1O2) O
donor O
chloramine O
T O
CT) O
, O
to O
destroy O
plasmatic O
PAI-1 O
and O
alpha2-antiplasmin O
O O
. O
After O
0 O
to O
80 O
minutes O
(37 O
degrees O
C) O
, O
50-microL O
samples O
were O
withdrawn O

added O
to O
100 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
oxidized O
with O
50 O
microL O
of O
20 O
mM O
CT O
. O
For O
determination O
of O
plasmin O

Sb(III) O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
TRR) O
inhibitors O
(aurothioglucose O
and O
Sb(III) O
) O

inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O

Estrogens O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Update O
on O
the O
use O
of O
aromatase O
inhibitors O
in O
breast O
cancer O
Estrogens O
are O
biosynthesised O
from O
androgens O
by O
the O
CYP450 O
enzyme O
complex O
called O
aromatase O
. O
Aromatase O
is O
expressed O
in O
the O
ovary O
, O
placenta O
, O
brain O
, O
bone O
, O
adipose O
tissue O
and O
breast O
tissue O
. O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O

sulfamates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O

to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O

rilmenidine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
potencies O
of O
alpha(2)-adrenoceptor O
agonists O
in O
inhibiting O
the O
electrically O
(2 O
Hz) O
evoked O
[(3)H]norepinephrine O
release O
and O
of O
antagonists O
in O
counteracting O
the O
alpha(2)-adrenoceptor-mediated O
inhibition O
induced O
by O
moxonidine O
. O
In O
the O
rabbit O
pulmonary O
artery O
, O
rilmenidine O
and O
oxymetazoline O
are O
potent O
full O
agonists O
, O
whereas O
in O
the O
human O
atrial O
appendages O

they O
are O
antagonists O
at O
the O
alpha(2)-autoreceptors O
O O
, O
sharing O
this O
property O
with O
rauwolscine O
, O
phentolamine O
, O
and O
idazoxan O
. O
In O
contrast O
, O
prazosin O
is O
ineffective O
. O
In O
addition O
, O
a O
partial O
nucleotide O
and O
amino O
acid O
sequence O
of O
the O
rabbit O
alpha(2A)-adrenoceptor O
(a O
region O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
O O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O

reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

niflumic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibitory O
effects O
of O
non-steroidal O
anti-inflammatory O
drugs O
on O
4-methylumbelliferone O
glucuronidation O
in O
recombinan O
human O
UDP-glucuronosyltransferase O
1A9 O
--potent O
inhibition O
by O
niflumic O
aci O
d.The B
inhibitory O
potencies O
of O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
on O
UDP-glucuronosyltransferase O

(UGT) O
1A9 O
activity O
were O
investigated O
in O
recombinant O
human O
UGT1A9 O
using O
4-methylumbelliferone O
(4-MU) O
as O
a O
substrate O
for O
glucuronidation O
. O
4-MU O
glucuronidation O
(4-MUG) O
showed O
Michaelis-Menten O
kinetics O
with O
a O
Km O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
vehicle O
for O
various O
periods O
of O
time O
(5 O
, O
30 O
min O
, O
18 O
h) O
at O
37 O
degrees O
C O
. O
After O
extensive O
washout O
(3 O
h O
, O
37 O
degrees O
C) O
, O
isometric O
contractions O
were O
measured O
to O
the O
full O
muscarinic O
receptor O
agonist O
methacholine O
, O
the O
partial O
muscarinic O
receptor O
agonist O
4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium O
(McN-A-343) O
and O
histamine O
O O
. O
Fenoterol O
treatment O
significantly O
reduced O

sensitivity O
(pEC(50)) O
to O
methacholine O
in O
a O
time-dependent O
manner O
, O
without O
affecting O
maximal O
contraction O
(E(max)) O
. O
Fenoterol O
treatment O
similarly O
reduced O
the O
pEC(50) O
of O
McN-A-343 O
and O
histamine; O
however O
, O
E(max) O
values O
were O
also O
reduced O
, O
to O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP O
-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

lanreotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
reduction O
of O
somatostatin O
receptor O
(SSTR) O
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR O
subtypes O
. O
There O
are O
five O
known O
SSTR O
subtypes O
. O
SSTR2 O
and O
SSTR5 O
are O
usually O
expressed O
in O
GH-secreting O
pituitary O
tumors O
, O
and O
both O
octreotide O
and O
lanreotide O
bind O
preferentially O
to O
SSTR2 O
and O
, O
to O
a O
lesser O
extent O
, O
to O
SSTR5 O
O O
. O
SA O
inhibitory O
effects O
on O
GH O
secretion O

tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events O
, O
depending O
on O
the O
tumor O
expression O
of O
SSTR O
subtypes O
involved O
in O
each O
mechanism O
. O
The O
development O
of O
specific O

saponins O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
of O
ginseng O
saponins O
on O
the O
stress-induced O
plasma O
interleukin-6 O
level O
in O
mice.The O
effect O
of O
ginseng O
saponins O
on O
plasma O
interleukin-6 O
(IL-6) O
in O
non-stressed O
and O
immobilization-stressed O
mice O
were O
investigated O
. O
Ginseng O
total O
saponins O
, O
ginsenosides O
Rb2 O
, O
Rg1 O
and O
Rd O
administered O
intraperitoneally O
attenuated O
the O
immobilization O
stress-induced O
increase O

in O
plasma O
IL-6 O
level O
. O
But O
, O
intracerebroventricular O
injection O
of O
each O
ginsenoside O
did O
not O
affect O
plasma O
IL-6 O
level O
induced O
by O
immobilization O
stress O
. O
Ginsenosides O
Rb2 O
, O
Rd O
and O
Rg1 O
significantly O
decreased O
norepinephrine O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O

CP-101,606 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Brain O
but O
not O
spina O
NR2B O
receptor O
is O
responsible O
for O
the O
anti-allodynic O
effect O
of O
an O
NR2B O
subunit-selective O
antagonist O
CP-101,60 O
6 O
in O
a O
rat O
chronic O
constriction O
injury O
model.In O
order O
to O
examine O
the O
site O
of O
action O
of O
an O
NR2B O
subtype-selective O
NMDA O
antagonist O
CP-101,606 O
, O
we O
investigated O
its O
analgesic O
effect O
in O
a O
rat O
model O
of O
neuropathic O

erlotinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proliferation O
and O
migration O
, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine O
kinase O
(TK) O
domain O
. O
The O
non-small O
cell O
lung O
cancer O
(NSCLC)-associated O
EGFR O
mutants O
, O
L858R O
and O
G719S O
, O
are O
constitutively O
active O
and O
oncogenic O
. O
They O
display O
sensitivity O
to O
TK O
inhibitors O
, O
including O
gefitinib O
and O
erlotinib O
O O
. O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O

T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
intro O
duc B
tion O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
Sitagliptin O
, O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
O O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O

post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O
2 O

SCH O
900229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase O
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
SCH O
900229) O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O

(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
o O
ABCC2 B
-dependent O
cisplati O
n O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O

5-fluorouracil O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzyme O
expression O
profiles O
suggest O
the O
novel O
tumor-activated O
fluoropyrimidine O
carbamate O
capecitabine O
(Xeloda) O
might O
be O
effective O
against O
papillary O
thyroid O
cancers O
of O
children O
and O
young O
adults.PURPOSE O
: O
The O
fluoropyrimidine O
carbamate O
(capecitabine) O
is O
converted O
to O
5-fluorouracil O
(5-FU) O
by O
thymidine O
phosphorylase O
(TP O
) O
inside O
target O
tissues O
. O
5-FU O

interferes O
with O
DNA O
synthesis O
by O
blocking O
thymidylate O
synthase O
(TS) O
but O
is O
inactivated O
by O
dihydropyrimidine O
dehydrogenase O
(DPD) O
. O
Favorable O
enzyme O
profiles O
(high O
TP O
and O
low O
DPD) O
generate O
high O
intratumor O
levels O
of O
5-FU O
that O
are O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O

clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O

Carvedilol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
labeling O
. O
CONCLUSION O
: O
HIF-1alpha O
and O
VEGF O
mRNA O
and O
protein O
expres O
sion O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure O
. O
Treatment O
with O
carvedilol O
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O
HIF-1alpha O
and O
VEGF O
in O
the O
failing O
ventricular O
myocardiu O
a O
and O
vascular O
endothelial O
growth O
factor O
in O
a O
rat O
model O
of O
volume-overload O
heart O

failure.BACKGROUND O
: O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
congestive O
heart O
failure O
. O
Hypoxia-inducible O
factor-1alpha O
(HIF-1alpha) O
is O
tightly O
regulated O
in O
the O
ventricular O
myocardium O
. O
However O
, O
the O

zileuton O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neither O
troglitazone O
nor O
zileuton O
affected O
antigen-induced O
production O
of O
PGD(2) O
, O
arachidonic O
acid O
release O
from O
membrane O
phospholipids O
and O
degranulation O
. O
3 O
. O
Troglitazone O
inhibited O
LTB(4) O
production O
by O
the O
supernatant O
fraction O
of O
RBL-2H3 O
cell O
lysate O
with O
similar O
potency O
to O
zileuton O
, O
suggesting O
that O
troglitazone O
inhibits O
LT O
production O
by O
direct O
inhibition O
of O
5-LOX O
activity O
. O
4 O
. O
Furthermore O
, O
it O
was O
shown O
that O

troglitazone O
as O
well O
as O
zileuton O
inhibited O
LTB(4) O
production O
in O
A23187-stimulated O
rat O
peritoneal O
neutrophils O
. O
5 O
. O
These O
findings O
suggest O
that O
troglitazone O
inhibits O
antigen-induced O
LT O
production O
in O
the O
IgE-sensitized O
RBL-2H3 O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O

of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
b O
ecause B
hypophysec O
tomy O
abrogates O
it O
. O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O

inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O

prednisone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
R O
monoclonal O
antibodies O
(moAbs) O
, O
anti-Tac O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 O
R O
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O

(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O

of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O

cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

lactate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH O
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O

we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
la O
ctat O
e O

proflavin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
site O
ligation O
in O
human O
thrombin O
: O
effect O
on O
the O
interaction O
with O
fibrinogen O
and O
the O
cleavable O
platelet O
receptor.An O
experimental O
strategy O
based O
on O
solution O
viscosity O
perturbation O
allowed O
us O
to O
study O
the O
energetics O
of O
amide-substrates O
, O
p-aminobenzamidine O
(p-ABZ) O
and O
proflavin O
binding O
to O
the O
catalytic O
site O
of O
two O
proteolyzed O
forms O
of O
alpha-thrombin O
O O
, O
i.e O
. O
zeta- O
and O
gamma O

ombin O
. O
These O
th O
rombin B
derivatives O
are O
cleaved O
at O
the O
Leu144-Gly150 O
loop O
and O
at O
the O
fibrinogen O
recognition O
exosite O
(FRS) O
, O
respectively O
. O
A O
phenomenological O
analysis O
of O
thermodynamic O
data O
showed O
that O
the O
amide O
substrates O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine I
transporter I
VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA O
) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O

(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O

Chalcogenopyrylium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP O
modulators O
and O
also O
show O
that O
within O
this O
core O
struc O
ture B
, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen O
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP O
4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O

chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O
doses O
. O
5 O
. O
Some O

physiological O

pemetrexed O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Akt O
phosphorylation O
was O
investigated O
with O
enzyme-linked O
immunosorbent O
assay O
, O
whereas O
quantitative O
polymerase O
chain O
reaction O
(PCR) O
was O
used O
to O
study O
target O
gene-expression O
profiles O
and O
its O
modulation O
by O
each O
drug O
. O
Synergistic O
cytotoxicity O
was O
demonstrated O
, O
and O
pemetrexed O
significantly O
decreased O
the O
amount O
of O
phosphorylated O
Akt O
, O
enhanced O
apoptosis O
, O
and O
increased O
the O
expression O
of O
dCK O
in O
A549 O
and O
Calu-6 O
cells O
, O
as O
well O
as O
the O
expression O

of O
the O
human O
nucleoside O
equilibrative O
transporter O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK O
expression O
and O
gemcitabine O
sensitivity O
, O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O

adipocytes O
. O

cinobufagin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O

downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O

Caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O

DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O

[(3)H]WIN O
35428 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O

in O
human O
dopamine O
transporter O
(DAT O
) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mo O
use B
nucleus O
accumbens O
shell O

AACOCF3 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
O O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O

are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O

brexpiprazole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
O O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O

5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
o O
baicalin B
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2 O
D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O

SC-51089 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O
sulprostone>PGE2 O
, O

PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
, O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
O O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O

Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O

and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O

[(125)I] O
RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
O O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O

Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O

decitabine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
gene O
promoter O
methylation O
decreased O
, O
and O
platelets O
and O
the O
proportion O
of O
megakaryocytes O
and O
erythroid O
cells O
in O
the O
marrow O
increased O
without O
a O
decrease O
in O
marrow O
cellularity O
, O
consistent O
with O
a O
DNA O
hypomethylating O
, O
noncytotoxic O
mechanism O
of O
action O
. O
Weekly O
subcutaneous O
decitabine O
produces O
cumulative O
increases O
in O
HbF O
and O
total O
hemoglobin O
through O
a O
noncytotoxic O
mechanism O
of O
action O
. O
Chronic O
dosing O
and O
sustained O
increases O
in O

hemoglobin O
F O
and O
total O
hemoglobin O
levels O
may O
be O
possible O
. O
Further O
studies O
in O
SSD O
and O
thalassemia O
are O
indicated O
. O

1O2 O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
400 O
U/mL O
PSAC O
, O
125 O
to O
4,000 O
U/mL O
RP O
, O
or O
0.31 O
to O
10 O
microg/mL O
TP O
. O
Ten O
IU/mL O
urokinase O
was O
also O
incubated O
with O
pooled O
plasma O
of O
stroke O
patients O
, O
that O
was O
previously O
oxidized O
with O
the O
singlet O
oxygen O
1O2) O
donor O
chloramine O
T O
(CT) O
, O
to O
destroy O
plasmatic O
PAI-1 O
and O
alpha2-antiplasmin O
. O
After O
0 O
to O
80 O
minutes O
(37 O
degrees O
C) O
, O

50-microL O
samples O
were O
withdrawn O
and O
added O
to O
100 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
oxidized O
with O
50 O
microL O
of O
20 O
mM O
CT O
. O
For O
determination O

2-Deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O

TSC2 O
O O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O

dihydroquinolinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT O
II O
inhibitors O
with O
excellent O
physicochemical O
properties O
. O
Compound O
20 O
is O
the O
most O
potent O
and O

lipophilically O
efficient O
of O
these O
new O
pyrazole O
analogs O
, O
with O
a O
k(inact)/K( O
i) O
valu O
e O
of O
112,000 O
M(-1)s(-1) O
and O
lipophilic O
efficiency O
(LipE) O
of O

anthranilic O
acid O
sulfonamides O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Discovery O
and O
optimization O
o O
anthranilic B
acid O
sulfonamides O
as O
inhibitors O
of O
methionine O
aminopeptidase-2 B
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumi O
n O
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O

BH(4) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Oral O
administration O
of O
tetrahydrobiopterin O
prevents O
endothelial O
dysfunction O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant O
rats.We O
have O
reported O
that O
a O
deficiency O
of O
tetrahydrobiopterin O
BH(4)) O
, O
an O
active O
cofactor O
of O
endothelial O
NO O
synthase I
(eNOS) O
, O
contributes O
to O
the O
endothelial O
dysfunction O
through O
reduced O
eNOS O
activity O
and O
increased O
superoxide O
anion O

(O(2)(-)) O
generation O
in O
the O
insulin-resistant O
state O
. O
To O
further O
confirm O
this O
hypothesis O
, O
we O
investigated O
the O
effects O
of O
dietary O
treatment O
with O
BH(4) O
on O
endothelium-dependent O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR O
-dependent O

luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O

AMPA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
heterocyclic O
rings O
, O
which O
have O
previously O
been O
incorporated O
as O
5-substituents O
in O
AMPA O
analogues O
, O
as O
exemplified O
by O
1 O
were O
also O
synthesized O
. O
Compounds O
4b-h O
were O
either O
inactive O
(4e,f) O
or O
weaker O
than O
4a O
as O
affinity O
ligands O
for O
GluR1-4 O
and O
GluR5 O
with O
relative O
potencies O
comparable O
with O
those O
of O
the O
corresponding O
AMPA O
analogues O
as O
AMPA O
receptor O
agonists O
. O
Compounds O
4a-h O
may O
be O
useful O
tools O
for O
the O
progressing O
pharmacophore O

mapping O
of O
the O
GluR5 O
agonist O
binding O
site O
. O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
proven O
efficacy O
in O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
: O
inhibition O
of O
dihydroorotate O
dehydrogenase O
(DHODH) O
and O
inhibition O
of O
tyrosine O
kinases O
O O
. O
DHODH O
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O

that O
of O
tyrosine O
kinases O
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR O
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O

Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O

diacylglycerol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inflammatory O
cytokine O
interleukin O
6 O
compared O
with O
PMA O
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction O
. O
I3A O
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b O
domain O
of O
PKC-delta O
with O
lipids O
, O
compared O
with O
PMA O
or O
the O
physiological O
regulator O
diacylglycerol O
O O
, O
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents O
, O
measured O
by O

plasmon O
resonance O
. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha O
induced O
by O
I3A O
was O
lower O
than O
that O
induced O

atomoxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
disorder.The O
selective O
norepinephrine O
(NE) O
transporter O
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
O O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O

and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O
Atomoxetine O
inhibited O
b O
inding B
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human O
NE O
, O
serotonin O
(5-HT) O
and O
dopamine O
(DA) O

(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone) O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 O

antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone) O
] O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

dabrafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-Ra O
(V600 O
E) O
inhibitor O
dabrafeni O
b O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O

naloxone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Changes O
of O
phosphorylation O
o O
cAMP B
response I
element I
binding O
protein O
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
: O
naloxon O
e O
reversal.AIM O
: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP O
response I
element I
binding I
protein I
(CREB) O
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
and O
its O
withdrawal O
. O
METHODS O
: O
Ethanol O
was O

Phenols O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O

sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O

c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα O
) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O

leukotriene O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene O
receptor O
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
O O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O

pranlukast O
in O
mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR O
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O

of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR O
-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD O
, O
siRNA-mediated O
Cx43 O
knock-down O
was O
not O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporatin O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydras O
e.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O

Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O

pyridoxal O
phosphate O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
forms O
of O
GAD67 O
(tGAD67) O
, O
HGAD67(Delta1-70) O
and O
HGAD67(Delta1-90) O
, O
were O
markedly O
activated O
by O
ApoCaM O
to O
an O
extent O
of O
141 O
and O
85% O
, O
respectively O
, O
while O
GST-HGAD67 O
was O
not O
significantly O
affected O
. O
The O
activation O
appears O
to O
be O
due O
to O
an O
increase O
of O
GAD O
affinity O
for O
its O
cofactor O
, O
pyridoxal O
phosphate O
(PLP) O
. O
This O
conclusion O
is O
based O
on O
the O
following O
observations O

. O
Firstly O
, O
the O
V(max) O
of O
GAD O
was O
increased O
when O
ApoCaM O
was O
present O
whereas O
the O
affinity O
for O
the O
substrate O
, O
glutamate O
, O
was O
not O
affected O
. O
Secondly O
, O
the O
affinity O
of O
GAD O
for O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
Licofelone O
, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX O
) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O

to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O

Carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
2.4 O
[1.3-4.5] O
, O
respectively) O
. O
Both O
of O
these O
predicted O
death O
or O
heart O
failure O
independent O
of O
age O
, O
New O
York O
Heart O
Association O
functional O
class O
, O
LV O
ejection O
fraction O
, O
previous O
myocardial O
infarction O
or O
previous O
admission O
with O
heart O
failure O
. O
Carvedilol O
reduced O
the O
risk O
of O
death O
or O
heart O
failure O
in O
patients O
with O
above-median O
levels O
of O
N-BNP O
or O
adrenomedullin O
, O
or O
both O
, O
to O
rates O
not O
significantly O
different O
from O
those O
observed O
in O
patients O
with O
levels O
below O
the O

median O
value O
. O
CONCLUSIONS O
: O
In O
patients O
with O
established O
ischemic O
LV O
dysfunction O
, O
plasma O
N-BNP O
and O
adrenomedullin O

amprenavir O
acts O
as O
AGONIST O
for O
what O
entity O
? O
a O
xenobiotic O
sensor O
to O
regulate O
xenobiotic O
metabolism O
in O
the O
liver O
and O
intestine O
. O
Recent O
studies O
indicate O
that O
PXR O
may O
also O
play O
an O
important O
role O
in O
the O
regulation O
of O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR O
-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR O
that O
constitute O
points O

of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O

cAMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cloning O
and O
characterization O
of O
a O
nove O
human O
phosphodiesterase O
that O
hydrolyzes O
both O
cAM O
P O
and O
cGMP O
(PDE10A).cDNA O
encoding O
a O
novel O
phosphodiesterase O
(PDE) O
was O
isolated O
from O
a O
human O
fetal O
lung O
cDNA O
library O
and O
designated O
PDE10A O
. O
The O
deduced O
amino O
acid O
sequence O
contains O
779 O
amino O
acids O
, O
including O
a O
putative O
cGMP O
binding O
sequence O
in O

aminoglycoside O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Apolipoprotein O
E3 O
(apoE3) O
safeguards O
pig O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 O
activity O
induced O
by O
gentamicin O
C.Megalin O
, O
a O
family O
of O
endocytic O
receptors O
related O
to O
the O
low-density O
lipoprotein O
(LDL) O
receptor O
, O
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside O
accumulation O
. O
We O
previously O
reported O
that O
aminoglycoside O
antibiotics O
reduce O
SGLT1-dependent O
glucose O
transport O
in O
pig O

proximal O
tubular O
epithelial O
LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity O
. O
In O
this O
study O
, O
using O
a O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV O
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV O
inhibitors O
based O
on O
the O
use O
of O
atorvastatin O
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

cisplatin O
acts O
as O
NOT O
for O
what O
entity O
? O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent O
cisplatin O
resistance O
in O
human O
cancer O
cells.The O
adenosine O
triphosphate O
binding O
cassette O
(ABC)-transporter O
ABCC2 O
(MRP2/cMOAT) O
can O
mediate O
resistance O
against O
the O
commonly O
used O
anticancer O
drugs O
cisplatin O
and O
paclitaxel O
. O
To O
overcome O
the O
ABCC2-depending O
drug O
resistance O
, O
two O
specific O
anti-ABCC2 O
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O

the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant O
human O

S-adenosylmethionine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Methionine O
adenosyltransferase O
II O
beta O
subunit O
gene O
expression O
provides O
a O
proliferative O
advantage O
in O
human O
hepatoma.BACKGROUND O
& O
AIMS O
: O
Of O
the O
2 O
genes O
(MAT1A O
, O
MAT2A) O
encoding O
methionine O
adenosyltransferase O
, O
the O
enzyme O
that O
synthesizes O
S-adenosylmethionine O
, O
MAT1A O
O O
, O
is O
expressed O
in O
liver O
, O
whereas O
MAT2A O
is O
expressed O
in O

tissues O
. O
In O
liver O
, O
MAT2A O
expression O
associates O
with O
growth O
, O
dedifferentiation O
, O
and O
cancer O
. O
Here O
, O
we O
identified O
the O
beta O
subunit O
as O
a O
regulator O
of O
proliferation O
in O
human O
hepatoma O
cell O
lines O
. O
The O

MG-132 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
P2X3 O
receptors O
, O
typically O
associated O
with O
receptor O
upregulation O
. O
CASK O
deletion O
mutants O
also O
enhanced O
P2X3 O
subunit O
expression O
. O
After O
silencing O
CASK O
, O
cell O
surface O
P2X3 O
receptor O
expression O
was O
decreased O
, O
which O
is O
consistent O
with O
depressed O
P2X3 O
currents O
. O
The O
reduction O
of O
P2X3 O
expression O
levels O
was O
reversed O
by O
the O
proteasomal O
inhibitor O
MG-132 O
O O
. O
Moreover O
, O
neuronal O
CASK/P2X3 O
interaction O
was O
upregulated O
by O

signaling O
and O
downregulated O
by O
P2X3 O
agonist-induced O
desensitization O
. O
These O
data O
suggest O
a O
novel O
interaction O
between O
CASK O
and O
P2X3 O
receptors O
with O
positive O
outcome O
for O
receptor O
stability O
and O
function O
. O

Prexige O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
No O
influence O
of O
moderate O
hepatic O
impairment O
on O
the O
pharmacokinetics O
of O
lumiracoxib O
, O
an O
oral O
COX-2 O
selective O
inhibitor.The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
hepatic O
impairment O
on O
the O
pharmacokinetics O
(PK) O
of O
the O
novel O
cyclooxygenase-2 O
(COX-2) O
selective O
inhibitor O
lumiracoxib O
(Prexige O
) O
, O
so O
that O
dose O
recommendations O
for O
clinical O
use O
can O
be O
provided O
. O
This O
was O
an O

open-label O
, O
single O
dose O
, O
case-controlled O
study O
in O
which O
eight O
subjects O
with O
liver O
cirrhosis O
classed O
as O
moderate O
hepatic O
impairment O
(Child-Pugh O
score O
: O
7-9) O
and O
eight O
demographically-matched O

F3(d)Thd O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated O
pyrimidines O
in O
human O
colorectal O
cancer O
cells.5-Fluorouracil O
(5-FU) O
, O
5-fluoro-2'-deoxyuridine O
(FdUrd) O
and O
5-trifluorothymidine O
F3(d)Thd) O
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O
inhibition O
of O
thymidylate O
synthase O
( O
TS O
) O

. O
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance O
, O
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs O
, O
and O
analyzed O
the O
cytotoxicity O

lisuride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Re-evaluation O
of O
lisuride O
pharmacology O
: O
5-hydroxytryptamine1A O
receptor-mediated O
behavioral O
effects O
overlap O
its O
other O
properties O
in O
rats.RATIONALE O
: O
There O
is O
substantial O
evidence O
that O
lisuride O
can O
produce O
effects O
linked O
to O
5-HT(1A) O
receptor O
occupancy O
. O
Nevertheless O
, O
this O
action O
has O
generally O
been O
ignored O
in O
the O
mechanism O
of O
action O
of O
lisuride O
, O
in O
favor O
of O
an O
exclusive O
role O
for O
dopamine O
receptors O
in O
considering O
its O
antiparkinsonian O
effects O
, O
or O

an O
exclusive O
role O
of O
5-HT(2A/2C) O

Pseudoephedrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O
tran O
scriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE O
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O
manage O
inflammatory O
disease O
T O
and O
AP-1 O
signaling O
pathways.Pseudoephedrine O
(PSE) O
is O
a O
stereoisomer O
of O
ephedrine O
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O

combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O
to O
rhArg-mediated O
arginine O
depletion O
. O
Therefore O
, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS O
and O
OTC O
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine O
depletion O
with O
arginine-depleting O
enzymes O
O O
. O
We O
have O
also O
shown O
that O
the O
rhArg O
native O
enzyme O
and O
the O
pegylated O

(rhArg-peg(5,000mw)) O
gave O
similar O
anticancer O
efficacy O
in O
vitro O
. O
Furthermore O
, O
the O
growth O
of O
the O
OTC-deficient O
Hep3B O
tumor O
cells O
(ASS-positive O
and O
ADI-resistant) O
in O
mice O
was O
inhibited O

TFP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O

of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O

quinazoline O
tyrosine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inh B
ibitor B
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O

sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
tissue O
by O
inhibition O
of O
PDE5 O
that O
breaks O
down O
cGMP O
, O
the O
key O
pathway O
for O
the O
production O
of O
erectile O
function O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
(Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE O
(PDE6) O
, O
which O
produces O

visual O
changes O
through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O

isoproterenol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
response O
, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol O
> O
norepinephrine O
= O
epinephrine O
. O
Finally O
, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O
subtype-selective O
betaAR O
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR O
subtype O
modulating O
hippocampal O
CA3 O
activity O
. O
The O
selective O
beta1AR O
antagonists O
atenolol O
and O
metoprolol O
blocked O
isoproterenol O
-induced O
enhancement O
, O
with O
apparent O
K(b) O
values O
of O
85 O

+/- O
36 O
and O
3.9 O
+/- O
1.7 O
nM O
, O
respectively O
. O
In O
contrast O
, O
the O
selective O
beta2AR O
antagonists O
ICI-118,551 O
and O
butoxamine O
inhibited O
isoproterenol-mediated O
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O

HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O

GW4064 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

CP[c]Ph O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
living O
organisms O
, O
mainly O
fish O
, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A O
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O

clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O

alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O

Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O

neostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium O
neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O

>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O

mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT O
/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O

ADP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O

. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2 O
-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O

noradrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
discriminate O
between O
alpha O
1A- O
and O
alpha O
1L-adrenoceptors O
, O
and O
RS-17053 O
competed O
for O
binding O
at O
the O
same O
site O
in O
the O
SMA O
. O
7 O
. O
In O
summary O
, O
data O
obtained O
in O
our O
experiments O
in O
rat O
SMA O
indicate O
that O
the O
alpha O
1-adrenoceptor O
mediating O
noradrenaline-induced O
contraction O
displays O
a O
distinct O
alpha O
1L-adrenoceptor O
pharmacology O
. O
This O
study O
does O
not O
provide O
evidence O
for O
the O
hypothesis O
that O
alpha O
1L-adrenoceptors O
represent O
an O
affinity O
state O
of O
the O
alpha O

1A-adrenoceptor O
in O
functional O
assays O
. O
Furthermore O
, O
there O
is O
no O
co-existing O
alpha O
1A-adrenoceptor O
in O
the O
SMA O
. O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
patients O
receiving O
multiple O
daily O
insulin O
injections O
, O
and O
11 O
patients O
receiving O
basal O
insulin O
with O
oral O
antidiabetic O
drugs O
(basal O
insulin O
therapy) O
. O
Concomitant O
oral O
drugs O
included O
sulfonylureas O
, O
α-glucosidase O
inhibitors O
and O
metformin O
. O
The O
hemoglobin O
A1c O
HbA1c) O
of O
all O
patients O
improved O
significantly O
from O
8.1±1.2% O
to O
7.6±1.1% O
after O
12 O
weeks O
of O
add-on O
therapy O
with O

sitagliptin O
(p<0.01) O
, O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O

losartan O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
mg/kg O
, O
orally) O
, O
the O
two O
drugs O
equally O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
, O
by O
50 O
mmHg O
. O
Both O
drugs O
increased O
RBF O
and O
GFR; O
however O
, O
only O
losartan O
shifted O
FENa O
and O
FEH2O O
curves O
leftward O
. O
Human O
and O
rat O
renin O
and O
angiotensinogen O
genes O
were O
downregulated O
in O
dTGR O
and O
were O
increased O
by O
losartan O
and O
cilazapril O
treatments O
, O
whereas O
no O
changes O
in O
the O
expression O
of O
rat O

ACE O
and O
AT1A O
receptor O
genes O
were O
observed O
. O
Endothelial O
NO O
synthase O
expression O
was O
increased O
by O
cilazapril O
but O
not O
by O
losartan O
. O
Neither O
inducible O
NO O
synthase O

DEGBG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG O
] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O

of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O

clofilium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
inner O
cavity O
of O
the O
channel O
and O
include O
aromatic O
residues O
in O
the O
S6 O
helix O
(Tyr-652 O
, O
Phe-656) O
and O
residues O
in O
the O
pore O
helix O
(Thr-623 O
, O
Ser-624 O
, O
Val-625) O
. O
We O
used O
mutagenesis O
of O
these O
residues O
, O
combined O
with O
an O
investigation O
of O
hERG O
block O
by O
close O
analogs O
of O
clofilium O
and O
ibutilide O
, O
to O
assess O
how O
specific O
alterations O
in O
drug O
structure O
affected O
potency O
and O
binding O
interactions O
. O
Although O
changing O
the O

basic O
nitrogen O
from O
quaternary O
to O
tertiary O
accelerated O
the O
onset O
of O
block O
, O
the O
IC(50) O
and O
kinetics O
for O
recovery O
from O

phenolics O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
GSH O
depletion O
occurred O
, O
p66Shc O
protein O
expression O
increased O
by O
about O
300% O
with O
respect O
to O
control O
(P<.001; O
LipE O
vs O
. O
control) O
. O
These O
effects O
were O
fully O
counteracted O
by O
dietary O
phenolics O
which O
inhibited O
ROS O
overproduction O
and O
GSH O
consumption O
, O
rendered O
the O
reactive O
transcription O
of O
glutathione-associated O
enzymes O
unnecessary O
and O
blocked O
the O
intracellular O
signals O
leading O
to O
the O
overexpression O
and O
rearrangement O
of O

p66Shc O
signalling O
molecule O
. O
Altogether O
, O
these O
results O
suggest O
that O
the O
impairment O
of O
the O
antioxidant O
system O
hijacks O
intestinal O
cells O
towards O
an O
apoptotic-prone O
phenotype O
via O
the O
activation O
of O
p66Shc O

BH(4) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
The O
BH(4) O
treatment O
also O
partially O
improved O
the O
insulin O
sensitivity O
and O
blood O
pressure O
, O
as O
well O
as O
the O
serum O
triglyceride O
concentration O
, O
in O
the O
fructose-fed O
rats O
. O
Moreover O
, O
BH(4) O
treatment O
of O
the O
fructose-fed O
rats O
markedly O
reduced O
the O
lipid O
peroxide O
content O
of O
both O
aortic O
and O
cardiac O
tissues O
and O
inhibited O
the O
activation O
of O
2 O
redox-sensitive O
transcription O
factors O
, O
nuclear O
factor-kappaB O
and O
activating O
protein-1 O

, O
which O
were O
increased O
in O
fructose-fed O
rats O
. O
The O
BH(4) O
treatment O
of O
control O
rats O
did O
not O
have O
any O
significant O
effects O
on O
these O
parameters O
. O
These O
results O

letrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
breast O
cancer O
, O
intratumoural O
aromatase O
is O
the O
source O
for O
local O
estrogen O
production O
in O
the O
tissue O
. O
Inhibition O
of O
aromatase O
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens O
in O
estrogen-dependent O
breast O
cancer O
. O
The O
potent O
and O
selective O
third-generation O
aromatase O
inhibitors O
anastrozole O
, O
letrozole O
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen O
therapy O
alone O
, O
or O
multiple O

hormonal O
therapies O
. O
Anastrozole O
and O
letrozole O
are O
both O
no O
n-steroida B
l O
aromatase I
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O

10074-G5 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O

oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
, O
a O
selective O
inhibitor O
of O
both O
BCL-2 O
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O

cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
th O
e B
effi I
cacy I
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O

ginsenosides O
Rb2 O
, O
Rg1 O
and O
Rd O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
inhibitory O
effect O
of O
ginseng O
saponins O
on O
the O
stress-induced O
plasma O
interleukin-6 O
level O
in O
mice.The O
effect O
of O
ginseng O
saponins O
on O
plasma O
interleukin-6 O
(IL-6) O
in O
non-stressed O
and O
immobilization-stressed O
mice O
were O
investigated O
. O
Ginseng O
total O
saponins O
, O
ginsenosides O
Rb2 O
, O
Rg1 O
and O
Rd O
administered O
intraperitoneally O

attenuated O
the O
immobilization O
stress-induced O
increase O
in O
plasma O
IL-6 O
level O
. O
But O
, O
intracerebroventricular O
injection O
of O
each O
ginsenoside O
did O
not O
affect O
plasma O
IL-6 O
level O
induced O
by O
immobilization O
stress O
. O
Ginsenosides O
Rb2 O
, O
Rd O
and O
Rg1 O
significantly O
decreased O
norepinephrine O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O

fluoxetine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
depression O
. O
In O
addition O
, O
by O
comparing O
the O
combined O
administration O
of O
(+/-)pindolol O
with O
either O
WAY100635 O
, O
GR127935 O
or O
isamoltane O
, O
we O
have O
determined O
that O
(+/-)pindolol O
produces O
much O
of O
its O
acute O
potentiation O
of O
fluoxetine-induced O
increases O
in O
extracellular O
5-HT O
via O
its O
action O
at O
the O
5-HT(1B/D) O
receptor O
in O
addition O
to O
any O
activity O
it O
has O
at O
the O
presynaptic O
5-HT(1A) O

receptor O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O

(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O

14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A O
; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O

thiourea O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resultin O
thiourea O
compounds O
with O
the O
lipoprotein O
targeting O
chaperone O
Lol O
A.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx O
) O
activities O
, O
while O
increased O
catalase O

(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O

barbiturates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O

L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs O
) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
binding O
of O
KIT O
by O
dasatinib O
. O
Base O
d O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutation O
V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O

oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O

Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR O
) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O

[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O

oxyresveratrol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O

, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

[(18)F]setoperone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
D(2) O
receptors O
in O
vitro O
. O
The O
affinity O
of O
ziprasidone O
for O
these O
receptors O
in O
vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study O
. O
METHOD O
: O
The O
authors O
conducted O
a O
PET O
study O
to O
evaluate O
D(2) O
occupancy O
(using O
[(11)C]raclopride) O
and O
5-HT(2) O
occupancy O
(using O
[(18)F]setoperone O
) O
in O
brain O
regions O
of O
interest O
in O

16 O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
randomly O
assigned O
to O
receive O
40 O
, O
80 O
, O
120 O
, O
or O
160 O
mg/day O
of O
ziprasidone O
, O
which O
reflected O
the O
recommended O
dose O
range O
. O
PET O
scanning O
was O
done O
after O
3 O

homomazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT O
) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O

lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
bloo O
d O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O

polyamine O
acts O
as O
NOT O
for O
what O
entity O
? O
oxidase O
are O
reported O
. O
Purified O
PAOh1/SMO O
oxidizes O
both O
spermine O
(K(m)=1.6 O
microM) O
and O
N(1)-acetylspermine O
(K(m)=51 O
microM) O
, O
but O
does O
not O
oxidize O
spermidine O
. O
The O
purified O
human O
enzyme O
also O
does O
not O
oxidize O
eight O
representative O
antitumor O
polyamine O
analogues; O
however O
, O
specific O
oligamine O
analogues O
were O
found O
to O
be O
potent O
inhibitors O
of O
the O
oxidation O
of O

spermine O
by O
PAOh1 O
/SMO O
. O
The O
results O
of O
these O
studies O
are O
consistent O
with O
the O
hypothesis O
that O
PAOh1/SMO O
represents O
a O
new O
addition O
to O
the O
polyamine O
metabolic O
pathway O
that O
may O
represent O
a O
new O
target O
for O
antineoplastic O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O

necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2 O
) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O
growth O
factor-beta1 O

NaAsO(2) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O

of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O

PtdSer O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
normal O
amounts O
of O
PtdSer O
. O
Our O
study O
demonstrates O
, O
that O
reduction O
of O
in O
vitro O
serine-exchange O
activity O
, O
even O
by O
97% O
, O
does O
not O
restrict O
the O
externalization O
of O
PtdSer O
during O
apoptosis O
. O
Moreover O
, O
a O
normal O
level O
of O
expression O
of O
PSS1 O
and/or O
PSS2 O
is O
not O
required O
for O
generating O
the O
pool O
of O
PtdSer O
externalized O
during O
apoptosis O
. O

exisulind O
acts O
as O
NOT O
for O
what O
entity O
? O
demonstrated O
that O
COX-1 O
and O
COX-2 O
inhibitors O
could O
inhibit O
the O
in O
vitro O
growth O
of O
human O
lung O
cancer O
cell O
lines O
. O
In O
this O
report O
, O
we O
evaluated O
the O
growth-inhibitory O
effects O
of O
sulindac O
sulfide O
, O
a O
COX-1 O
and O
COX-2 O
inhibitor; O
exisulind O
(sulindac O
sulfone) O
, O
a O
novel O
proapoptotic O
agent O
that O
does O
not O
inhibit O
COX O
enzymes; O
and O
nordihydroguaiaretic O
acid O
(NDGA) O
, O
a O

lipoxygenase O
inhibitor O
on O
human O
lung O
cancer O
cell O
lines O
. O
We O
compared O
these O
effects O
with O
those O
of O
13-cis-retinoic O
acid O
, O
a O
chemoprevention O
agent O
, O
and O
with O
the O
cytotoxic O
chemotherapeutic O
agents O
paclitaxel O
and O

diphenylhydantoin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
an O
established O
sodium O
channel O
blocker O
and O
is O
a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic O
, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain O
. O
In O
this O
study O
, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide O
analogues O
of O
diphenylhydantoin O
and O
examined O
their O
ability O
to O
inhibit O
human O
Na(V)1.5 O
sodium O
channels O
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells O
. O
Phenyl O
ring O
substitutions O
were O

examined O
including O
para-methyl O
, O
para-fluoro O
, O
para-chloro O
, O
ortho-chloro O
and O
meta-chloro O
. O
We O
have O
found O
that O
pheny O
l I
ring I
substitu O
tions I
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O

methionine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O

surface-coate O
d O
with O
b O
ifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O

acetyl-CoA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
conversion O
of O
acetyl-CoA O
and O
carnitine O
to O
acetylcarnitine O
and O
free O
CoA O
. O
To O
redesign O
the O
specificity O
of O
rat O
CrAT O
toward O
its O
substrates O
, O
we O
mutated O
Met564 O
. O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT O
, O
and O
lower O
activity O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
O O
. O

constants O
of O
the O
mutant O
CrAT O
show O
ed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O
(Gly553) O

gemcitabine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
phosphorylated O
Akt O
, O
enhanced O
apoptosis O
, O
and O
increased O
the O
expression O
of O
dCK O
in O
A549 O
and O
Calu-6 O
cells O
, O
as O
well O
as O
the O
expression O
of O
the O
human O
nucleoside O
equilibrative O
transporter O
1 O
(hENT1) O
in O
all O
cell O
lines O
. O
PCR O
demonstrated O
a O
correlation O
between O
dCK O
expression O
and O
gemcitabine O
sensitivity O
, O
whereas O
expression O
of O
TS O
, O
DHFR O
, O
and O
GARFT O
was O
predictive O
of O
pemetrexed O
chemosensitivity O

. O
These O
data O
demonstrated O
that O
1) O
gemcitabine O
and O
pemetrexed O
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt O
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O

choline O
acts O
as O
NOT O
for O
what O
entity O
? O
Live O
choline O
dehydrogenase O
and O
kidney O
betaine-homocysteine O
methyltransferase O
expression O
are O
not O
affected O
by O
methionine O
or O
cholin O
e O
intake O
in O
growing O
rats.Choline O
dehydrogenase O
(CHDH) O
and O
betaine-homocysteine O
methyltransferase I
(BHMT) O
are O
2 O
enzymes O
involved O
in O
choline O
oxidation O
. O
BHMT O
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O

terazosin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
appears O
to O
be O
a O
common O
feature O
in O
symptomatic O
BPH O
and O
alpha1aARs O
are O
enriched O
in O
prostatic O
tissue O
, O
drugs O
that O
demonstrate O
high O
alpha1aAR O
selectivity O
have O
attracted O
attention O
. O
Tamsulosin O
, O
which O
has O
high O
affinity O
for O
alpha1aAR O
and O
alpha1dAR O
subtypes O
but O
not O
for O
alpha1bAR O
, O
shows O
efficacy O
similar O
to O
the O
nonsubtype O
selective O
agents O
terazosin O
and O
doxazosin O
. O
It O
is O
associated O
with O
fewer O
cardiovascular O
side O
effects O
, O
although O
it O

has O
some O
ejaculatory O
side O
effects O
. O
The O
nonsubtype O
selective O
agent O
alfuzosin O
also O
demonstrates O
efficacy O
and O
offers O
an O
enhanced O
side O
effect O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
o O
phosphorylated B
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esteras O
e.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase I
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O

Amprenavir O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir-mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O
in O
lipid O
homeostasis O

. O
These O
findings O
provide O
critical O
mechanistic O
insight O
for O
understanding O
the O
impact O
of O
PIs O
on O
cardiovascular O
disease O
and O
demonstrate O
a O
potential O
role O
of O
PXR O
in O
mediating O
adverse O
effects O

ginseng O
saponins O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rg1 O
significantly O
decreased O
norepinephrine O
and/or O
epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
cell O
line O
(RAW O
264.7) O
. O
Thus O
, O
it O
can O
be O
suggested O
that O
the O
inhibitory O
action O
of O
ginseng O
saponins O
against O
the O
immobilization O
stress-induced O
increase O
of O
plasma O
IL-6 O
level O
would O
be O
in O
periphery; O
at O
least O
in O
part O
, O
mediated O
by O
blocking O
norepinephrine- O
and/or O

epinephrine-induced O
increase O
of O
IL-6 O
level O
in O
macrophage O
rather O
than O
in O
the O
brain O
. O
Ginseng O
saponins O
might O
be O
proposed O
as O
a O
possible O
candidate O
in O
the O
research O
or O
therapeutic O
modulation O
of O
stress-related O
disorders O
. O

cGMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Cloning O
and O
characterization O
of O
a O
novel O
human O
phosphodiesterase O
that O
hydrolyzes O
both O
cAMP O
an O
cGMP O
(PDE10 O
A).cDNA O
encoding O
a O
novel O
phosphodiesterase O
(PDE) O
was O
isolated O
from O
a O
human O
fetal O
lung O
cDNA O
library O
and O
designated O
PDE10A O
. O
The O
deduced O
amino O
acid O
sequence O
contains O
779 O
amino O
acids O
, O
including O
a O
putative O
cGMP O
binding O
sequence O
in O
the O
amino-terminal O
portion O
of O
the O

A-61603 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
SMA O
. O
The O
potency O
of O
the O
selective O
alpha O
1D-adrenoceptor O
antagonist O
BMY O
7378 O
against O
noradrenaline O
(pA2 O
= O
6.16 O
+/- O
0.13) O
and O
of O
the O
selective O
alpha O
1A-adrenoceptor O
antagonist O
RS-17053 O
against O
noradrenaline O
(pKB O
= O
8.35 O
+/- O
0.10) O
and O
against O
the O
selective O
alpha O
1A-adrenoceptor O
agonist O
A-61603 O
(pKB O
= O
8.40 O

+/- O
0.09) O
were O
too O
low O
to O
account O
for O
alpha O
1D- O
and O
alpha O
1A-adrenoceptor O
involvement O
. O
4 O
. O
The O
potency O
of O
RS-17053 O
(pKB/pA2's O
= O
7.72-8.46) O
was O
not O
affected O
by O
lowering O
temperature O
, O
changing O
experimental O
protocol O
or O
inducing O
myogenic O
tone O

BLT O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O

a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O

AMPA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
pharmacology O
a O
AMPA O
and O
kainate O
preferring O
glutamate O
receptor I
s O
of O
4-heteroarylmethylidene O
glutamate O
analogues.2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
(1) O
is O
a O
potent O
AMPA O
receptor O
agonist O
with O
moderate O
affinity O
for O
native O
kainic O
acid O
(KA) O
receptors O
, O
whereas O

(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
(3) O
show O
high O
affinity O
for O
the O
GluR5 O
subtype O
of O
KA O
receptors O
and O

felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
the O
NMDA O
receptor O
channel O
complex O
. O
The O
higher O
affinity O
of O
felbamate O
block O
of O
NMDA O
receptors O
containing O
the O
NR2B O
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites O
. O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA O
receptors O
composed O
of O
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivity O
. O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
o O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p1 O
6 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O

5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
O O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O

mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O

COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O

darapladib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O

probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

paraoxon O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O
Based O
on O
these O
studies O
, O
the O
frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE O
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O

hpf O
are O
sensitive O
to O
paraoxon O

Conivaptan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
demonstrable O
bene O
fit O
from O
this O
action O
was O
not O
ed O
in O
patients O
with O
chronic O
compensated O
heart O
failure O
and O
it O
is O
not O
approved O
for O
this O
indication O
. O
Consideration O
should O
be O
given O
to O
further O
evaluation O
of O
its O
potential O
benefits O
in O
patients O
with O
acute O
decompensated O
heart O
failur O
2 O
antagonist O
[corrected].Several O
fluid O
retentive O
states O
such O
as O
heart O
failure O
, O
cirrhosis O
of O
the O
liver O
, O
and O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
secretion O
are O
associated O
with O
inappropriate O
elevation O
in O
plasma O
levels O
of O
arginine O

vasopressin O
(AVP) O
, O
a O
neuropeptide O
that O
is O
secreted O
by O
the O

nandrolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O

(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O

quinpirole O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
for O
seven O
consecutive O
days O
. O
Dopamine O
D2 O
receptor O
priming O
was O
verified O
through O
a O
yawning O
behavioural O
test O
, O
a O
D2 O
receptor-mediated O
event O
, O
before O
olanzapine O
was O
administered O
as O
well O
as O
after O
olanzapine O
treatment O
and O
behavioural O
testing O
were O
complete O
. O
Results O
showed O
that O
neonatal O
quinpirole O
treatment O
induced O
D2 O
priming O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
On O
the O
MWM O
place O
version O
, O
D2-primed O
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine O
treatment O
, O

but O
olanzapine O
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O

Mn O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT O
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK O
phosphorylation O
in O
LRRK2 O
deficient O
cells O
compared O
to O
controls O
. O
Consistent O
with O
studies O
demonstrating O
that O
LRRK2 O
plays O

a O
role O
in O
the O
phosphorylation O
of O
p38 O
, O
our O
results O
similarly O
demonstrate O
a O
decrease O
in O
p38 O
activation O
in O
LRRK2 O
knock-down O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependent O
mibefradil O
block O
of O
Na+ O
channels.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells O
: O
Nav1.5 O
(cardiac) O
, O
Nav1.4 O
(skeletal O
muscle) O

, O
Nav1.2 O
(brain) O
, O
and O
Nav1.7 O
(peripheral O
nerve) O
. O
Mibefradil O
blocked O
Nav1.5 O
in O
a O
use/frequency-dependent O
manner O
, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization O
. O
Mibefradil O
blocked O
currents O
of O
all O
Na+ O
channel O
isoforms O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O

Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O

Loperamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
th O
e B
involvement O
of O
di O
fferent B
intracellular O
ACTH-secreting O
mechanisms O
, O
an O
influence O
of O
loperamide O
on O
some O
suprapituitary O
factors O
modulating O
the O
ACTH O
response O
is O
suggeste O
n O
in O
patients O
with O
Addison's O
disease.Loperamide O
is O
a O
peripheral O
opiate O
agonist O
able O
to O
inhibit O
ACTH O
secretion O
. O
In O
this O
work O
, O
the O
interactions O
between O
loperamide O
and O
two O

ACTH O
secretagogues O
, O
lysine O
vasopressin O
(LVP) O
and O
corticotropin-releasing O
hormone O
(CRH) O
, O
were O
investigated O
in O
patients O
with O
Addison's O

CGP O
12177A O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O

effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O

Orlistat O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
type O
2 O
diabetes O
, O
hypertension O
or O
sleep O
apnoea O
. O
The O
main O
indication O
for O
operative O
treatment O
is O
morbid O
obesity O
(body O
mass O
index O
greater O
than O
40 O
kg/m2) O
or O
severe O
obesity O
(body O
mass O
index O
> O
35 O
kg/m2) O
with O
comorbidities O
of O
obesity O
. O
Orlistat O
is O
a O
new O
inhibitor O
of O
pancreatic O
lipase O
enzyme O
. O
At O
doses O
of O
120 O
mg O
three O
times O
per O
day O
with O
meals O
it O
results O
in O
a O
30% O
reduction O
in O
dietary O
fat O
absorption O
, O
which O
equals O
approximately O
200 O

kcal O
daily O
energy O
deficit O
. O
In O
the O
long O
term O
, O
orlistat O
has O

lithium O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
f O
lop I
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O

R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis O
Licofelone O
, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O

to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O

PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
O O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O

Rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR B
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O

proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O
the O
20S O
catalytic O
core O

toremifene O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
homeostasis O
of O
the O
normal O
male O
skeleton O
, O
and O
estrogen O
deficiency O
rather O
than O
testosterone O
deficiency O
seems O
to O
be O
primarily O
responsible O
for O
the O
adverse O
skeletal O
effects O
of O
GnRH O
agonists O
. O
In O
randomized O
controlled O
trials O
, O
bisphosphonates O
(pamidronate O
and O
zoledronic O
acid) O
and O
selective O
estrogen O
receptor O
modulators O
(raloxifene O
and O
toremifene O
) O
increased O
bone O
mineral O
density O
in O
GnRH O
agonist-treated O
men O
. O
Two O
ongoing O
large O
randomized O

placebo-controlled O
studies O
will O
prospectively O
define O
fracture O
outcomes O
in O
men O
with O
prostate O
cancer O
and O
assess O
the O
efficacy O
of O
novel O
pharmacologic O
interventions O
(AMG162 O
, O
toremifene) O
during O
GnRH O

procyanidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O
HLA-DR O
expression O
via O
the O
ubiquitin-proteasome O
pathway O
. O
Furthermore O
, O
the O
up-regulation O
of O
IL-12 O
and O
TNF-α O
was O
found O
in O
the O
procyanidin O
trimers-treated O
cells O
in O
the O
presence O
of O
OVA O
. O
These O
results O
suggest O
that O
apple O

polyphenols O
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

bisindolylmaleimide O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O

bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O

polyethylene O
glycol O
acts O
as O
PART-OF O
for O
what O
entity O
? O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O

nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
rec O
eptor B
(E O
GFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O
and O
neck O
cancer O
cells O
in O

diethylglyoxal O
bis-(guanylhydrazone) O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone) O
; O
DEGBG] O
led O
to O
depletion O
of O

spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O

methyl O
alpha-D-glucopyranoside O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
SGLT1 O
activity O
. O
We O
employed O
apolipoprotein O
E3 O
(apoE3) O
and O
lactoferrin O
as O
ligands O
for O
megalin O
. O
Then O
the O
cells O
were O
treated O
with O
various O
concentrations O
of O
apoE3 O
, O
lactoferrin O
and O
bovine O
serum O
albumin O
with O
or O
without O
100 O
microg/ml O
of O
GMC O
, O
and O
the O
SGLT1-dependent O
methyl O
alpha-D-glucopyranoside O
(AMG) O
uptake O
and O
levels O
of O
SGLT1 O
expression O
were O

determined O
. O
As O
a O
result O
, O
we O
demonstrated O
that O
the O
apoE3 O
significantly O
protects O
these O
cells O
from O
GMC-induced O
reduction O
in O
AMG O
uptake O
, O
but O
neither O
lactoferrin O
nor O
albumin O
does O
. O
In O
accord O
with O
a O
rise O

all-trans-retinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O

Cyp26A1 O
O O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O

TDCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver O
fatty-acid O
binding O
protein O
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
, O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 O
O O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O

revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O

ceramides O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O

phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O

Cyclopentenone O
prostaglandins O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
NFkappaB O
transcriptional O
activity O
in O
the O
nucleus O
. O
Thus O
, O
our O
data O
suggest O
the O
existence O
of O
a O
novel O
pathway O
me O
diated O
by O
cyclopentenone O
prostaglandins O
, O
which O
may O
represent O
part O
of O
a O
feedback O
mechanism O
leading O
to O
the O
cessation O
of O
inflammatory O
glial O
responses O
in O
the O
brai O
e O
by O
15-deoxy-Delta12,14-prostaglandin O
J2.Mechanisms O
leading O
to O
down-regulation O
of O
activated O
microglia O
and O
astrocytes O

are O
poorly O
understood O
, O
in O
spite O
of O
the O
potentially O
detrimental O
role O
of O
activated O
glia O
in O
neurodegeneration O
. O
Prostaglandins O
, O
produced O
both O
by O
neurons O
and O
glia O
, O
may O
serve O
as O
mediators O
of O
glial O

eformoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Arformoterol O
: O
(R,R)-eformoterol O
, O
(R,R)-formoterol O
, O
arformoterol O
tartrate O
, O
eformoterol-sepracor O
, O
formoterol-sepracor O
, O
R,R-eformoterol O
, O
R,R-formoterol.Sepracor O
in O
the O
US O
is O
developing O
arformoterol O
[R,R-formoterol] O
, O
a O
single O
isomer O
form O
of O
the O
beta(2)-adrenoceptor O
agonist O

formoterol O
[eformoterol O
] O
. O
This O
isomer O
contains O
two O
chiral O
centres O
and O
is O
being O
developed O
as O
an O
inhaled O
preparation O
for O
the O
treatment O
of O
respiratory O
disorders O
. O
Sepracor O
believes O
that O
arformoterol O
has O
the O
potential O
to O
be O
a O
once-daily O
therapy O
with O
a O
rapid O
onset O
of O

4'-(9-acridinylamino)methanesulfon-m-anisidide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O

etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide O
) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(les O
s B
tha I
n O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O

MNU O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
complex O
showed O
that O
the O
DL O
developed O
tumors O
exclusively O
in O
the O
periurethral O
area O
and O
showed O
intense O
AR O
, O
PCNA O
, O
and O
MGMT O
immunostaining O
. O
Moreover O
, O
VL O
lesions O
emerged O
throughout O
the O
entire O
lobe O
. O
MNU-induced O
lesions O
presented O
markers O
indicative O
of O
an O
aggressive O
phenotype O
: O
lack O
of O
basal O
cells O
, O
rupture O
of O
the O
smooth O
muscle O
cell O
layer O
, O
loss O
of O
E-cadherin O
O O
, O
and O
high O
MGMT O
staining O
. O
CONCLUSIONS O
: O
There O
are O
distinct O

involved O
in O
tumor O
progression O
in O
gerbil O
prostate O
lobes O
. O
This O
animal O
provides O
a O
good O
model O
for O
prostate O
cancer O
since O

4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
DOI O
, O
and O
failed O
to O
substitute O
for O
(+)-amphetamine O
. O
Lisuride O
produced O
a O
significant O
dose-related O
increase O
in O
flat O
body O
posture O
, O
forepaw O
treading O
, O
and O
lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) O
receptors O
. O

Only O
pMPPI O
4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride] O
, O
a O
selective O
5-HT(1A) O
antagonist O
, O
was O
effective O
in O
inhibiting O
all O
5-HT O
syndrome O
behaviors O
produced O
by O
lisuride O
, O
whereas O
pMPPI O
was O
without O
effect O
on O
any O
behavior O
induced O
by O
LSD O
. O
Lisuride O
dose O
dependently O
decreased O
body O
temperature O
in O
rats O
with O
a O
potency O
similar O
to O
that O

anthranilic O
acid O
sulfonamides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
aminopeptidase-2 O
: O
a O
structural O
basis O
for O
the O
reduction O
of O
albumin O
binding.Methionine O
aminopeptidase-2 O
(MetAP2) O
is O
a O
novel O
target O
for O
cancer O
therapy O
. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2 O
, O
a O
series O
of O
anthranilic O
acid O
sulfonamides O
with O
micromolar O
affinities O
for O
human O
MetAP2 O
were O
identified O
using O
affinity O
selection O
by O
mass O
spectrometry O
(ASMS) O

scree O
ning O
. O
These O
m O
icromolar B
hits O
were O
rapidly O
improved O
to O
nanomolar O
leads O
on O
the O
basis O
of O
insights O
from O
protein O
crystallography; O
however O
, O
the O
compounds O
displayed O
extensive O
binding O
to O
human O

cocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
O O
, O
which O
was O
further O
supported O

[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O

GW572016 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts O
. O
Inhibition O
of O
p95ErbB2 O
, O
p185ErbB2 O
, O
and O
EGFR O
phosphorylation O
by O
GW572016 O
resulted O
in O
the O
inhibition O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
and O
cyclin O
D O
steady-state O
protein O
levels O
. O
Increased O
phosphorylation O
of O
p95ErbB2 O
and O
AKT O

in O
response O
to O
HRG O
was O
abrogated O
to O
varying O
degrees O
by O
GW572016 O
O O
. O
In O
contrast O
, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 O
phosphorylation O
or O
the O
expression O
of O
downstream O
phospho-Erk1/2 O
, O
phospho-AKT O
, O
or O
cyclin O
D O
. O
It O
is O
tempting O
to O
speculate O
that O
trastuzumab O
resistance O
may O
be O
mediated O
in O
part O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion O
protein O
PrP(C) O
consists O
of O
two O
domains--a O
flexible O
N O
-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O

[(13)C]formate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
O O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
O O
: O
1; O
in O
roots O

O O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O

pelargonidin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O

in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O

chlorethylclonidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha O
1B-adrenoceptors O
by O
treatment O
with O
chlorethylclonidine O
O O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O

a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O

all-trans-13,14-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat O
A O
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O

all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O

Alprenolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
the O
isoprenaline O
responses O
with O
alprenolol O
and O
BAAM O
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
m O
in O
, O
which O
is O
indicati O
ve O
of O
reversible O
antagonism O
. O
We O
conclude O
that O
alprenolol O
and O
BAAM O
are O
competitive O
slowly O
reversible O
beta O
1-adrenoceptor O
antagonists O
on O
rat O
left O
atri O
s O
of O
rat O
left O
atria.We O
studied O
the O
effects O
of O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O

. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O

escitalopram O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
antidepressant O
which O
is O
the O
S-enantiomer O
of O
citalopram O
, O
is O
in O
clinical O
development O
worldwide O
for O
the O
treatment O
of O
depression O
and O
anxiety O
disorders O
. O
Preclinical O
studies O
demonstrate O
that O
the O
therapeutic O
activity O
of O
citalopram O
resides O
in O
the O
S-isomer O
and O
that O
escitalopram O
binds O
with O
high O
affinity O
to O
the O
human O
serotonin O
transporter O
O O
. O
Conversely O
, O
R-citalopram O
is O
approximately O
30-fold O
less O
potent O
than O
esc B
italopram O
at O
this O

r O
. O
Escitalopram O
has O
linear O
pharmacokinetics O
, O
so O
that O
plasma O
levels O
increase O
proportionately O
and O
predictably O
with O
increased O
doses O
and O
its O
half-life O
of O
27 O
- O
32 O

Rg1 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35 O
-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O

: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O

U50,488H O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
(proteasome O
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O

down-regulation O
. O
These O
results O
indicate O
that O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
involves O
GRK- O
, O
arrestin-2- O
, O
dynamin- O
, O
rab5- O
, O
and O
rab7-dependent O
mechanisms O
and O
receptors O
seem O
to O
be O
trafficked O
to O
lysosomes O
and O
proteasomes O
for O
degradation O
. O
Thus O
, O
U50,488H-induced O
internalization O
and O
down-regulation O
of O
the O
hkor O
share O
initial O
common O
mechanisms O
. O
To O
the O
best O
of O
our O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
linkage O
between O
NRF2 O
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
O O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O

sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O

EETs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
CYP2J2 O
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
CYP2J2) I
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs O
) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O

in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O

UDP-Glc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O

(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O

AICAR O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2 O
, O
while O
no O
alteration O
of O
pro-apoptotic O
Bax O
was O
observed O
. O
Compound O
C O
diminished O
AMPK O
phosphorylation O
and O
enzymatic O
activity O
, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl O
CoA O
carboxylase O
. O
AMPK O
activators O
metformin O
and O
AICAR O
partly O
prevented O
the O
cell O
cycle O
block O
, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C O
. O
The O

small O
interfering O
RNA O
(siRNA) O
targeting O
of O
human O
AMPK O
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest O
, O
but O
failed O
to O
induce O
oxidative O
stress O
and O

meloxicam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
diclofenac O
on O
human O
thromboxane O
biosynthesis O
after O
single O
doses O
and O
at O
steady O
state.OBJECTIVE O
: O
To O
evaluate O
the O
extent O
of O
human O
cyclooxygenase-1 O
(COX-1) O
inhibition O
by O
meloxicam O
, O
which O
has O
been O
reported O
to O
preferentially O
inhibit O
cyclooxygenase-2 O
(COX-2) O
. O
The O
effects O
of O
meloxicam O
were O
compared O
with O
those O
of O
diclofenac O
, O
a O
nonselective O
COX O

inhibitor O
. O
METHODS O
: O
COX-1 O
inhibition O
was O
dete O
rmin B
ed O
by O
measuring O
thromboxane O
B2 O
(TXB2)-generation O
from O
clotting O
whole O
blood O
ex O
vivo O
after O
single O
oral O
doses O
of O
7.5 O
and O
15 O
mg O
meloxicam O
and O
75 O
mg O
diclofenac O
and O
at O
steady O
state O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
+ O
prazosin O
+ O
imiloxan; O
slightly O
blocked O
by O
SB224289 O
+ O
rauwolscine; O
and O
markedly O
blocked O
by O
SB224289 O
+ O
rauwolscine O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O

alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptors O
. O

DRF O
2655 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
DRF O
2655 O
: O
a O
unique O
molecule O
that O
reduces O
body O
weight O
and O
ameliorates O
metabolic O
abnormalities.OBJECTIVE O
: O
Preclinical O
evaluation O
of O
DRF O
2655 O
, O
a O
peroxisome O
proliferator-activated O
receptor O
alpha O
(PPARalpha O
) O
and O
PPARgamma O
agonist O
, O
as O
a O
body-weight O
lowering O
, O
hypolipidemic O
and O
euglycemic O
agent O
. O
RESEARCH O
METHODS O
AND O
PROCEDURES O
: O
DRF O
2655 O
was O
studied O
in O
different O
genetic O
, O
normal O
, O

and O
hyperlipidemic O
animal O
models O
. O
HEK O
293 O
cells O
were O
used O
to O
conduct O
the O

KAD-1229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O

K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O

etomidate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg) O
. O
Etomidate O
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O
mice O
. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors O
, O
etomidate O
inhibited O
binding O
of O
the O
alpha2-antagonist O
, O
[3H]RX821002 O
, O
with O
higher O
potency O
from O
alpha2B- O
and O

alpha2C-receptors O
than O
from O
alpha2A-receptors O
(Ki O
alpha2A O
208 O
microm O
, O
alpha2B O
26 O
microm O
, O
alpha2C O
56 O
microm) O
. O
In O
alpha2B-receptor-expressing O
HEK293 O
cells O
, O
etomidate O
rapidly O
increased O
phosphorylation O
of O
the O
extracellular O
signal-related O
kinases O
ERK1/2 O
. O
CONCLUSIONS O
: O
These O
results O
indicate O
that O
etomidate O

epinastine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O

stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Preferential O
block O
of O
late O
sodium O
current O
in O
the O
LQT3 O
DeltaKPQ O
mutant O
by O
the O
class O
I(C) O
antiarrhythmic O
flecainide.Flecainide O
block O
of O
Na(+) O
current O
(I(Na)) O
was O
investigated O
in O
wild-type O
(WT) O
or O
the O
long O
QT O
syndrome O
3 O
(LQT3) O
sodium O
channel O
alpha O
subunit O
mutation O
with O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O

patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
O O

To O
determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O

Nor-NOHA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O

prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
tacrine>pyridostigmine=edrophonium=galanthamine O

>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O

morantel O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
pylori O
mutants O
became O
readily O
infected O
. O
These O
data O
indicate O
that O
FRD O
plays O
a O
crucial O
role O
in O
H O
. O
pylori O
survival O
in O
the O
gastric O
mucosa O
of O
mice O
. O
Given O
that O
FRD O
, O
present O
in O
all O
H O
. O
pylori O
strains O
, O
is O
immunogenic O
in O
H O
. O
pylori O
-infected O
patients O
and O
H O
. O
pylori O
growth O
in O
vitro O
can O
be O
inhibited O
by O
three O
anthelmintics O
(morantel O
O O
, O
oxantel O
and O
thiabendazole) O
, O
this O
enzyme O
could O
potentially O
be O

both O
as O
a O
novel O
drug O
target O
as O
well O
as O
in O
the O
development O
of O
vaccines O
for O
H O
. O

Felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
We O
conclude O
that O
felbamate O
ex O
hibits O
modest O
selectivity O
for O
N O
MDA O
receptors O
composed O
of O
NR1a/NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivit O
s O
: O
selectivity O
for O
the O
NR2B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O

neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA O
receptor O
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O

pranlukast O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O

CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
O O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O

sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
bot O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafi O
l.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
results O
indicate O
that O
the O
glutathione O
conjugates O
of O
BPDE O
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O

ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O

Thiazolidinediones O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells O
Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin O
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O

vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O

Cyp1a1 O
O O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX O
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
O O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O

tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O
double-blind O
, O
pla O
cebo-controlled B
, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline O
magnesium O
trisalicylate O
(CMT O
, O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O

(MAO-A) O
inhibitor O
harmaline O
(5 O
mg O
/ O
kg) O
increases O
system O
ic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves O
a O
1 O
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves O
a O
1s O
O O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
at O
S536 O
, O
but O
not O
p65 O
at O
S276 O
. O
This O
was O
confirmed O
by O
their O
ability O
to O
selectively O
abrogate O
the O
induction O
of O
IL-8 O
transcription O
, O
whereas O
the O
ICAM-1 O
gene O
, O
which O
is O
not O
transcribed O
selectively O
by O
an O
NF-κB O
complex O
containing O
a O
form O
of O
p65 O
phosphorylated O
on O
Ser O
536 O
, O
did O
not O
change O
. O
Finally O
, O
the O
plant O
extracts O
at O
200μg/mg O
could O
normalize O
the O
LPS-induced O
elevation O
of O
spleen O
index O
as O
well O
as O
NF-κB O
and O
p38 O
activations O

in O
CD1 O
mice O
. O
CONCLUSION O
: O
The O
present O
studies O
presents O
the O
potential O
utilization O
of O
this O

MG-132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I O
or O
rab7-N125I O
blunted O
U50,488H-induced O
down-regulation O
. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O

proteasome O
inhibitors O
proteasome O
inhibitor O
I O
, O
MG-132 O
O O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O
down-regulation O
. O
These O
results O
indicate O
that O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
involves O
GRK- O
, O
arrestin-2- O
, O
dynamin- O
, O
rab5- O
, O
and O
rab7-dependent O
mechanisms O

mifepristone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
[Effect O
of O
mifepristone O
on O
the O
expression O
of O
progesterone O
receptor O
messenger O
RNA O
and O
protein O
in O
uterine O
leiomyomata].OBJECTIVE O
: O
To O
determine O
the O
expression O
of O
progesterone O
receptor I
(PR) O
mRNA O
and O
PR O
protein O
levels O
in O
the O
myometrium O
and O
leiomyomata O
from O
untreated O
and O
mifepristone O
pretreated O
women O
with O
leiomyoma O
and O
to O
examine O
the O
mechanism O
of O
mifepristone O
treatment O
on O
uterine O
leiomyomata O
. O

METHODS O
: O
Expression O
of O
PR O
mRNA O
and O
PR O
protein O
were O
determined O
by O
Northern O
blot O
and O
HAP O
of O
single-dose O
saturated O
analysis O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Fisetin O
regulates O
obesity O
by O
targeting O
mTORC1 O
signaling.Fisetin O
, O
a O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O

biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O

gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O

(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
Ho O
wever O
, O
DeltahPPAR-alpha O

telmisartan O
acts O
as O
AGONIST O
for O
what O
entity O
? O
through O
the O
blood-brain O
barrier O
. O
Differences O
in O
binding O
mode O
and O
tissue O
penetration O
are O
also O
associated O
with O
differences O
in O
pharmacokinetic O
profile O
, O
particularly O
duration O
of O
action O
. O
Although O
generally O
highly O
specific O
for O
angiotensin O
II O
type O
1 O
receptors O
, O
some O
ARBs O
, O
particularly O
telmisartan O
, O
are O
partial O
agonists O
at O
peroxisome O
proliferator-activated O
receptor-γ O
O O
. O
All O
of O
these O
properties O
are O
comprehensively O
reviewed O
in O
this O
article O
. O
Although O
there O
is O
general O
consensus O
that O
a O
continuous O
receptor O
blockade O
over O
a O
24-hour O
period O

desirable O
, O
the O
clinical O
relevance O
of O
other O
pharmacological O
differences O
between O
individual O

ethanol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Changes O
of O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
: O
naloxone O
reversal.AIM O
: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP O
response I
element I
binding I
protein I
CREB) B
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
and O
its O
withdrawal O
. O
METHODS O
: O
Ethanol O
was O
given O
in O
drinking O
water O
at O
the O
concentration O
of O
6 O
% O
(v/v) O
, O
for O
one O
month O
. O
Changes O

in O
the O
levels O
of O
CREB O
and O
phospho-CREB O
(p-CREB) O
protein O
in O
the O
nucleus O
accumbens O

EX527 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527 O
) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O

induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O

vitamin O
A2 O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat O
A O
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O

all-trans-3,4-didehydroretinol O
(vitamin O
A2 O
) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O

N(5) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Contrasting O
effects O
of O
N5-substituted O
tetrahydrobiopterin O
derivatives O
on O
phenylalanine O
hydroxylase O
, O
dihydropteridine O
reductase O
and O
nitric O
oxide O
synthase.Tetrahydrobiopterin O
[(6R)-5,6,7,8-tetrahydro-L-biopterin O
, O
H(4)biopterin] O
is O
one O
of O
several O
cofactors O
of O
nitric O
oxide O
synthases O
(EC O
1.14.13.39) O

. O
Here O
we O
compared O
the O
action O
of O
N(5)-substituted O
derivatives O
on O
recombinant O
rat O
neuronal O
nitric O
oxide O
synthase O
with O
their O
effects O
on O
dihydropteridine O
reductase O
(EC O
1.6.99.7) O
and O
phenylalanine O
hydroxylase O
(EC O
1.14.16.1),the O
well-studied O
classical O
H(4)biopterin-dependent O
reactions O
. O
H(4)biopterin O
substituted O
at O
N(5) O
with O
methyl O
, O
hydroxymethyl O
, O
formyl O
and O
acetyl O
groups O
were O
used O
. O

Substitution O
at O
N(5) O
occurs O
at O

Artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O
CoA O
reductase O
gene O
, O
which O
is O
mediated O
by O
C/EBP O
α O
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibito O
e O
gene.Cholesterol O
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation O
. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O

of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O

cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O

subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O

4-PIOL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O
computational O
technique O
with O
a O
high-quality O
low-throughput O
screen O
identified O
5-(4-piperidyl)-3-isoxazolol O
4-PIOL) O
as O
a O
potent O
plasminogen O
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O
Remarkably O
, O

4-PIOL O
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA O
. O

alpha-linolenic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 O
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
t O
he B
eff I

ect O
of O
alpha-linolenic O
acid O
(ALA) O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O

ICRF-187 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non-S-phase O
cells O
. O
First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O

the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
(RNAP O
LS) O
became O
progressively O

dopamine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O
reinforce O
previous O
assumptions O
that O
dopamine O
may O
interact O
with O
eicosanoid O
metabolism O
by O
means O
of O
D(2) O
receptor O
activation O
, O
and O
implicate O
an O
involvement O
of O
cPLA(2) O
and O
COX-2 O
in O

this O
effect O
. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced O
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) O
receptor O
function O
in O
vitro O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Histone O
deacetylase O
3 O
is O
required O
for O
maintenance O
of O
bone O
mass O
during O
aging.Histone O
deacetylase O
3 O
(Hdac3) O
is O
a O
nuclear O
enzyme O
that O
removes O
acetyl O
groups O
from O
lysine O
residues O
in O
histones O
and O
other O
proteins O
to O
epigenetically O
regulate O
gene O
expression O
. O
Hdac3 O
interacts O
with O
bone-related O
transcription O
factors O
and O
co-factors O
such O
as O
Runx2 O
and O
Zfp521 O
, O
and O
thus O
is O
poised O
to O
play O
a O
key O
role O
in O
the O
skeletal O
system O
. O
To O
understand O
the O
role O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating O
Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1 O
/GluN2B I
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O

gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O

astemizole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine O
H1-receptor O
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor I
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O

chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O

flecainide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
three O
amino O
acids O
deleted O
(DeltaKPQ) O
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell O
, O
patch-clamp O
recordings O
. O
Flecainide O
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) O
in O
a O
concentration-dependent O
manner O
. O
Compared O
with O
WT O
, O
DeltaKPQ O
I(Na) O
was O
more O
sensitive O
to O
flecainide O
O O
, O
and O
flecainide O
preferentially O
inhibited O

I(Na) O
(mean O
current O
between O
20 O
and O
23.5 O
ms O
after O
depolarization) O
compared O
with O
peak O
I(Na) O
. O
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) O
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O

R(-) O
isomer O
of O
MDA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
[3H]inositol O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A O
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O

R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O

A-64662 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin I
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O

0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O

polyamine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Structures O
of O
wild-type O
and O
mutant O
human O
spermidine/spermine O
N1-acetyltransferase O
, O
a O
potential O
therapeutic O
drug O
target O
Spermidine/spermine O
N1-acetyltransferase O
(SSAT) O
is O
a O
key O
enzyme O
in O
the O
control O
of O
polyamine O
levels O
in O
human O
cells O
, O
as O
acetylation O
of O
spermidine O
and O
spermine O
triggers O
export O
or O
degradation O
. O
Increased O
intracellular O
polyamine O
levels O
accompany O
several O
types O
of O

cancers O
as O
well O
as O
other O
human O
diseases O
, O
and O
compounds O
that O
affect O
the O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
biogenesis O
remains O
unknown O
. O
We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf-dependent O
adaptors O
(AP-1 O
and O
GGAs) O
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo O
proteins O
(furin O
, O
mannose-6-phosphate O
receptor O
(M6PR) O
and O
M6PR O
lacking O
a O
C-terminal O
domain O
M6PRΔC O
) O
. O
We O
find O
that O
cargo O
promotes O
the O
recruitment O
of O
specific O
adaptors O
, O
suggesting O
that O
it O
is O
part O
of O
an O
upstream O
signaling O
event O
. O

Cargos O
do O
not O
promote O
adaptor O
recruitment O
to O
all O
compartments O
in O
which O
they O
reside O
and O
thus O
additional O
factors O

dronedarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O

inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O

EtOH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH O
+DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O

. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O

with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O

oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O

AuF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF-induced O
MAPK O
, O
JNK O
and O
p38 O
(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O

caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O

rosiglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O

Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O

ginsenoside O
Rg1 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Activating O
glucocorticoid O
receptor-ERK O
signaling O
pathway O
contributes O
t O
ginsenoside O
Rg1 O
protection O
against O
β-amyloid O
peptid O
e-induced O
human O
endothelial O
cells O
apoptosis.The O
deposition O
of O
β-amyloid O
(Aβ) O
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O

mibefradil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
State-dependen O
mibefradil O
block O
of O
Na+ O
channel O
s.Mibefradil O
is O
a O
T-type O
Ca2+ O
channel O
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels O
, O
including O
K+ O
, O
Cl- O
, O
and O
Na+ O
channels O
. O
Using O
whole-cell O
voltage O
clamp O
, O
we O
examined O
mibefradil O
block O
of O
four O
Na+ O
channel O
isoforms O
expressed O
in O

saccharin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R O
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
. O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O

receptors O
are O
activated O
by O

Dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
diosci O
n-ind B
uced B
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reactio O
K/Akt O
and O
ERK O
and O
JNK O
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines.Our O
previous O
study O
has O
revealed O
that O
dioscin O
, O
a O
compound O
with O

anti-inflammatory O
, O
lipid-lowering O
, O
anticancer O
and O
hepatoprotective O
effects O
, O
may O
induce O
autophagy O
in O
hepatoma O
cells O
. O
Autophagy O
is O
a O
lysosomal O
degradation O
pathway O

rasagiline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
activation O
, O
a O
reduction O
in O
superoxide O
generation O
and O
a O
trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential O
. O
Rasagiline O
induced O
an O
increase O
in O
cellular O
glutathione O
levels O
. O
The O
results O
support O
a O
role O
for O
rasagiline O
in O
protecting O
dopaminergic O
cells O
against O
free O
radical O
mediated O
damage O
and O
apoptosis O
in O
the O
presence O
of O
alpha-synuclein O
over-expression O
. O
The O
data O
are O
of O
relevance O
to O
the O
interpretation O
of O
the O
potential O
mechanisms O
of O
action O
of O
rasagiline O
in O
explaining O
the O
results O
of O
disease O
modification O

trials O
in O
PD O
. O

kurarinol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol O

acyltransferase O
(DGAT O
) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O

Juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
ju O
glo B
ne O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O
AR O
expression O
. O
Therefore O
, O
our O
results O
indicated O
that O
juglone O
may O
be O
a O
potential O
candidate O
of O
drug O
for O
androgen-sensitive O
prostate O
cance O
R O
expression O
in O
human O
prostate O
cancer O
LNCaP O
cells.Juglone O
is O
a O
natural O
compound O
which O
has O
been O
isolated O
from O
Juglans O
mandshurica O
Maxim O
. O
Recent O

studies O
have O
shown O
that O
juglone O
had O
various O
pharmacological O
effects O
such O
as O
anti-viral O
, O
anti-bacterial O
and O
anti-cancer O
. O
However O
, O
its O
anti-cancer O
activity O

glutamate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O

desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T O
. O
, O
Monyer O
, O
H. O
, O
Higu O
chi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) O
blockers O
, O
bis-(o-aminophenoxy) O
ethane-N,N,N',N'-tetra-acetic O
acid O
acetoxymethyl O
ester O
(BAPTA-AM) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O

phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
O O
, O
and O
the O
translocation O
of O
NF-κB O
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine O

>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contrast O
, O
no O
differences O
in O
receptor O
occupancy O
were O
detected O
at O
the O
level O
of O
the O
pituitary O
gland O
. O
Clinical O
outcomes O
, O
in O
particular O
a O
full O
extra O
pyramidal O
tolerability O
, O
were O
similar O
. O
In O
this O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients O
, O
olanzapine O
and O
clozapine O
showed O
a O
different O
pattern O
of O
occupancy O
of O
D2-like O
receptor O
despite O
a O
common O
lack O
of O
extrapyramidal O
side-effects O
. O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O

interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 O
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro O
Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4 O
-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O

interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O

arylhydroxylamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O

carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O

1,2,2-trimethyl-propylmethylphosphonofluoridate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
AChE) B
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate O
) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O

dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O

Alcohol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
pr O
oteasomal B
pathway O
. O
Suc O
h O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O
molecular O
mechanism O
underlying O
the O
pathogenesis O
of O
FAS O
during O
mammalian O
developmen O
s O
and O
methyl O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O

(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(one O
mutant) O
, O
F420L O
(one O
mutant) O
, O
and O
P430S O
(five O
mutants) O
in O
the O
C-terminal O
part O
of O
the O
protein; O
and O
three O
mutants O
carried O
an O
L251F O
exchange O
in O
the O
central O
part O
of O
the O
protein O
. O
Interestingly O
, O
all O
exchanges O
identified O
involved O
amino O
acids O
which O
are O
conserved O
in O
the O
squalene O
epoxidases O
of O
yeasts O
and O
mammals O
. O
Two O
mutations O
that O
were O
generated O
by O
PCR O
mutagenesis O
of O
the O
ERG1 O
gene O
and O
that O
conferred O
terbinafine O
resistance O
mapped O
in O
the O
same O
regions O

of O
the O
Erg1 O
protein O
, O
with O
one O
resulting O
in O
an O

I3A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
the O
interaction O
of O
ingenol O
3-angelate O
with O
protein O
kinase O
C.Ingenol O
3-angelate O
(I3A) O
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus O
, O
which O
has O
been O
used O
in O
traditional O
medicine O
. O
Here O
, O
we O
report O
the O
initial O
characterization O
of O
I3A O
as O
a O
protein O
kinase O
C O
(PKC O
) O
ligand O
. O
I3A O
bound O
to O
PKC-alpha O
in O
the O
presence O
of O
phosphatidylserine O
with O
high O
affinity; O
however O
, O
under O
these O
assay O
conditions O
, O
little O

PKC O
isoform O
selectivity O
was O
observed O
. O
PKC O
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
activator O
of O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O

not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O

progestins O
acts O
as O
NOT O
for O
what O
entity O
? O
studies O
on O
the O
prevention O
of O
heart O
disease O
by O
estrogens O
and O
progestins O
warrant O
a O
better O
understanding O
of O
nuclear O
hormone O
receptor O
function O
and O
interaction O
. O
To O
address O
this O
issue O
and O
taking O
into O
account O
that O
effects O
of O
synthetic O
progestins O
are O
not O
only O
referable O
to O
action O
through O
the O
progesterone O
receptor O
but O
may O
also O
be O
mediated O
by O
other O
steroid O
receptors O
, O
we O
characterized O
cardiovascular O
function O
and O
inflammatory O
gene O
expression O
in O
aldosterone O
salt-treated O
rats O
on O
lo O
ng-term B
administration O
of O
17beta-estradiol O
, O

medroxyprogesterone O
acetate O
, O
and O
drospirenone O
, O
a O
new O
progestogen O
exhibiting O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cellular O
mechanisms O
of O
insulin O
resistance O
: O
role O
of O
stress-regulated O
serine O
kinases O
and O
insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation.Insulin O
receptor O
substrates O
IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O

the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O

cAMP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
pathways O
which O
involve O
intracellular O
cAMP O
accumulation O
and O
protein O
synthesis O
. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far O
, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O
TPO O
. O
TSH O
and O
cAMP O
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO O
in O
thyroid O
cells O
from O
different O
species O
. O
Whether O
this O
phenomenon O
is O
due O
to O
a O
direct O
transcriptional O
regulation O
of O
the O
TPO O
gene O
, O
as O
shown O
in O
dog O
thyroid O
cells O
, O
or O
to O

posttranscriptional O
effects O
, O
as O
it O
would O
appear O

Minocycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
respectively O
, O
at O
1 O
, O
5 O
, O
10 O
, O
30 O
, O
50 O
, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week O
. O
Our O
results O
have O
shown O
that O
MMP-9 O
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline O
starting O
at O
10 O
mg/kg/day O
(P<0.02) O
. O
Minocycline O
showed O
more O
potent O
inhibition O
on O
MMP-9 O
mRNA O
expression O
, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O

more O
than O
30 O
(P<0.001) O
mg/kg/day O
. O
At O
the O
enzymatic O
activity O
level O
, O
doxycycline O
started O
to O
suppress O
MMP-9 O
activity O
at O
5 O
mg/kg/day O
(P<0.001) O
, O
while O
minocycline O
had O
an O
effect O
at O
a O

DXM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A I
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O

(2'CMP O
) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O

CR O
1409 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O

D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
O O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O

. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O

pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
M O
g(2+) O
, O
or O
Mn(2+) O
, O
but O
not O

phenytoin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
patients O
, O
respectively O
. O
We O
report O
that O
a O
known O
functional O
polymorphism O
in O
CYP2C9 O
is O
highly O
associated O
with O
the O
maximum O
dose O
of O
phenytoin O
(P O
= O
0.0066) O
. O
We O
also O
show O
that O
an O
intronic O
polymorphism O
in O
the O
SCN1A O
gene O
shows O
significant O
association O
with O
maximum O
doses O
in O
regular O
usage O
of O
both O
carbamazepine O
and O
phenytoin O
(P O
= O
0.0051 O
and O
P O
= O
0.014 O
, O
respectively) O
. O
This O
polymorphism O
disrupts O
the O

consensus O
sequence O
of O
the O
5' O
splice O
donor O
site O
of O
a O
highly O
conserved O
alternative O
exon O
(5N) O
, O
and O
it O
significantly O
affects O
the O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

phthalide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O

phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O

(+/-)-tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(+/-)-tamsulosin O
, O
an O
alpha O
1A-adrenoceptor O
antagonist O
, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O

1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O

spermine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase O
3 O
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O

and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O

levobetaxolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
sodium O
channel O
(Na(+) O
channel) O
in O
rat O
cerebrocortical O
synaptosomes O
. O
Betaxolol O
inhibited O
specific O
[(3)H]-batrachotoxinin-A O
20-alpha-benzoate O
([(3)H]-BTX-B) O
binding O
to O
neurotoxin O
site O
2 O
in O
a O
concentration-dependent O
manner O
with O
an O
IC(50) O
value O
of O
9.8 O
microM O
. O
Comparison O
of O
all O
the O
beta-adrenoceptor O
antagonists O
tested O
revealed O
a O

potency O
order O
of O
propranolol>betaxolol O
approximately O
levobetaxolol O
>levobunolol O
approximately O
carteolol>/=timolol>atenolol O
. O
None O
of O
the O
drugs O
caused O
a O
significant O
inhibition O
of O
[(3)H]-saxitoxin O
binding O
to O
neurotoxin O
receptor O
site O
1 O
, O
even O
at O
concentrations O
as O
high O
as O
250 O
microM O
. O
Saturation O
experiments O
showed O
that O
betaxolol O
increased O
the O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O

sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
and O
contractile O
function O
. O
Real-time O
quantitative O
reverse-transcription O
polymerase O
chain O
reaction O
and O
immunohistochemical O
analysis O
were O
performed O
to O
determine O
mRNA O
levels O
and O
receptor O
protein O
expressions O
respectively O
, O
for O
alpha(1A)- O
, O
alpha(1B)- O
and O
alpha(1D)-adrenoceptors O
in O
hamster O
ureteral O
smooth O
muscle O
. O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O

hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha( O
1a)- O
, O
alpha(1b)- O
and O
a O
lpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O

glucuronic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O

pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
O O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O

AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

F3(d)Thd O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated O
pyrimidines O
in O
human O
colorectal O
cancer O
cells.5-Fluorouracil O
(5-FU) O
, O
5-fluoro-2'-deoxyuridine O
(FdUrd) O
and O
5-trifluorothymidine O
F3(d)Thd) O
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O
inhibition O
of O
thymidylate O
synthase O
(TS) O

. O
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance O
, O
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs O
, O
and O
analyzed O
the O
cytotoxicity O
and O

fenclozic O
acid O
acts O
as O
NOT O
for O
what O
entity O
? O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450 O
-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human O
cytochrome O
P450 O

enzymes O
, O
inhibition O
of O
the O
biliary O
efflux O
transporters O
BSEP O
and O
MRP2 O
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O

fenoterol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
control O
preparations O
, O
consistently O
restored O
the O
reduced O
pEC(50) O
and O
E(max) O
values O
of O
the O
contractile O
agonists O
. O
Remarkably O
, O
in O
the O
presence O
of O
timolol O
the O
pEC(50) O
values O
of O
McN-A-343 O
and O
histamine O
in O
fenoterol-treated O
airways O
were O
significantly O
enhanced O
compared O
to O
controls O
. O
In O
conclusion O
, O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor O
activity O
reduces O
muscarinic O
receptor O
agonist- O
and O
histamine-induced O
contractions O
of O

bovine O
tracheal O
smooth O
muscle O
, O
which O
can O
be O
reversed O
by O
the O
inverse O
agonist O
timolol O
. O
Moreover O
, O
after O
beta(2)-adrenoceptor O
agonist O
treatment O
, O
inverse O
agonism O
by O
beta-adrenoceptor O
antagonists O
may O
cause O
enhanced O
airway O
reactivity O
to O

methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter I
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O

inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O

RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O

sulindac O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
O O
. O
These O
results O

that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O
one O
pathway O
. O
Using O
similar O
combinatorial O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis O
: O
a O
case O
study O
with O
paraoxon.Using O
paraoxon O
as O
a O
reference O
acetylcholinesterase O
(AChE) O
inhibitor O
, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O
Within O
normal O
zebrafish O
embryos O
, O
we O
first O
demonstrated O
that O
ache O
transcripts O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
+ O
prazosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptor O
e O
in O
vagosympathectomised O

dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors O
. O
The O
present O
study O
has O
reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetise O
zosin O
, O
SB224289 O
+ O
prazosin O
+ O
BRL44408 O
or O
SB224289 O
+ O
prazosin O
+ O
MK912 O
. O
Thus O
, O
the O
cranio-selective O

vasoconstriction O
elicited O
by O
ergotamine O
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B O
receptors O
as O
well O
as O
alpha2A/2C-adrenoceptor O
subtypes O
and O
, O
to O
a O
lesser O
extent O
, O
by O
alpha1-adrenoceptor O
e O
in O
vagosympathectomised O
dogs.It O
has O
previously O
been O
suggested O
that O
ergotamine O
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D O
receptors O
and O
alpha2-adrenoceptors O
. O
The O
present O
study O
has O
reanalysed O
this O

suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination O
. O
Fifty-two O
anaesthetised O

clofarabine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma O
. O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
O O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O

other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O

testosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O

testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cellular O
mechanisms O
of O
insulin O
resistance O
: O
role O
of O
stress-regulated O
serine O
kinases O
and O
insulin O
receptor O
substrates O
(IR O
S) I
serin I
e O
phosphorylation.Insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O

activated O
by O
the O

morphine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Galanin O
attenuates O
cyclic O
AMP O
regulatory I
element-binding I
protein I
(CRE O
B) I
phosphorylation O
induced O
by O
chronic O
morphin O
e B
and O
naloxone O
challenge O
in O
Cath.a O
cells O
and O
primary O
striatal O
cultures.Repeated O
morphine O
administration O
leads O
to O
molecular O
alterations O
of O
the O
neural O
circuitry O
in O
the O
locus O
coeruleus O
and O
nucleus O
accumbens O
. O
These O
changes O
include O
increased O
activity O
of O
several O
components O
of O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP O
-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O

ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

pranlukast O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O

blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O

MDMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O
MDMA-induced O
reductions O
in O
SERT O
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O
of O
brain O
serotonin O
, O
but O
may O
occur O
in O
response O
to O
some O
other O
stimulus O
or O
to O
the O
neurotoxic O
effects O
of O
MDMA O
. O

AACOCF3 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 O
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O

that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O

HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O

Imatinib O
acts O
as O
NOT O
for O
what O
entity O
? O
inhibitor O
Z-VAD-fmk O
. O
The O
ability O
of O
imatinib O
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O
by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity O
. O
Imatinib O
was O
also O
found O
to O
inhibit O
M-CSF-induced O
osteoclast O
survival O
as O
well O
as O
M-CSF-induced O
osteoclast O
bone O
resorbing O
activity O
, O
but O
was O
without O
effect O
on O
interleukin O
1alpha O
(IL-1alpha) O
and O
receptor O
activator O
of O
nuclear O
factor O
kappa O
B O

ligand O
(RANKL O
)-induced O
inhibition O
of O
osteoclasts O
apoptosis O
, O
further O
supporting O
the O
hypothesis O
that O
imatinib O
may O
affect O
mature O
osteoclasts O
through O
the O
inhibition O
of O
c-FMS O
. O
Taken O
together O
, O

ellagic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
O O
, O
EC O
4.2.1.1) O
. O

mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hC O
A O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron O
; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O

spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
nM O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-- O
Ser O
replacement O
in O
the O
Rdl O
GABA O
receptor O
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O

[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O

diclofenac O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
thromboxane O
biosynthesis O
after O
single O
doses O
and O
at O
steady O
state.OBJECTIVE O
: O
To O
evaluate O
the O
extent O
of O
human O
cyclooxygenase-1 O
(COX-1) O
inhibition O
by O
meloxicam O
, O
which O
has O
been O
reported O
to O
preferentially O
inhibit O
cyclooxygenase-2 O
(COX-2) O
. O
The O
effects O
of O
meloxicam O
were O
compared O
with O
those O
of O
diclofenac O
, O
a O
nonselective O
COX O
inhibitor O
. O

METHODS O
: O
COX-1 O
inhibition O
was O
determined O
by O
measuring O
thro O
mboxane B
B2 O
(TXB2)-generation O
from O
clotting O
whole O
blood O
ex O
vivo O
after O
single O
oral O
doses O
of O
7.5 O
and O
15 O
mg O
meloxicam O
and O
75 O
mg O
diclofenac O
and O
at O
steady O
state O
(15 O
mg O
meloxicam O

spermine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Properties O
of O
purified O
recombinant O
human O
polyamine O
oxidase O
, O
PAOh1/SMO.The O
discovery O
of O
an O
inducible O
oxidase O
whose O
apparent O
substrate O
preference O
is O
spermine O
indicates O
that O
polyamine O
catabolism O
is O
more O
complex O
than O
that O
originally O
proposed O
. O
To O
facilitate O
the O
study O
of O
this O
enzyme O
, O
the O
purification O
and O
characterization O
of O
the O
recombinant O
human O
PAOh1/SMO O
polyamine O
oxidase O
are O
reported O
. O
Purified O
PAOh1/SMO O
oxidizes O
both O

spermine O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn-induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT O
) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O

HEK O
cells O
reveal O
that O
Mn O
is I
e I
qually O
toxic O
to O
both O
cell O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O

LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O

Sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
VEGFR O
and O
PDGFR O
signaling) O
. O
In O
phase O
I O
and O
phase O
II O
clinical O
trials O
, O
soraf O
enib B
showed O
limited O
side O
effects O
and O
, O
more O
importantly O
, O
disease O
stabilization O
. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinoma O
K O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR/PDGFR O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O

, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt O
-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O

mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
safety O
of O
the O
dipeptidyl O
peptidase-4 O
inhibitor O
, O
sitagliptin O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
, O
a O
highly O
selective O
once-daily O
oral O
dipeptid O
yl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O

type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
[glycosylated O
haemoglobin O
(HbA(1c)) O
>or=7.5% O
and O
<or=10.5%] O
while O
on O
glimepiride O
alone O
or O
in O
combination O
with O
metformin O
. O
METHODS O
: O
After O
a O
screening O
, O
diet/exercise O
run-in O
and O
drug O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
thromboxane O
B2 O
production O
from O
who O
le O
blood O
. O
Licof O
elone B
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profil O
e O
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis.Licofelone O

, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O

LY541850 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O
mGlu O
receptors O
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O
orthosteric O
mGlu2 O
agonist O
and O
mGlu3 O
antagonist O
. O
We O
have O

verified O
this O
pharmacological O
profile O
of O
LY541850 O
in O
hippocampal O
sl O
ices O
. O
Field O
excitatory O
post-synaptic O
potentials O
(fEPSPs) O
evoked O
by O
stimulation O
of O
the O
temporo-ammonic O
path O
(TAP) O
input O
to O
CA1 O
stratum O
lacunosum O

2,6-dichloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro O
- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O

inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O

cinnamic O
aldehyde O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O

treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O

(+/-)-tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
accumulation O
of O
inositol O
monophosphat O
e O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphate O
r O
antagonist O
, O
inhibits O
the O
positive O
inotropic O

effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O

silodosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O

Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O

phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu O
Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O

TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 O
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 O
-1639G>A O
genotype O
. O
RESULTS O
: O
Eighty O
percent O
of O
CYP2C9*1/*1 O
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin O
had O
at O
least O
1 O
VKORC1 O
-1639A O

allele O
. O
Mean O
warfarin O
doses O
(SD) O
were O
6.7 O
(3.3) O
, O
4.3 O
(2.2) O
, O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 O
-1639GG O
, O
GA O
, O
and O
AA O
genotypes O
, O
respectively O
. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin O

isoproterenol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
activity O
, O
as O
measured O
by O
an O
increase O
in O
frequency O
of O
spontaneous O
burst O
discharges O
recorded O
in O
the O
CA3 O
region O
. O
In O
the O
presence O
of O
alphaAR O
blockade O
, O
concentration-response O
curves O
for O
isoproterenol O
, O
norepinephrine O
, O
and O
epinephrine O
suggested O
that O
a O
beta1AR O
was O
involved O
in O
this O
response O
, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol O
> O
norepinephrine O
= O
epinephrine O
. O
Finally O
, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O

subtype-selective O
betaAR O
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR O
subtype O
modulating O
hippocampal O
CA3 O
activity O
. O
The O
selective O
beta1AR O
antagonists O
atenolol O
and O
metoprolol O
blocked O

GCS O
acts O
as O
NOT O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
O O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O

of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O

inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O

MSG O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1 O
) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O

0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O

Silibinin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
arrest O
in O
human O
gastric O
cells O
culture O
system O
using O
SGC-7901 O
as O
the O
model O
. O
Silibinin O
treatment O
could O
inhibit O
the O
cell O
growth O
and O
cause O
a O
prominent O
G2 O
phase O
arrest O
and O
apoptosis O
in O
dose- O
and O
time-dependent O
manner O
. O
In O
mechanistic O
studies O
, O
Silibinin O
decreased O
the O
protein O
level O
of O
p34cdc2 O
O O
, O
which O
might O
be O
the O
possible O
molecular O
mechanism O
of O
Silibinin O
efficacy O
on O
the O
growth O
inhibition O
in O
SGC-7901 O
cells O
. O
In O
addition O
, O

caused O
an O
increase O
in O
p53 O
and O
p21 O
protein O
level O
as O
well O
as O
mRNA O
levels O
. O
Interestingly O
, O

troglitazone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 O
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O

PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O

SoRI-9804 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
SoRI-9804) O
, O

N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O

[(125)I]RTI-55 O
from O
the O
DAT O
O O
, O
and O
p B
arti O
ally O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O

LY541850 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptors O
usin O
LY541850 O
, O
an O
mGlu O
2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O

mGlu O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O

determine O
whether O
arginases O
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O

S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O

olanzapine O
acts O
as O
NOT O
for O
what O
entity O
? O
version O
. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
hippocampal O
NGF O
, O
BDNF O
and O
ChAT O
that O
was O
eliminated O
by O
olanzapine O
treatment O
. O
Neonatal O
quinpirole O
treatment O
produced O
a O
significant O
decrease O
in O
BDNF O
and O
ChAT O
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine O
treatment O
. O
These O
results O
show O
that O
olanzapine O
eliminates O
D2 O
receptor O
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O

produced O
by O
D2 O
priming O
in O
the O
hippocampus O
. O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drug O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain I
K(+) I
channe I
l.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) I
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O

N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O

(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O

the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
O O
, O
a O
nd O
p B
artially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor O
Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human O
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin I
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O

0.1 O
mg/kg O
induced O
little O
hemodynamic O

15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O
selective O
cyclooxygenase-2 O
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O

apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O
NSAIDs O
, O
which O
could O
induce O
apoptosis O
, O
increased O
the O
activation O
of O
PPARgamma O
in O
synovial O
cells O
. O
Furthermore O
, O
the O
ability O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V O
-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O

patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD816V O
mutation O
destabilizes O
the O
inactive O
conformation O

CGP O
12177A O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor O
; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O

We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O

MDZ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ O
) O
as O
an O
indu O
cer I
an I
d I
a I
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O

DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O

imatinib O
mesylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Imatinib O
mesylate O
(Gleevec) O
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity.Recent O
studies O
have O
reported O
that O
imatinib O
mesylate O
, O
a O
kinase O
inhibitor O
that O
targets O
the O
intracellular O
tyrosine O
kinase O
BCR-ABL O
and O
the O
platelet O
derived O
growth O
factor O
(PDGF) O
receptor O
, O
is O
an O
effective O
inhibitor O
of O
the O
macrophage O
colony O
stimulating O
factor O
(M-CSF) O
receptor O
, O

c-FMS O
. O
Given O
that O
M-CSF O
signalling O
through O
c-FMS O
plays O
an O
important O
role O
in O
osteoclast O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
interphotoreceptor O
matrix O
where O
it O
surrounds O
both O
rods O
and O
cones O
. O
The O
functional O
protein O
contains O
1160 O
amino O
acids O
with O
a O
large O
central O
mucin O
domain O
, O
three O
consensus O
sites O
for O
glycosaminoglycan O
attachment O
, O
two O
epidermal O
growth O
factor-like O
repeats O
, O
a O
putative O
hyaluronan-binding O
motif O
, O
and O
a O
potential O
transmembrane O
domain O
near O
the O
C O
-terminal O
. O
Lectin O
and O
Western O
blotting O
indicate O
an O
M(r) O
around O
400,000 O
before O
and O
230,000 O
after O
chondroitinase O
ABC O
digestion O
. O
Removal O

of O
N- O
and O
O-linked O
oligosaccharides O
reduces O
the O
M(r) O
to O
approximately O
160,000 O
, O
suggesting O
that O
approximately O
60% O
of O
the O

adrenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O
cells O
with O
pertussis O
toxin O
. O
In O
contrast O
to O
adrenaline O
and O
somatostatin O
, O
galanin O
, O
another O
inhibitor O
of O
insulin O
secretion O
, O
reduced O
Ca2+ O
currents O
by O
about O
40% O

in O
a O
pertussis O
toxin-insensitive O
manner O
. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis O
toxin-sensitive O
G-proteins O
including O
Gi1 O
, O
Gi2 O
, O
Go2 O
, O

H(4)biopterin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
on O
the O
substituent O
, O
were O
competitive O
inhibitors O
of O
phenylalanine O
hydroxylase O
: O
N(5)-methyl- O
and O
N(5)-hydroxymethyl O
H(4)biopterin O
inhibited O
phenylalanine O
hydroxylase O
, O
whereas O
N(5)-formyl- O
and O
N(5)-acetyl O
H(4)biopterin O
had O
no O
effect O
. O
Our O
data O
demonstrate O
differences O
in O
the O
mechanism O
of O
stimulation O
of O
phenylalanine O
hydroxylase O

and O
nitric O
oxide O
synthase O
by O
H(4)biopterin O
O O
. O
They O
are O
compatible O
with O
a O
novel O
, O
non-classical O
, O
redox-active O
contribution O
of O
H(4)biopterin O
to O
the O
catalysis O
of O
the O
nitric O
oxide O
synthase O
reaction O

choline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
0.8%) O
and O
choline O
(0 O
or O
25 O
mmol/kg O
diet) O
. O
Liver O
and O
kidney O
BHMT O
and O
CHDH O
were O
assessed O
using O
enzymatic O
, O
Western O
blot O
, O
and O
real-time O
PCR O
analyses O
. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis O
. O
Liver O
BHMT O
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met O
deficient O
diet O
containing O
choline O
O O
, O
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein O
. O
Independent O
of O

choline O
, O
supplemental O
Met O
increased O
hepatic O
BHMT O
activity O
approximately O
30% O
. O
Kidney O
BHMT O
and O
liver O
CHDH O
expression O
were O
refractory O

ATP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
O O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O

racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O

cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O

BNZ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
one O
cytochrome O
P450 O
isoform O
can O
significantly O
influence O
the O
catalytic O
activity O
of O
another O
isoform O
. O
In O
this O
study O
, O
we O
assessed O
whether O
CYP2E1 O
could O
influence O
the O
catalytic O
activity O
of O
CYP2B4 O
under O
steady-state O
turnover O
conditions O
. O
The O
results O
show O
that O
CYP2E1 O
inhibits O
CYP2B4-mediated O
metabolism O
of O
benzphetamine O
(BNZ O
) O
with O
a O
K(i) O
of O
0.04 O
µM O
. O
However O
, O
CYP2B4 O

is O
not O
an O
inhibitor O
of O
CYP2E1-mediated O
p-nitrophenol O
hydroxylation O
. O
When O
these O
inhibition O
studies O
were O
perfor O
med B
wit O
h O
the O
artificial O
oxidant O
tert-butyl O
hydroperoxide O
, O
CYP2E1 O
did O
not O
significantly O
inhibit O
CYP2B4 O
activity O
. O
Determinations O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O

extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sorafenib O
(BAY O
43-9006 O
Nexavar) O
, O
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK O
pathway O
in O
tumor O
cells O
and O
tyrosine O
kinases O
VEGFR O
/PDGF O
R O
in O
tumor O
vasculature.Activating O
mutations O
in O
Ras O
and O
B-RAF O
were O
identified O
in O
several O
human O
cancers O
. O
In O
addition O
, O
several O
receptor O
tyrosine O
kinases O
, O
acting O
upstream O
of O
Ras O
, O
were O
found O
either O
mutated O
or O
overexpressed O
in O

BPs O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
O O
, O
and O
enhancing O
Bim O

through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O

vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O

pyrano[2,3-b]quinolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
BuChE) O
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O

4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O

4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O

[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O

VK2-2,3 O
epoxide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O

. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O

mifepristone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
month O
before O
operation O
. O
PR O
protein O
levels O
in O
these O
tissues O
showed O
significant O
decrease O
in O
all O
6 O
cases O
. O
CONCLUSION O
: O
There O
are O
overexpression O
of O
PRmRNA O
and O
PR O
protein O
in O
leiomyomata O
. O
One O
of O
the O
mechanism O
of O
mifepristone O
action O
on O
decreasing O
leiomyomata O
volume O
may O
be O
related O
to O
suppression O
on O
expression O
of O
PR O
gene O
O O
. O
It O
seems O
that O
suppression O
on O
transcription O
of O
PR O
gene O
is O
reversible O
, O
but O
on O
translation O
of O
PR O
gene O
may O
maintain O
in O
a O
relatively O
longer O
period O

Rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR B
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
conc O
entrations B

. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O
the O
20S O
catalytic O
core O
proteasome O
. O
These O
protein O
complexes O
are O

Genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK O
) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O

phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O

LY139037 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
of O
nizatidine O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs.Nizatidine O
LY139037) O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O

mucosa O
of O
the O
bullfrog O
. O
Nizatidine O
was O
8.9 O
times O
as O
active O
as O

BH4 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
in O
median O
raphe O
nucleus O
(MRN) O
and O
dorsal O
raphe O
nucleus O
(DRN) O
, O
respectively O
, O
without O
significantly O
altering O
TPH O
mRNA O
levels O
in O
the O
pineal O
gland O
. O
In O
contrast O
, O
there O
was O
little O
change O
in O
mRNA O
levels O
for O
GTP O
cyclohydrolase O
I O
GTPCH) O
, O
the O
rate O
limiting O
enzyme O
in O
synthesis O
of O
the O
tetrahydrobiopterin O
(BH4 O
) O
, O
the O
obligate O
cofactor O
for O
TPH O
. O
This O
is O
the O
first O
study O
to O
reveal O
stress-elicited O
activation O
of O
TPH O
gene O
expression O

. O

PSE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE O
on O
T-cell O
activation O
events O
. O
We O
found O
that O
PSE O
inhibits O
interleukin-2 O
(IL-2 O
) O
and O
tumor O
necrosis O
factor O
(TNF) O
alpha-gene O
transcription O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O

cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
GLR3.2 O
and O
GLR3.4 O
caused O
the O
same O
and O
equally O
severe O
phenotype O
, O
namely O
, O
a O
large O
overproduction O
and O
aberrant O
placement O
of O
lateral O
root O
primordia O
. O
Loss O
of O
GLR3.3 O
did O
not O
affect O
lateral O
root O
primordia O
. O
These O
results O
support O
the O
hypothesis O
that O
apoplastic O
amino O
acids O
acting O
through O
heteromeric O
GLR3.2 O
/GLR3.4 O
channels O
affect O
lateral O
root O
development O
via O
Ca(2+) O
signaling O
in O
the O
phloem O
. O

Wellbutrin O
SR O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O
interindividual O
variation O
in O
CYP2B6 O
activity O
in O
vivo O
, O
we O
evaluated O
these O
effects O
in O
healthy O
volunteers O
using O
bupropion O
Wellbutrin O
SR O
GlaxoSmithKline O
, O
Research O
Triangle O
Park O
, O
NC) O
as O
a O
CYP2B6 O
probe O
substrate O
. O
A O
fixed O
150-mg O
oral O
sustained-release O
dose O
of O
bupropion O
was O
administered O
to O
100 O
healthy O

volunteers O
comprising O
four O
sex/ethnicity O
cohorts O
(n O
= O
25 O
each) O
: O
Caucasian O
men O
and O
Caucasian O
, O
African O
American O
, O
and O
Hispanic O
women O
. O
Blood O
samples O

15d-PGJ2 O
acts O
as O
NOT O
for O
what O
entity O
? O
their O
precursors O
, O
prostaglandins O
E2 O
and O
D2 O
. O
15-Deoxy-Delta12,14-prostaglandin O
J2 O
(15d-PGJ2) O
was O
the O
most O
potent O
prostaglandin O
among O
those O
tested O
. O
In O
activated O
microglia O
, O
15d-PGJ2 O
suppressed O
iNOS O
promoter O
activity O
, O
iNOS O
mRNA O
, O
and O
protein O
levels O
. O
The O
action O
of O
15d-PGJ2 O
does O
not O
appear O
to O
involve O
its O
nuclear O
receptor O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma) O

because O
troglitazone O
, O
a O
specific O
ligand O
of O
PPARgamma O
, O
was O
unable O
to O
inhibit O
iNOS O
induction O
, O
and O
neither O
troglitazone O
nor O
15d-PGJ2 O
could O
stimulate O
the O
activity O
of O
a O
PPAR-dependent O
promoter O
in O
the O
absence O
of O
cotransfected O
PPARgamma O
. O

Glufosinate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Herbicidal O
inhibitors O
of O
amino O
acid O
biosynthesis O
and O
herbicide-tolerant O
crops.Acetohydroxyacid O
synthase O
(AHAS) O
inhibitors O
interfere O
with O
branched-chain O
amino O
acid O
biosynthesis O
by O
inhibiting O
AHAS O
. O
Glyphosate O
affects O
aromatic O
amino O
acid O
biosynthesis O
by O
inhibiting O
5-enolpyruvylshikimate-3-phosphate O
synthase O
(EPSPS) O
. O
Glufosinate O
inhibits O
glutamine O

synthetase O
and O
blocks O
biosynthesis O
of O
glutamine O
. O
AHAS O
gene O
variants O
that O
confer O
tolerance O
to O
AHAS O
inhibitors O
have O
been O
discovered O
in O
plants O
through O
selection O
or O
mutagenesis O
. O
Imidazolinone-tolerant O
crops O
have O
been O
commercialized O
based O
on O
these O
AHAS O
gene O
variants O
. O
A O
modified O
maize O
EPSPS O

thiazolidinediones O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Correlation O
between O
activation O
o O
PPARγ O
and O
resistin O
downregulation O
in O
a O
mouse O
adipocyte O
cell O
line O
by O
a O
series O
of O
thiazolidinedione O
s.The O
present O
study O
shows O
significant O
correlations O
between O
the O
EC50 O
for O
PPARγ O
activation O
in O
a O
reporter O
gene O
cell O
line O
and O
resistin O
downregulation O
in O
mouse O
adipocytes O
, O
and O
between O
the O
IC50 O
for O
resistin O
downregulation O
and O

